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Abstract
The fight against bacterial infections and innovations in antibiotic therapy has never
halted throughout human history. However, bacteria have evolved smartly and resistance against
practically all conventional antibiotics has been developed. Furthermore, bacteria can form
biofilms, which are surface-attached multicellular colonies. Biofilms shield bacteria against
antibiotics and makes it harder to entirely eradicate infections . Under antibiotics stress, bacteria
evolve into different phenotypes like hyper motile, hyper adherent and hyper virulent which are
tolerant and persistent to antibiotic treatment. The use of antibiotic therapy to combat such
resilient bacterial phenotypes is extremely tough. As a result, the scientific community is always
looking for novel ways to defeat these resilient phenotypes. It important to notice that all
antibiotic induce tolerant and persistent phenotypes and there is no direct remedy for eradication
of these phenotypes. On other hands, resistance to one antibiotic can be tackled by alternative
antibiotic usage.
Here, we demonstrate a class of small molecules that inhibits a wide range of phenotypes
of Pseudomonas aeruginosa and enables the antibiotics to kill tolerant bacteria and to prevent
formation of new persistent bacteria. We identified two proteins, type IV pili and lectin LecA as
receptors for our molecules by different methods, including a new label-free assay based on
bacterial motility sensing the environment, chemical inhibition of bacteriophage adsorption on
pili appendages of bacteria, and fluorescence polarization. Structure-activity relationship studies
reveal a molecule that inhibits only pili appendage, and a class of chimeric ligands that inhibit
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both LecA and pili, with important structural elements of the ligand identified for each protein.
This selective control of two proteins makes the correlation between the protein receptor to their
controlled phenotypes. Inhibiting LecA results in reducing biofilm formation, eliminating small
colony variants, and correlates with killing tolerant bacteria and preventing the development of
new persistent bacteria. Inhibiting pili appendages impedes the swarming and twitching
motilities, and pyocyanin and elastase production. Because these phenotypes are controlled by a
broad range of signaling pathways, this approach simultaneously control the multiple signaling
mechanisms, by which bacteria elude antibiotic treatments.
Glycolipid, ganglio-N-tetraosylceramide (asialo-GM1), on the mammalian cells are
known to be recognized by type IV pili of Pseudomonas aeruginosa. In this work, we show that
asialo-GM1 can also be recognized by Lectin A (LecA), another adhesin protein of the P.
aeruginosa, by a fluorescent polarization assay, a label-free bacterial motility enabled binding
assay, and bacterial mutant studies. On hydrated semi-solid gel surfaces, asialo-GM1 enables
swarming and twitching motilities, while on solid surfaces facilitates the bacterial
adherence of P. aeruginosa. These results indicate that asialo-GM1 can modulate bioactivities,
adherence, and motilities, that are controlled by opposite signaling pathways. We demonstrate
that when a solution of pilin monomers or LecA proteins are spread on hydrated gel surfaces, the
asialo-GM1 mediated swarming motility is inhibited. Treatment of
artificial liposomes containing asialo-GM1 as a component of lipid bilayer with pilin monomers
or LecA proteins caused transient leakage of encapsulated dye from liposomes. These results
suggest that pili and LecA proteins not only bind to asialo-GM1 but can also cause asialo-GM1
mediated leakage. We also show that both pili and LecA mutants of P. aeruginosa adhere to

asialo-GM1 coated solid surfaces, and that a class of synthetic ligands for pili and LecA inhibits
both pili and LecA-mediated adherence of P. aeruginosa on asialo-GM1-coated surfaces.
The inspired by adjuvant molecule’s control over different P. aeruginosa phenotypes, we
here designed new class of antibiotics which showed broad spectrum activity against different
bacteria. This class of antibiotics inhibits pili and lecA and hence control multiple phenotypes in
P. aeruginosa. This antibiotic also did not show emergence any tolerant population. We also did
not develop any resistance against this class of antibiotics after repeated exposure.
Silver therapy is most commonly used against burn wounds to treat P. aeruginosa and S.
aureus infections. These bacteria develop cooperative resistance against silver with the help of
pyocyanin, a virulence factor of P. aeruginosa. Here, we showed Farnesol as adjuvant molecule
with silver therapy against P. aeruginosa and S. aureus. Farnesol eradicates resistance against
silver by inhibition of pyocyanin. Farnesol also potentiated silver against dual biofilms of P.
aeruginosa and S. aureus.
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Chapter 1 Introduction: Challenges in antibiotic therapy against bacterial
infections
1.1. Pseudomonas aeruginosa and pathogenesis.
Gram-negative bacteria have emerged as a major cause of nosocomial infections and
have been associated with higher morbidity and mortality rates.1-15 Common gram-negative
bacteria and the infections they lead to include Pseudomonas - lung and urinary tract infections,
Escherichia coli (E. coli )-food poisoning, urinary tract infections, gastroenteritis, Klebsiellameningitis, and pulmonary, urinary tract, and bloodstream infections, Acinetobacter baumanniiwound infections, Neisseria gonorrhoeae-gonorrhea.8 Pseudomonas, a strictly aerobic, gramnegative bacterium was discovered in 1882 by Gessard. This bacterium is ubiquitous in nature,
primarily found in moist environments like soil, water, plants, and animals. Pseudomonas
aeruginosa (P. aeruginosa) is the most common pseudomonal species.9-15 and reportedly occurs
in more than 50% of humans.14 Pseudomonas aeruginosa is a clinically significant and
opportunistic pathogen, lead cause of serious and life-threatening diseases in critically ill and
immunocompromised patients.14 The estimated 51,000 nosocomial Pseudomonal infections
occur in the U.S. each year with 20% - 35% death rates.9
1.2 Antibiotic therapy against Pseudomonas aeruginosa are trouble than answer.
The antibiotic therapy used to treat pseudomonal infections includes aminoglycosides
(gentamicin, tobramycin, amikacin, netilmicin), carbapenems (imipenem, meropenem),
cephalosporins (ceftazidime, cefepime), fluoroquinolones (ciprofloxacin, levofloxacin),
penicillin with β-lactamase inhibitors (BLI) (ticarcillin and piperacillin in combination with
clavulanic acid or tazobactam), monobactams (aztreonam), Fosfomycin and polymyxins
(colistin, polymyxin B).14
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As Pseudomonas aeruginosa quickly acquire resistant to one antibiotic class, infections are
usually treated by combinations of antipseudomonal beta-lactam antibiotics and aminoglycoside
antibiotics.14 It has been shown to use combination of carbapenems or quinolones along with
aminoglycoside tobramycin in clinical setting.14
The copious and misuse of broad-spectrum antibiotics like beta-lactams, quinolones and
aminoglycosides contribute to emergence of multi-drug resistant (MDR) pseudomonal species.15
Pseudomonas aeruginosa species showed high propensity to acquire antibiotic resistance
through different mechanisms including decreased permeability (porins), expression of efflux
systems, production of antibiotic degrading enzymes (beta-lactamases) and target/receptor
modifications.10,16-18 P. aeruginosa exhibits these resistance mechanisms through both intrinsic
chromosomally encoded or genetically imported resistance determinants affecting the major
classes of antibiotics such as β-lactams, aminoglycosides, quinolones and polymyxins.18-20
Antibiotic resistance presents an alarming and rising threat over years and technological
advances have been trying hard to combat antibiotic resistance.11 Resistance is the inherited
ability of microorganisms to grow in the presence of antibiotics, regardless of the duration of
treatment.11,21 Resistance factors like gene enable resistant bacteria to survive at higher
antibiotic concentrations that would usually eradicate susceptible ones.21 Resistance is measured
by the MIC, which can be defined as the minimum inhibitory concentration of an antibiotic that
is required to prevent growth of the culture.21 For resistance, bacteria with a higher MIC will be
regarded as more resistant than one with lower MIC.21
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1.3 Tolerance and persistence paves the way for resistance.
Tolerance, on the other hand, prolongs the duration of antibiotic treatment that bacteria
can sustain.21,22 A tolerant cells do not carry resistance factor like gene and can regrow normally
after removal of antibiotic.21,22 Tolerance enables bacteria to survive longer duration of antibiotic
exposure.21,22 Tolerance can originate from environmental factors like nutrients availability, slow
growth, biofilms or genetic.21,22 As tolerant bacteria may have the same MIC as non-tolerant
bacteria, the MIC is not informative as a metric to evaluate tolerance. Recently, the MDK
(Minimum duration of Kill) was described as a quantitative measure of tolerance that can be
extracted from time–kill curves.21 The MDK is defined as the typical duration of antibiotic
treatment that is required to kill a given proportion of the bacterial population at concentrations
higher than the MIC. There have been two main forms of tolerance i.e. 'tolerance by slow
growth' and 'tolerance by lag'.21
Antibiotic persistence is a phenomenon that comprise of the presence of two
subpopulations, consisting of susceptible that are killed fast by the antibiotic and tolerant cells
that may survive over longer period.21,23 By definition, antibiotic persistence is always connected
with a heterogeneous population, in which only a part of the population consists of tolerant
cells.21 A persister cell is a tolerant cell originating from a population that displays antibiotic
persistence.21,23-26 Persisters constitute the subpopulation (typically less than 1%) and are not
killed by antibiotic treatment. (Fig. 1.1)
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Figure 1.1 Difference between susceptible, tolerance, persistence, and resistance. The plot of
bacterial population (log of colony forming units per ml) under antibiotic treatment vs time
duration of antibiotic treatment.
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Adopted from “E.M. Windels, J.E. Michiels, B. Van den Bergh, M. Fauvart, J. Michiels, Antibiotics: combatting tolerance to stop resistance,
MBio, 10 (2019) e02095-02019.”

Figure 1.2 Framework for how antibiotic tolerance and persistence accelerate the evolution of
genetic resistance. First, in populations displaying high levels of tolerance or persistence, an
increased number of viable cells is available for mutation, increasing the likelihood for a
resistant mutant to arise. Second, persistence is linked with higher mutation rates, again causing
an increased likelihood for the occurrence of resistance-conferring mutations. Future research
will reveal if a similar link exists between tolerance and mutation rates.26

These resilience by sub-population of bacteria via tolerance or persistence is often
overlooked in clinical setting and currently underappreciated role in the recalcitrance and relapse
of pseudomonal infections.15,26 It has been shown that tolerance leads to resistance in long term
therapies (Fig.1.2). Unfortunately years of efforts have so far proved inadequate to curb
emergence and spread of multidrug resistant species. These direct us to other resilient approaches
adopted by bacteria against antibiotic therapy.14,27-37 It has been shown that Pseudomonas
aeruginosa exhibit wide variety of responses to different class of antibiotics and leads resilient
phenotypes (Table 1).
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Table1.1 Different class of antibiotics and emerging resilient phenotypes.
Emerging phenotypes27-37

Class

Antibiotics

β-lactams

Carbenicillin, Aztreonam

1. Biofilms
2. Filaments

Polymyxins

Colistin

1. Biofilms
2. Motility

Aminoglycosides

Tobramycin, gentamicin

1. Biofilms
2. Swarming motility
3. Small colony variants

Fluoroquinolones

Ciprofloxacin, Levofloxacin

1. Biofilms
2. Mucoid (Alginates)

Pseudomonas aeruginosa promote biofilms as response to antibiotic treatment. Biofilms
are involved in a broad range of infections.38,39 Indeed, about 80% of the chronic and recurrent
microbial infections in humans are caused by biofilms, some of which result in high mortality
and morbidity rates.38-40 In addition, biofilms are highly resistant to the host immune defenses
and clearance mechanisms.40 Other nosocomial infections include those caused by biofilms
strongly adhered to implants and catheters or medical devices.40

1.4 Pseudomonas respond to antibiotics with emergence of phenotypic resilience.

Biofilms are house of microorganisms attached to each other, or to a surface, and encased
in a protective, self-produced matrix.31,40-42 Biofilm cells are encased within a self-produced
matrix comprised of extracellular polymeric substances (EPS) including polysaccharides,
extracellular DNA (eDNA), proteins and lipids.31,41,42 The EPS matrix provides protection for the
cells inside biofilms by acting as a shield and is central to biofilm structure and integrity.31
6

The sub-inhibitory concentrations of beta-lactam antibiotics stimulate biofilm formation
in P. aeruginosa but mechanism of promotion is still unknown. Aminoglycosides antibiotics
promote biofilms through aminoglycoside response regulator (arr) gene.33 Interestingly, repeated
antibiotic usage has led to emergence of phenotype in clinical setting called as small colony
variants (SCVs) which exhibit high resistance to antibiotic treatments.43-45 SCVs are defined as
colonies whose size is 5 or 10 times smaller than normal colony phenotype.43-45 Compared to
wild-type P. aeruginosa, SCVs show increased antibiotic resistance, enhanced biofilm
formation, reversion to wild-type-like morphotypes, reduced motility, and slow and autoaggregative growth behavior.43,44 The clinical patients small colony variants were observed with
long term tobramycin treatment.43

Antibiotics are shown to behave like intermicrobial signaling molecules in P.
aeruginosa.30,46,47 Tobramycin increases bacterial motility, and tetracycline triggers expression
of P. aeruginosa type III secretion system and consequently bacterial cytotoxicity.30,47
Interestingly, aminoglycoside antibiotics also promote swarming motility in P. aeruginosa.47
Beta-lactam antibiotics with dose-related affinities for penicillin-binding proteins (PBPs) and at
low concentrations, these antibiotics inhibit PBPs, leading to filament formation.48,49 Filaments
are long strands of non-dividing bacteria that contain enhanced quantities of endotoxin
molecules. Filamentous bacteria show enhanced resilience to antibiotic treatment.49
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Figure 1.3 Map of antibiotics and promoted bacterial phenotypes that increases their resilience
(tolerance, persistence, or resistance). Arrows indicate promotion of the phenotype.

Prophages contribute significantly to resistance to sub-lethal concentrations of
fluroquinolones and β-lactam antibiotics primarily through proteins that inhibit cell division.
Fluroquinolones induce prophage that mediates horizontal gene transfer.50-53 Moreover, the
prophages play vital role for withstanding osmotic, oxidative, and acid stresses, for increasing
growth, and for augmenting biofilm formation Fluroquinolones antibiotics also induce SOS
response in P.aeruginosa which leads to formation of filamentous bacteria.51-53 Ciprofloxacin
also enhances alginate production in P.aeruginosa resulting in mucoid phenotype.54 Polymyxin
antibiotic like colistin induce biofilm formation and these biofilms harbors colistin tolerant cells.
These colistin tolerant cells use P. aeruginosa type IV pili mediated motility for survival against
colistin.55
Overall, conventional antibiotics are suffering from either motility mediated tolerance or
biofilms mediated tolerance in P. aeruginosa. Motilities in P. aeruginosa governed by mostly
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surface appendages like flagella, pili, and fimbria. There are multiple factors that contribute to
biofilm formations but Lectins serve as glue for biofilms and play major role in structure and
integrity of P. aeruginosa biofilms.56 Some appendages like pili also play crucial roles in biofilm
formation.57 We believe that antibiotics induce augmented activities of these receptor proteins
and lead to enhanced motilities or biofilm formations.

1.5 This dissertation is organized in the following 6 chapters.
In chapter 2, we design and synthesize ligands which targets two different protein
receptors in P. aeruginosa. We identify two proteins, type IV pili and lectin LecA as receptors
for our molecules by different methods, including a new label-free assay based on bacterial
motility sensing the environment, chemical inhibition of bacteriophage adsorption on pili
appendages of bacteria, and fluorescence polarization. We also discuss structure-activity
relationship studies which shades light on how a class of chimeric ligands that inhibit both LecA
and pili. Here, we show how chimeric ligands control different phenotypes in P. aeruginosa. We
also describe how chimeric ligands eradicate antibiotic induced tolerance and prevent formation
of new persister populations in P. aeruginosa biofilms.
In chapter 3, we expand role type IV pili and Lectin A as adhesin in P. aeruginosa
infections. We show how pili and Lectin A of P. aeruginosa recognize glycosphingolipid present
in mammalian cell membrane and initiate infection. We describe how P. aeruginosa use pili and
Lectin A proteins as adhesins and bind to mammalian cells and mediate motilities or adherence.
Here, we show extended application of chimeric ligands from chapter 2 as anti-adhesin
molecules. We present chimeric ligands as anti-adhesin molecules which prevent motility and
adherence mediated by glycosphingolipid binding to pili or LecA. We also show how binding of
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glycosphingolipid to pili or LecA cause transient leakage in artificial liposomes which mimic
biological membranes. This provide probable mode of interaction of bacteria and mammalian
cells.
In chapter 4, we design and synthesize new class of antibiotic which inhibits functions of
penicillin binding proteins of gram-positive and gram-negative bacteria. Here, we show broad
spectrum activity of new class of antibiotic and control over resilient phenotypes of P.
aeruginosa. We also demonstrate that how this antibiotic is chimeric and targets pili and LecA.
We also perform multistep resistance studies to determine emergence of antibiotic resistance.
In chapter 5, we illustrate power of naturally occurring terpenoid Farnesol against burn
wound microbiome. We also demonstrate how P. aeruginosa –Staphylococcus aureus help each
other in burn wound environment against silver therapy and develop resistance. We show how
farnesol inhibit virulence factors like pyocyanin in P. aeruginosa and eradicate collaborative
silver resistance in P. aeruginosa –Staphylococcus aureus coinfection.
In chapter 6, the conclusions and summary of our findings in this thesis are discussed. We
also present the existing open questions and future directions of development of this new class of
antibiotic.
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Chapter 2 Chimeric Ligands of Pili and Lectin A Inhibit Tolerance,
Persistence, and Virulence Factors of Pseudomonas aeruginosa over A Wide
Range of Phenotypes.
2.1 Background and Significance
Bacteria exhibit adaptive responses to a wide range of stresses from environmental cues
to antibiotic treatments leading to many resilient phenotypes,33,43,55,58-72 including augmented
biofilm formation,33,60 enhanced motilities,63,64 surface attachment,66-68 chemical induced
virulence,62,69 and emergence of small colony variants (SCVs).43,70,71 These diverse phenotypes
are often controlled by or correlated to both high and low levels of the global small molecule
messenger, bis-(3'-5')-cyclic dimeric guanosine monophosphate (cdG).73-76 For both in vitro and
in vivo conditions, antibiotics treatments or host immune defense can trigger the increase in cdG
levels in bacteria, leading to phenotypes that exhibit high drug tolerance and persistence,
including biofilms,33,72 small colony variants (SCVs)43,70,71 and overexpression of exopolymeric
substances (EPS).77
Recent studies revealed that low cdG phenotypes can also be highly virulent.55,69,76
Swarming bacteria, a low cdG phenotype, requires rhamnolipids78-80 and exhibit antibiotic
resistance.64,65 Dispersing bacteria from biofilms by nitric oxide donor69 switches bacteria to low
cdG phenotypes and causes increased production of virulence factors, including induction of
type II and III secretion system, which has been shown to kill even macrophage.69 Surprisingly,
under different conditions, the same antibiotic, tobramycin, can promote P. aeruginosa to form
either high or low cdG phenotype to counter the stresses. Sub-lethal dose of tobramycin
promotes the high cdG phenotypes including increased biofilms and increased exopolymers
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production,33 and causes formation of SCVs in vivo.71 In contrast, on hydrated agar surface,
tobramycin also promotes the swarming motility of P. aeruginosa.63 These findings indicate that,
although the two types of protein domains, diguanylate cyclases and phosphodiesterases, that
regulates the synthesis and hydrolysis of cdG are well-established,73,75 how they respond to
external stresses is complex and still unpredictable. More importantly, these findings suggest that
inhibiting high cdG phenotypes alone, such as biofilms formation, would not be sufficient to
control drug tolerance and persistence as bacteria can transition readily between high and low
cdG phenotypes.
In past study, we showed a broad class of disugar-derivatized hydrocarbons that inhibit
both biofilm formation and swarming motility of P. aeruginosa bacteria.81,82 These dual
inhibitors are intriguing as biofilm formation and swarming motility are controlled by the
opposite signaling pathways mediated by high and low cdG levels, respectively.74 Because both
high or low cdG phenotypes can be virulent, and bacteria can readily transition between these
phenotypes, this class of molecules provide opportunities to control drug tolerance, persistence,
and resistance; and also block bacterial signaling that escape drug treatments by transitioning
between phenotypes.
In this work, we demonstrate a specific class of molecules that inhibits a wide range of
phenotypes that are associated with both high and low cdG levels. These phenotypes include
formation of biofilms, small colony variants, pellicles; and swarming and twitching motilities,
and production of virulence factors including pyocyanin and elastase. Antibiotics like tobramycin
promote these phenotypes33,70,83 and these phenotypes are shown to be dwelling in chronic and
acute infections.33 We also demonstrate that, when combined with tobramycin, this class of
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molecules enables the killing of tolerant bacteria and prevents of the formation of nascent
persistent bacteria in biofilms.
To elucidate the mechanism behind this simultaneous control of the wide range of phenotypes
associated with opposite signaling pathways (low and high cdG levels), we identify pili
appendages and LecA as two protein receptors targeted by the same small molecule (Fig. 2.1).

Figure 2.1 Venn diagram of structures of chimeric ligand molecules for type IV pili and Lectin
LecA proteins, and ligand molecules for only pilin, and only LecA.
We confirmed the binding of small molecule to pili by multiple methods, including a
novel bacterial motility enabled binding assay, which is modified from the swarming experiment
without any chemical labeling, and the small molecule inhibition of pili-specific bacteriophage
adsorption on of P. aeruginosa. The LecA binding was characterized by fluorescence
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polarization method and by the bacterial motility enabled binding assay without chemical
modification. Structure-activity studies identified the different structural elements of the small
molecule ligands that are important for each protein, pilin and LecA, making this class of
molecule a structural chimera. The selective ligand-receptor bindings of two proteins reveal the
mapping between the proteins and the phenotypes they control.
2.2 Results and discussion
2.2.1 Design and synthesis of ligands
Our past studies reveal that two most active molecules among these dual synthetic
inhibitors as saturated farnesol-β-cellobioside or -β-maltoside (SFβC and SFβM, Fig. 2.1.1).81
Early structural studies indicates that the methyl substitution in the aliphatic chains is important:
linear C12-aliphatic chain does not exhibit strong bioactivity, whereas the 3,7,11-trimethyl
substituted aliphatic chain does.81,82 In search for more potent molecules through synthesis of
structural variants, we explored new methyl positions on the C12-alphatic chain resulting in new
molecules 3,5-diMeDβM and 3,5-diMeDβC (Fig. 2.2 and Fig. S1-S16).
We synthesized alcohol precursor, 3,5-dimethyldodecanol from alkylation of cyclic
ketone (3,5-dimethylcyclohexanone) followed by Baeyer-Villiger oxidation. Ring opening was
followed by mesylation and one-step reduction of the ester and the mesylated alcohol to generate
the desired branched alcohol. Glycosylation with protected maltoside and cellobioside, followed
by basic deprotection generated the final products of 3,5-dimethyl-dodecyl maltoside 3,5diMeDβM, and 3,5-dimethyl dodecyl cellobioside 3,5-diMeDβC (Fig. 2.2).
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Figure 2.2 Synthetic scheme for 3,5-diMeDβM (1a) and 3,5-diMeDβC (1b).
We found these disugars tethered with 3,5-dimethyl substituted dodecyl group exhibited
stronger biofilm inhibition activities against P. aeruginosa with an IC50 of 29 µM and 36 µM,
respectively, whereas SFβM/βC from past studies showed IC50s of 73 µM and 52 µM,
respectively (Table 2.1). Here, we explore these molecules for controlling wide range of bacterial
activities induced by sub-MIC of the antibiotic tobramycin.
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Table 2.1 3,5-diMeDβM/βC are more potent than SFβM/βC at inhibition and dispersion of wild
type P. aeruginosa (wt PAO1) biofilms.a
Biofilm Inhibition
Molecule

SFβM

Biofilm Dispersion

b

c

IC50 ± s.d. [µM]

DC50± s.d. [µM]

w/o Tob

w/ 0.3 µg/ml Tob

w/o Tob

73 ±2 µM*

85±4.6 µM

126±5.5

w/o 0.3 µg/ml
Tob
>150 µM

µM*
SFβC

52±2.4

79±3.3 µM

83±3.3 µM*

>150 µM

µM*
3,5-diMeDβM

36±2.2 µM

62±2.2 µM

54±5.5 µM

98±3.3 µM

3,5-diMeDβC

29±3.2 µM

58±2.1 µM

48±4.6 µM

95±2.9 µM

a. The biofilms were characterized by a Crystal violet staining assays on the pegs of MBEC™
microtiter plates b. IC50 values were obtained by plotting concentration of the molecule against
% biofilm inhibition after 24 h without shaking at 50% of biofilm inhibition. c. DC50 values were
obtained by plotting concentration of molecule against % biofilm dispersion after 24 h with
shaking at 100 rpm shaking, at 50 % biofilm dispersion. Experiments were performed in
triplicate and the results are an averaged value; error bars reflect the standard deviation of each
point. The curve fitting was performed with GraphPad Prism 6.0 software.*indicated values
extracted from literature81
2.2.2 Reversing Tobramycin Induced Phenotypes of P. aeruginosa
In general, antibiotics can promote biofilm formation.33,60 Sub-inhibitory concentration of
tobramycin causes two-fold increase in biofilm mass formed by wild type P. aeruginosa (wt
PAO1) on abiotic surfaces including glass, polystyrene, and stainless steel.33 The small
molecules 3,5-diMeDβM and 3,5-diMeDβC not only inhibit biofilm formation (Table 2.1), but
also inhibited the promotion of biofilm formation by 0.3 µg/ml tobramycin (0.3-Tob) and
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reduced 0.3-Tob stressed biofilm mass by 80%, revealed by crystal violet staining. For biofilms
formed by using wild type P. aeruginosa (PAO1) constituently expressing green fluorescent
protein (GFP), we validated that these molecules inhibited formation of unstressed biofilms (Fig.
2.3), with a reduction of biofilm mass by ~55 % (from 27.5 µm3/µm2 to ~12.3 µm3/µm2). This
assay demonstrated that 0.3-Tob caused 40% increase in biofilm mass (from 27.5 to 38.6
µm3/µm2) on polystyrene surfaces, and combination with 3,5-diMeDβM/βC (85 µM) reduced the
biofilm mass by 50% (Fig. 2.4A).

Figure 2.3 3,5-diMeDβM/βC inhibit unstressed biofilm formation in P. aeruginosa. 24 h
biofilms of GFP-tagged PAO1 were grown in M63 medium with and without 85 µM 3,5diMeDβM/βC on polystyrene surface. Images were acquired by confocal laser scanning
microscope. The central pictures show horizontal optical sections, and the flanking pictures show
vertical optical sections. P. aeruginosa biomass was quantified with the COMSTAT program.
Scale bars, 20 μm. Emission of 488 nm was used to visualize live cells within the biofilms
formed by PAO1-EGFP strain. The biomasses fluorescing green reveal the amounts of living
bacteria in a biofilm. The COMSTAT program was used to report the percentage of live
biomasses in the stacks of images.

Antibiotics of aminoglycosides causes the bacteria to form phenotypes of small colony
variants (SCVs) in lungs of cystic fibrosis patients; these SCVs are tolerant in clinical
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infections.70-72 We discovered that, in vitro, sub-inhibitory amount of tobramycin also caused
SCVs formation (Figure 3B). When wt PAO1 were cultured with 0.3-Tob for 6 h followed by
growth on Columbia agar gel (24 h) containing 0.3-Tob, 13-fold of SCVs (1 mm in diameter,
4.2×107 CFU/ml) was observed over wild type colonies (1 cm in diameter, 3.2×106 CFU/ml).
Under the same condition, combining 85 µM of 3,5-diMeDβM/βC with 0.3-Tob abolished
formation of SCVs entirely (Fig. 2.4B).

Figure 2.4 (A) Fluorescent images of 24 h unstressed (0-Tob) and 0.3 µg/ml tobramycin (0.3Tob) stressed biofilms of GFP-tagged wt PAO1 grown in M63 medium on polystyrene surface
with and without 85 µM of 3,5-diMeDβM/βC. Scale bar = 20 μm. (B) Images of wt PAO1
colonies (37 ℃, 3 days) on Columbia blood agar plates. Scale bar = 2 cm. (C) Colony
morphology of wt PAO1 inoculated on 1% agar plates containing Congo red and Coomassie
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brilliant blue dyes. The colonies were grown for 3 days at 37°C. Scale bar =1 cm. (D). Images of
swarming patterns of 3 µL of wt PAO1 inoculated for 24 h on soft gels (0.5 % agar in LB). The
agar plates for SCV, colony morphology, and swarming motility contain 0-Tob, 0.3-Tob, with
and without 85 µM of 3,5-diMeDβM/βC.

Antibiotics are also known to increase the production of extracellular polymeric
substances (EPS) composed of polysaccharides and proteins.84 To directly visualize effect of 3,5diMeDβM/βC on overall EPS, wt PAO1 culture (OD600= 0.6) was inoculated on Congo red
containing hard agar plates supplemented with 0.3-Tob for 3 days with and without the presence
of 3,5-diMeDβM/βC. We found that 0.3-Tob caused rugose/wrinkled colony morphotype
(diameter, 2 cm), which is caused by Congo red binding to the exopolysaccharides. In contrast,
including 85 µM 3,5-diMeDβM/βC with 0.3-Tob resulted in large colony morphotype that is
similar to normal wild type morphotype in size (diameter, 3 cm) and smooth texture (Fig. 2.4C).
For pellicle formation,84 which represent pel polysaccharide among the three types of
exopolysaccharides, 0.3-Tob caused increased pellicle (3 days without shaking) at air-liquid
interfaces by 60%, whereas including 3,5-diMeDβM/βC (85 µM) completely abolished effect of
0.3-Tob at promoting pellicle formation (Fig. 2.5).
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Figure 2.5 3,5-diMeDβM/C inhibit 0.3-Tob induced pellicles in static wild type P. aeruginosa
cultures. Pellicle formation in wt PAO1 were observed and quantified by Congo red (CR)
binding assay. Pellicles were formed for 3 days under static conditions. Overnight wt PAO1
bacterial cultures were diluted 1:100 in LB medium without NaCl with and without 85 µM 3,5diMeDβM (βM) or 3,5-diMeDβC (βC) in the presence of 0.3 µg/ml tobramycin (0.3-Tob). The
cultures were grown statically (in glass tubes) for 3 days at 37°C. Then Congo red binding by
pellicles was calculated as the difference between absorbance for reference solution containing
the starting concentration of Congo red (40 µg/ml) and the absorbance of the supernatant. Error
bars indicate standard deviations of independent triplicates. The pellicles formed without
tobramycin (0-Tob) was considered as control. *P = 0.02 vs control; **P <0.005 vs control as
evaluated using two-tailed unpaired Student’s t-test.

Subinhibitory concentrations of tobramycin also promote swarming motility in P.
aeruginosa.63 This particular response to antibiotic exposure is intriguing because swarming and
biofilm formation are inversely regulated in P. aeruginosa.74,75 We show that having 0.3-Tob in
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the soft gel (0.5 wt% of agar) caused the swarm area to increase from 24 cm2 to 30 cm2 (about 25
%). When the gel supplemented with 85 µM of 3,5-diMeDβM or 3,5-diMeDβC, the swarming
motility was inhibited entirely in the presence of 0.3-Tob (Fig. 2.4D). Together, these results
showed that 3,5-diMeDβM/βC inhibit both high and low cdG phenotypes that are promoted by
tobramycin.
2.2.3 Inhibition of Tobramycin-Induced Persistent Populations in Biofilms
High doses of antibiotics are often used to kill bacteria in biofilms, which inevitably lead
to antibiotic tolerance and persistence.58,60 We first studied the effect of our molecule on
persistent and tolerant bacteria in unstressed and 0.3-Tob stressed biofilms. We used a reported
isolation method for persistent population,85 for which all biofilms were sonicated for 15 mins in
saline to release the bacteria from the biofilms into a saline solution. The saline solution was
treated with 20 µg/ml tobramycin to isolate the persistent population, which was then
enumerated on agar plates without antibiotics. This procedure kills the viable biofilm bacteria,
including the tolerant population, resulting in isolating the persistent bacteria developed during
the drug/agent treatment of biofilm, which will revitalize in the absence of antibiotics.85 We
found that there were about 10 times more persistent bacteria in 0.3-Tob stressed biofilms
(1.2×105 CFU/ml) than in unstressed biofilms (1.7×104 CFU/ml) (Fig. 2.6A).
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Figure 2.6 Persistent bacterial count in (A) unstressed (0-Tob) and 0.3-Tob stressed biofilms
PAO1 biofilm (24-h) without 50-Tob treatment. Error bars indicate the standard deviations of
means of triplicates. *P < 0.001 vs 0-Tob biofilm. Student’s t-test. (B) unstressed and stressed
PAO1 biofilm (24 h) that were further treated with 50-Tob in LB, with and without 3,5diMeDβM (βM) and 3,5-diMeDβC (βC) for another 24 h. *P < 0.05; **P < 0.01 vs 0-Tob
biofilm. Student’s t-test. The types of biofilms are shown above the bars, and 50-Tob treatments
with and without agents are indicated below. (C) The confocal fluorescent images of unstressed
and stressed biofilms of GFP-tagged PAO1 (24 h), further treated with 50-Tob, and with and
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without 85 µM 3,5-diMeDβM/βC for another 24 h. The biofilms were stained with propidium
iodide dye to show living (green), and dead (yellow/red) bacteria. Scale bar = 20 µm.

To evaluate the effect of high dose of tobramycin on increasing persistent bacteria in a
biofilm, 50 µg/ml tobramycin (50-Tob) was applied to already formed biofilm to kill biofilm
bacteria.85,86 When unstressed and 0.3-Tob stressed biofilms were treated with 50-Tob for another
24 h, about 100 times more persistent bacteria were observed in 0.3-Tob stressed biofilm
(~5.8×106 CFU/ml) than in unstressed biofilm (~5.9×104 CFU/ml) (Fig. 2.6B). These results
indicate that high dose of tobramycin caused certain precursor bacteria in biofilms to transition to
persistent populations. Comparing to without 50-Tob treatment, unstressed biofilm increase the
persistent population by about 3 times; but 0.3-Tob stressed biofilms increase about 48 times.
Together, stressing biofilms with at sub-MIC tobramycin (0.3-Tob) causes considerable amount
of precursor bacteria that can readily transition to persistent populations.
To evaluate the effect of our agents on the persistent population, molecule 1a or 1b (85
µM) was combined with 50-Tob treatment. In the presence of 85 of either 1a or 1b, 50-Tob did
not cause the increase of persistent population seen without the agent (Fig. 2.6B), suggesting that
our agents prevents the development of nascent persistent population caused by high applying
dosage of tobramycin on biofilms.
To further validate the above results, we grew unstressed and 0.3-Tob stressed biofilms of
GFP-tagged PAO1 on polystyrene chips (~1 cm2) and treated the preformed biofilms with 50Tob for another 24 h and monitored the development of live and dead subpopulations by green
and red fluorescence, respectively, by confocal image acquisition. We found that treatment of 50Tob caused about 8 times more dead bacteria in unstressed biofilms than 0.3-Tob stressed
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biofilms. When combining 85 μM 3,5-diMeDβM/βC with 50-Tob, a substantial decrease in live
bacteria, and about 10 times increase in dead bacteria was seen in 0.3-Tob stressed biofilms (Fig.
2.6C).

2.2.4 Killing Tobramycin-Tolerant Bacteria and Preventing Emergence of Nascent Persistent
Bacteria in Biofilms
The rate of killing susceptible populations reveal how drug-tolerant the populations are.
We believe that the nascent persistent population are transitioned from drug-tolerant
bacteria.61,72,87 To explore this transition, and to examine the source of the nascent persistent
bacteria in 0.3-Tob stressed biofilm due to 50-Tob treatment, we performed a time-kill study over
24 h, and used the Minimum Duration for Killing 99.9 % (MDK99.9) of total bacterial population
as a measure of the tolerance of the bacteria.72,87 Treating the 24-h old biofilms with 50-Tob over
24 hours showed a rapid decrease of viable bacteria for the first 18 h, followed by plateaus for
the rest of the 6 h (Fig. 2.7). This biphasic killing curve is consistent with a mixture of
susceptible, tolerant, and persistent population. We found the MDK99.9 for unstressed biofilms to
be about 12 hours, whereas for 0.3-Tob stressed biofilms, about 18 hours (Fig. 2.7), indicating
that there was a higher population of tolerant bacteria in 0.3-Tob stressed biofilms than in
unstressed biofilms.
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Figure 2.7 Percentage of bacterial survival (CFU during 50-Tob treatment/initial CFU) of 0.3Tob stressed biofilms and unstressed biofilms of wt PAO1 (24 h) further treated with 50 µg/ml
tobramycin, and with and without 85 µM of 3,5-diMeDβM or 3,5-diMeDβC, for different time
intervals at 37 °C. Error bars indicate the standard deviations of means of triplicates.

These results indicate that 0.3-Tob stressed biofilm contains high level of tolerant
populations, and the high dose 50-Tob treatment converts these tolerant bacteria into persistent
populations in biofilms. Combining 50-Tob with 85 µM of 1a or 1b reduced the MDK99.9 from ~
18 to ~ 12 hours (Fig. 2.7). This killing rate is similar to that for the unstressed biofilm and
suggests that the molecules enabled 50-Tob to kill the pre-existed tolerant bacteria in the 0.3-Tob
stressed biofilms. Between 18-24 h, the number of viable bacteria started to plateau for all
biofilms. For 0.3-Tob stressed biofilms, with the presence of 1a or 1b, the bacterial count
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reduced to ~3.9×105CFU/ml without our molecules, ~5.8×106 CFU/ml; further confirming that
our molecules prevented the formation of nascent persistent bacteria. Overall, our molecules
enable the high dose tobramycin treatment to reduce 100-fold of persistent bacteria in
tobramycin- stressed biofilms.
To understand the mode of action, we first confirmed that these molecules do not affect
planktonic growth of wt PAO1. We grew the wild type PAO1 in the presence of 85 µM 3,5diMeDβM for 24 hours. We found that 3,5-diMeDβM does not affect growth of wild type P.
aeruginosa (Fig. 2.8).

Figure 2.8 3,5-diMeDβM does not affect growth of wild type P. aeruginosa. The diluted
overnight wt PAO1 culture (1:100) in MHB with and without 85 µM 3,5-diMeDβM were
incubated for 24 h under 250 rpm shaking conditions and optical density OD600 was observed
during 24 h .

The glycolipids 3,5-diMeDβM and 3,5-diMeDβC contains both the hydrophilic sugar
groups and the lipophilic lipid residues, they likely to behave like amphiphiles. The amphiphiles
will self-assemble in aqueous solution beyond critical aggregation concentration.88 Because of
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their amphiphilic character, we characterized the critical aggregation concentrations (CAC) by a
Nile red assay. The Nile red dye is minimally fluorescent in water and fluorescence intensity of
Nile red increases in hydrophobic micellar envirornment.89 We found that 3,5-diMeDβM/βC selfaggregate at 134 and 140 µM, respectively in water (Fig. 2.9). All bioactivities against wild type
P. aeruginosa and their mutants were observed at concentrations lower than critical aggregation
concentration for respective glycolipids molecules.

Figure 2.9 The critical aggregation concentrations for 3,5-diMeDβC, 3,5-diMeDβM, and
SFEG4OH was ~140 µM, 138 µM and 118µM. Nile red fluorescence intensity against
concentration of 3,5-diMeDβC, 3,5-diMeDβM, and SFEG4OH in deionized water. The critical
aggregation concentrations (CAC) correspond to the concentration at the transition of increase of
Nile red fluorescence.

2.2.5 Protein Receptors that Control Opposite Signaling Pathways
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To identify potential proteins that are the receptors to our molecule, we consider type IV
pili and Lectin A protein on bacteria. We believe that inhibition of these receptors also controls
the opposite cdG signaling leading to different phenotypes. From structural point of view, both
proteins bind sugar moieties,90,91 and hydrophobic moieties are reported to be important pili,90
and hydrophobic spacer between multivalent sugar molecules are vital for LecA inhibition.91 In
addition, type IV pili is necessary for swarming and twitching motility;78,92,93 and our molecules
inhibit both motilities. For signaling, P. aeruginosa utilize type IV pili proteins that transduces
environment cues to signaling events leading to different phenotypes 66-68,93-97 and facilitate
horizontal gene transfer.98 In contrast, for biofilm formation, pili appendages initiate surface
attachment that eventually triggers the transition into high cdG phenotypes, which lead to
antibiotic tolerance.66,96 Interestingly, before colonization and biofilm formation, pili-mediated
surface sensing increases the quorum sensing that promote pyocyanin production and induces
type II secretion system.67 These virulent phenotypes are the same low cdG phenotype caused by
dispersing bacteria from the biofilms.69 Small colony variants of P. aeruginosa, which exhibit
high cdG levels, are also hyperpiliated.71 Thus, pili appear to mediate transitions between low
and high cdG levels and are important for virulence production at both end of signaling.
Inadvertently, type IV pili of P. aeruginosa have been shown to assemble over wide range of cdG
levels.94
Another adhesin LecA, is crucial for biofilm formation.91,99-102 The LecA is positively
correlated to biofilm formation.100 The mutant that overproduces LecA forms more biofilms,
whereas the mutant of lacking LecA has low level of cdG and form weak/loose biofilm100. Thus,
LecA mainly correlates high cdG phenotypes, and has been considered as a therapeutic target.101
Chemical inhibition of LecA has led to inhibition of biofilm formation.91,101
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2.2.6 Direct Ligand-Pilin Interaction based on Bacterial Motility Enabled Binding Assay
Type IV pili (TFP) are one of appendages on the surface of bacteria. They are involved in
bacterial movement, such as twitching motility, swarming motility in Pseudomonas and
Neisseria species,96,103 and are essential for microbial adhesion.57,67 As pili are necessary for
swarming and twitching67,78,96 and bind to different carbohydrate moieties;90 we propose that 3,5diMeDβM/βC bind and inhibit pili appendages. We performed four different experiments to test
this hypothesis. First we tested effect of 3,5-diMeDβM/βC on P. aeruginosa motility. P.
aeruginosa exhibit different types of motilities like swarming , twitching, and swimming.96,104-106
We found that 3,5-diMeDβM/βC inhibited swarming motility in wild type P. aeruginosa. (Fig.
2.10). At 3,5-diMeDβM/βC concentrations higher than 10 µM, no swarming motility was
observed.
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Figure 2.10 3,5-diMeDβM/βC inhibit swarming motility of wild type P. aeruginosa Swarming
motility assay; The representative images of swarming motilities wt PAO1 on semisolid gel
(~0.5% agar) with different concentrations of 3,5-DiMeDβM/βC after 24 h. The concentrations
are indicated between the images.

As twitching motility is pili dependent and mutation or defect in pili totally abolish
twitching motility in P. aeruginosa,95,96,103,107 we tested effect of 3,5-diMeDβM/βC on twitching
motility of wild type P. aeruginosa. We discovered that 30 µM of 3,5-diMeDβM/βC inhibited
twitching motility (Fig. 2.11). It has been showed that swimming motility is solely mediated by
flagella, another surface appendage on P. aeruginosa surface.105,106 We observed no effect on
swimming motility of P. aeruginosa in the presence of 3,5-diMeDβM/βC suggesting that these
molecules may not inhibit flagella mediated motility. These results are consistent with molecules
binding to surface appendage pili and inhibiting its function like swarming and twitching
motility.

Figure 2.11 3,5-diMeDβM/βC inhibit twitching motility in wild type P. aeruginosa. 3,5DiMeDβM/βC inhibit pili-mediated twitching motility in wt P. aeruginosa. LB agar plates (1%)
were stab inoculated with a toothpick to the bottom of the plate and incubated for 48 h at 37 ° C
with and without 30 µM 3,5-diMeDβM/βC. The light haze of growth, the twitch zone, at the
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agar-plate interface is a measure of twitching motility (red arrow). The smaller, denser zone
represents surface colony growth. Images were taken under 365/254nm UV irradiation.

Second, as there are no strong synthetic inhibitors reported for type IV pili, and no wellestablished binding assays for ligand binding to pili, we created a new binding assay based on
modifying the swarming motility experiment that studied the direct binding interactions between
pilin proteins and proposed ligand candidates.108 We spread a solution of pilin protein on the
swarming gel surface and examined if the ligand candidate in the gel will be sequestered by the
added protein, depleting the ligands availability on the gel surface. The experimental scheme is
that, as pili appendages on bacteria detect the lack of ligand molecules on the gel surfaces, the
swarming motility changes. We demonstrated that spreading the pilin proteins that are expressed
and purified from a clinical P. aeruginosa strain,109 PA1244N3-pPAC46 (100 µL of 1 mg/mL,
~616 nmol), on the gel surface (0.5% soft agar, 10 cm in diameter) inhibited the swarming
motility of wt PAO1 (Fig. 2.12A).
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Figure 2.12 Images of swarming patterns of wt PAO1 (18 h) on the soft gel (0.5% agar in LB),
(A) with and without spreading 100 µl of 1 mg/ml of pilin or Bovine serum albumin (BSA) on
gel surface, and (B) with the gel containing 15, 20 and 30 µM of 3,5-diMeDβM (1a) and having
100 µl of 1 mg/ml of pilin spread on gel surface. (C) Plot of swarming area of wt PAO1 versus
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concentration of 3,5-diMeDβM (1a) in the gel, with pilin spread on surface. Error bars indicate
the standard deviations of means of duplicates.

This result is consistent with externally introduced pilin proteins on gel surfaces
sequestered the signaling molecule, likely rhamnolipids, that are necessary for swarming
motility,78,80 making them unavailable to the pili appendage on the bacterial surface and
abolished the swarming motility. To test if the expressed pilin proteins bind and sequester our
molecules, we spread the pilin protein on swarming gels prepared with different concentrations
of 3,5-diMeDβM (0-30 µM) and examined the swarming motility of wt PAO1 (Fig. 2.12B, Fig.
2.13). We observed that, while pilin alone or just 3,5-diMeDβM inhibited the swarming motility,
having both pilin on gel surface and the molecule in gel caused the reactivation of swarming
motility of PAO1 over a small range of concentration of 3,5-diMeDβM. With 626 nmol of pilin
protein (100 µL of 1 mg/ml) spread on a gel surface (10 cm in diameter), PAO1 started to swarm
when the concentration of 3,5-diMeDβM was increased to 12 µM in gel. The swarming motility
reached a maximum (as measured by the area of the swarming pattern) around 15 µM of the 3,5diMeDβM and decreased as the concentration was increased further (Fig. 2.12C). This reversal
of swarming motility as a function of concentration of the molecule is consistent with spread
pilin proteins binding and sequestering 3,5-diMeDβM from the gel surface. As the ligand (3,5diMeDβM) concentration increases in the gel, binding with pilin proteins abolishes each other’s
ability to inhibit the pili appendages on bacteria, and thus permitting the swarming motility.
When the concentration of 3,5-diMeDβM was increased beyond binding capacity of added pilin
proteins, the excess ligand molecules inhibit pili appendages on the bacteria, resulting in
reducing the swarming motility again. The peak of around 15 µM of 3,5-diMeβM represents the
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optimal inhibitory concentration against 7.8 nmol/cm2 of pilin on gel. The control protein Bovine
serum albumin (BSA) has no effect on wt PAO1 swarming with and without 3,5-diMeDβM.
Round I

Round II

Figure 2.13 Bacterial Motility Enabled Binding Assay. Externally added pilin protein and 3,5diMeDβM in gel neutralize each other’s swarming inhibition activities. Repetitions of pili-ligand
binding assay. 100 µL of pili protein (1mg/ml) expressed from (PA1244N3-pAC46) was spread
on the surface of 0.5% agar (10 cm in diameter) containing different concentrations (0-30 µM) of
3,5-diMeDβM, followed by bacterial inoculation (3 µL of culture, OD600 = 0.6). Pictures were
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taken after the plates were incubated at 37 ℃ for 12 h and then room temperature for another 12
h. The swarming area was estimated by measuring diameter of swarm area on agar gel.
Third, to directly evaluate the effect of this molecule on the pili appendages of PAO1
surfaces, we examined the proteins sheared from the bacterial surfaces (wt PAO1) on agar gel
(1.5 % agar for growing bacteria),110 prepared with 85 µM of 3,5-diMeDβM. The amount of pilin
and other proteins are characterized by using SDS-polyacrylamide gel electrophoresis (SDSPAGE) with the same protein mass loaded (See experimental section for details). Without
presence of molecule in the hard agar, we observed a band with molecular weight around 16 kD,
same as the expressed pilin protein from PA1244N3-pPAC46 (Fig. 2.14). For agar gel containing
85 µM of 3,5-diMeDβM, only a faint band of 16kD was observed, whereas other proteins
showed intense bands (Fig. 2.14). This result indicated that the presence of 3,5-diMeDβM
reduced the amount of pili on bacterial surfaces. As pili can retract in response to chemotaxis,66,67
we examined the effect of our molecules on a nonretracting transposon mutant of pilin assembly
protein, pilT(pilT::Tn).111 We observed that the pilin bands were equally intense for bacteria
grown with and without 3,5-diMeDβM on agar surfaces (Fig. 2.14) Because our molecules
showed no effect on non-retracting pili, we believe that 3,5-diMeDβM binding to pili likely
caused pilT-mediated retraction.
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Figure 2.14 Sheared surface proteins assay. P. aeruginosa treated with 3,5-diMeDβM have fewer
surface pili. Gel electrophoresis (SDS-PAGE) of sheared surface proteins of wt PAO1, pilT::Tn
grown on 1.5% agar with and without 85 µM of 3,5-diMeDβM. From left to right lanes:
molecular size markers, standard of expressed pilin from PA1244N3-pAC46, proteins from
PAO1 and pilT::Tn without and with 3,5-diMeDβM.
2.2.7 Chemical Inhibition of Type IV Pili Mediated Bacteriophage infection on P. aeruginosa
Last, pili appendages are the key receptor proteins for direct binding and adsorption of
bacteriophage, which facilitate the injection of DNA into bacteria. Lytic bacteriophage ϕKMV
targets specifically type IV pili of P. aeruginosa for adsorption on and subsequent lysis of
bacteria.46, 47 Nonpiliated strain ΔpilA,112 or retraction mutant pilT (pilT::Tn) are resistant to lysis
by bacteriophages.111 Here, we studied the effect of 3,5-diMeDβM/βC on the bacteriophage
ϕKMV adsorption to three P. aeruginosa strains: PAO1k, phage sensitive strain wt PAO1; pilideficient mutant ΔpilA;112 and the nonretracting mutant pilT.111 We found that mixing ϕKMV
(5.8×106 PFU/ml) with excess of PAO1k (2.8 x107 CFU/ml) for 10 min, the phage titer in
supernatant culture was reduced to 6.8×105 PFU/ml, indicative of ~86% of the phage was
adsorbed on PAO1k (Figure 7A). In contrast, culturing bacteria in the presence of 3,5-diMeDβM
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(85 µM), the phage count in solution was 4.2×106 PFU/ml, indicating of only ~16 % of phage
adsorption on PAO1k. For pili deficient mutant, ΔpilA, under the same condition, a low level of
adsorption of added phage (~4.5 %) was observed (Fig. 2.15A). The presence of our agent did
not exhibit a noticeable effect on phage adsorption on ΔpilA. Because of the lack of pili on
ΔpilA, we consider this ~4.5 % as non-pili mediated phage adsorption. Thus, for PAO1k, the pili
mediated phage adsorption is about 86 – 4.5 = 81.5% without the agents, and about 16 – 4.5 =
11.5% with the presence of agents. This result suggests that our agents cause about (81.5 –
11.5)/81.5 = 86 % reduction in bacteriophage adsorption on pili of PAO1. As phage ϕKMV is
lytic phage, we also tested effect of 3,5-diMeDβM on the killing kinetics of ϕKMV on phage
sensitive P. aeruginosa (PAO1k). The kinetics of P. aeruginosa PAO1k which is incubated with
3,5-diMeDβM for 6 h (before phage infection) showed slower rate of lysis (measured as drop in
optical density per time) by phage ϕKMV than control P. aeruginosa (Fig. 2.15B).
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Figure 2.15 (A) Percentage of ϕKMV phage adsorbed on PAO1k (wt PAO1 strain that is
sensitive to ϕKMV) and ΔpilA, pilT::Tn mutants over 10 min in LB containing 85 µM of 3,5diMeDβM (1a). Error bars indicate the standard deviations of means of triplicates. *P < 0.01;
**P < 0.01 vs control without 3,5-diMeDβM (1a), Student’s t-test. (B) ϕKMV phage killing
kinetics against PAO1k (OD600=0.6) cultured with and without 85 µM of 3,5-diMeDβM (1a) for
8 h. The optical density (OD600) of the bacterial cultures were measured every 30 minutes. Error
bars indicate the standard deviations of means of triplicates.
To explore the mechanism of the inhibition of phage adsorption, the study of nonretracting mutant pilT::Tn revealed that high levels of phage adsorption (~87%) were observed
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(Fig. 2.15A). The presence of 3,5-diMeDβM did not exhibit a noticeable effect on phage
adsorption on pilT::Tn. These results further support that our molecules bind and retract pili
appendages of PAO1 – likely by pilT retraction mechanism.111 To corroborate these results, we
used another synthetic molecule saturated farnesol derivative, SFEG4OH, (Fig. 2.1), which
inhibits swarming motility, but not biofilm formation.81 We found that in the presence of
SFEG4OH, phage adsorption on PAO1k pili was also inhibited by ~72% (Fig. 2.16).

Figure 2.16 SFEG4OH inhibits bacteriophage adsorption on P. aeruginosa PAO1k with
functional pili. PAO1k (6x107 CFU/ml) pretreated with and without 60 µM SFEG4OH and
infected with ~106 PFU/ml phage, 10 min, 100 rpm. The phages left in supernatant (not adsorbed
on pili) were quantified by plaque formation assay. The % phage adsorption was calculated as 1(titer in supernatant/ titer of phage added) ×100.112 Error bars indicate standard deviations of
independent triplicates. *P=0.01 vs control as evaluated using two-tailed unpaired Student’s ttest.
We note that while pili deficient mutant ΔpilA was resistant (Fig. 2.17), PAO1k was
killed by phage ϕKMV in 8 h (Fig. 2.15B). The presence of 3,5-diMeDβM, however, caused a
delay of killing of PAO1k by 4 h, and an increase in residual live bacteria after 8 h (Fig. 2.15B).
This result is consistent with the past finding that anti-pilin antibody can delay the killing of
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bacteria by another predator strain through pili binding.113 The control molecule SDS has no
effect on either phage adsorption or phage mediated killing.

Figure 2.17 ϕKMV phage with and without 3,5-diMeDβM does not kill pili-deficient mutant
(ΔpilA). Overnight cultures of ΔpilA were diluted 100-fold, and subcultured with the presence of
10 mM MgSO4, and with and without 3,5-diMeDβM (85 µM), to an OD600 of 0.6, and then
infected with ϕKMV phage (PFU/ml ~108). The optical density (OD600) of the bacterial cultures
were measured after 12 h. Cultures were incubated at 37℃ at 250 rpm.
All in all, pili play different role in motility, receptor for phage adsorption and subsequent
lysis. These four different experiments support that our molecules bind to pilin proteins and
inhibit function of pili appendages on bacteria. Our results also suggested plausible mechanism
for inhibition of pili mediated activities. We suggest that our molecules may target pilT proteins
in pili machinery which is responsible for retraction. This proposition is consistent with literature
that pilT proteins are necessary for motility and extent of surface piliation.
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2.2.8 Ligand binding and inhibition of LecA
We examined the binding of a collection of pili ligands to LecA, including 3,5diMeDβM/βC, rhamnolipids and SFEG4OH (Fig. 2.1), by using an established fluorescence
polarization-based competitive binding assay.114 For this assay, we designed and synthesized a
Dansyl fluorophore-tagged galactose ligand (βGal-aryl-Dansyl, Figure 1) for LecA protein. The
fluorescent polarization of the fluorophore-tagged ligand will increase when bound to a protein
receptor because of the reduction in dynamic and will decrease when the fluorophore ligand is
displaced from the protein by another ligand. The βGal-aryl-Dansyl (200 nM) showed an
increase in its fluorescence polarization with increasing concentrations of LecA (0-100 μM), with
a transition indicative of a Kd ~10.7 μM, whereas for the control protein, bovine serum albumin
(BSA), no significant increase in fluorescence polarization was observed (Fig. 2.18A).
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Figure 2.18 Fluorescence polarization of (A) of 200 nM of βGal-Dansyl versus concentrations of
LecA and BSA proteins, and (B) of 100 uL of LecA (20 µM) and βGal-Dansyl (200 nM) versus
concentration of candidate ligands, 3,5-diMeDβM (βM), 3,5-diMeDβC (βC), SFEG4OH,
rhamnolipids mixtures. Error bars indicate the standard deviations of means of triplicates.

42

To estimate the binding strength of the potential ligands, 3,5-diMeDβM/βC, to LecA
protein, the molecules were titrated against complex of βGal-aryl-Dansyl (200 nM) and LecA (20
μM) to displace the βGal-aryl-Dansyl from LecA. We found that 3,5-diMeDβM and 3,5diMeDβC caused a decrease of fluorescence polarization indicative displacement of βGal-arylDansyl with an IC50 of 15 µM and 13 µM, respectively (Fig. 2.18B). Interestingly, rhamnolipids
and SFEG4OH did not cause a decrease of fluorescence polarization. These results are consistent
with the knowledge that glucose containing disugars are capable of binding to LecA. 115,116
While LecA of Pseudomonas aeruginosa was initially discovered to have an affinity for
galactose, having glucose as part a galactose-glucose disugar can actually increase its binding to
LecA protein as compare to other galactose-galactose disuger.115 More notably, di-glucose linked
by oligo(ethylene glycol) without any galactose groups exhibited considerably strong binding to
LecA.116 Varrot and coworkers has demonstrated that crystal structure with a secondary sugar
binding site for glucose.115 It is important to note that binding to LecA is enhanced by
multivalent array of galactose,99,101,117 and glucose115 The space between the binding sites on
LecA likely play a significant role for binding. Evidently, tethering aromatic groups to single
sugar galactose greatly enhance its binding to LecA.101 Binding does not necessarily impact
activities of respective protein. Inhibition of biofilm by single galactose derivatives or sugar
without attaching groups are often not reported. For our case, β-Gal-Dansyl exhibited a weak
biofilm inhibition,IC50 120 uM,. As indicated by Imberty, Romer, Winssinger’s work on LecA,
the space between the two sugar binding sites has potential to interact with the group attaching
the sugar.101,117
We believe that the branch hydrocarbon chain tethering the cellobioside or maltoside
plays an enhancing role for binding and for controlling LecA’s activity. In this case tethering with
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a hydrophobic group, glucose has an indispensable advantage of high-water solubility over
galactose. This binding effect is an ongoing subject of our research.
To further corroborate for these LecA binding studies, we performed a bacterial motilityenabled binding assay.108 In this assay, we spread LecA on the soft agar gel containing 3,5diMeDβM that inhibited swarming motility. We observed that while the swarming motility of
PAO1 was inhibited completely on gels containing 20 µM of 3,5-diMeDβM/βC, spreading LecA
(100 µL of 1 mg/ml, 780 nmol) on the gel surfaces reactivated the swarming motility (Fig. 2.19).
This result is consistent with LecA binding and sequestering 3,5-diMeDβM/C on the gel surface,
depleting their availability for pili appendages on bacteria, and thus abolishing their swarming
inhibition activities. For pilin binding, in contrast, branched aliphatic chains having different
water-soluble group, tetra(ethylene glycol) (SFEG4OH), or disugar of 3,5-diMeDβM/βC,
supported binding to pili and inhibition of pili-mediated motilities (Fig. 2.13). These results
indicate that 3,5-diMeDβM/βC are chimeric ligands for LecA and pili, whereas SFEG4OH is a
ligand for pili alone.

Figure 2.19 LecA remove effect of 3,5-diMeDβM/C on swarming motility. Swarming of wt
PAO1 on 0.5% agar (10 cm in diameter) containing 20 µM of 3,5-diMeDβM/βC without (a) and
with (b) 100 µL of LecA protein (1 mg/mL) was spread on the agar gel surface. Upon
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inoculation, the plates were incubated at 37 ℃ for 12 h and then at room temperature for another
12 h, followed by taking the pictures.

2.2.9 Chemical Control and Correlation of Receptor Proteins to Their Phenotypes
The chimeric ligands (3,5-diMeDβM/βC) inhibited biofilms and associated tolerance and
persistence, small colony variants, rugose colony, and pellicles formation, as well as swarming
and twitching motility for wild type P. aeruginosa. Because the two motilities are associated with
low cdG levels,75,94,95 whereas other phenotypes are of high cdG levels. We also evaluated other
low cdG controlled virulence factors of P. aeruginosa, including the pyocyanin,76 proteolytic
enzyme-elastase. Pyocyanin production is augmented in low cdG mutants.76 Elastase production
increases during pili sensing a surface,68 We found that pili inhibitor alone, SFEG4OH, reduced
type PAO1’s pyocyanin and elastase levels by 50% and 49%, respectively (Fig. 2.20). This result
makes the correlation of inhibiting pilin proteins to inhibits pili-associated activities that also
associated with low cdG levels.94 The chimeric ligand for both LecA and pili (3,5-diMeDβM/βC)
also reduced wild pyocyanin production by ~60%, and elastase activity by ~45%.

Figure 2.20 P. aeruginosa Virulence assay. (a) Pyocyanin levels in supernatant of planktonic
cultures of wt PAO1 treated with and without 85 µM of 3,5-diMeDβM/βC, SFEG4OH for 12 h in
LB. The pyocyanin levels were measured as µg/ml/OD600 of the bacterial culture. (b) Elastase
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production in the planktonic culture of wt PAO1 treated with and without 85 µM of 3,5diMeDβM/βC, SFEG4OH for 18 h were determined using the Elastin-Congo Red (ECR) assays.
The % of elastase activity was calculated as OD495 (with agent) - OD495 (without agent). (c)
Rhamnolipids productions by planktonic cultures of wt PAO1 treated with and without 85 µM of
3,5-diMeDβM/βC, SFEG4OH for 18 h were determined using an established methylene blue
complexation assays.25 The positively charged methylene blue form noncovalent complex
preferentially with negatively charged surfactants and does not bind to nonionic surfactants. The
methylene blue bound with negatively charged surfactants has an increased partition into the
organic chloroform phase bought in contact with the aqueous solution. The methylene blue in
the chloroform phase were measured for its UV absorbance, which infers the concentration of
rhamnolipids (µg/ml) in the culture.

Overall, the chimeric ligands for LecA and pili proteins inhibited all eight phenotypes
(biofilms, SCVs, rugose colony, pellicles, twitching, swarming motilities, elastase, and
pyocyanin production). In contrast, pili ligand alone, SFEG4OH, has no effect on biofilm, SCV,
rugose and pellicles; but inhibited swarming, twitching motilities, and elastase and pyocyanin
production. These results show that the chimeric ligands (for LecA and pili) inhibit phenotypes
for both high and low cdG levels, whereas pili ligand inhibits only low cdG levels
(Supplementary Table 2). This selective inhibition of LecA and pili enables the correlation
between the phenotypes and the receptor proteins. Because inhibiting pili alone by SFEG4OH
has no effect on biofilms, SCVs and EPS, pellicle formation, these high cdG phenotypes99 are
primarily controlled by inhibition of LecA. In contrast, the low cdG phenotypes, overproduction
of pyocyanin and elastase, as well as swarming and twitching motilities, can be controlled by pili
inhibition alone.
Pili retraction resulted from sensing a surface activates virulence factor regulator (vfr)
gene and type III secretion system, which promotes pyocyanin and elastase, respectively.66,67
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This important knowledge suggests that pili sensing can feedback to signal to the production of
virulence factors correlated with low cdG levels. Our results show that chemical inhibition of pili
not only inhibits activities directly controlled by pili (swarming and twitching motility), and but
also virulence factors (pyocyanin, elastase) that are signaled by pili sensing the environment.
We also evaluated the production of rhamnolipids in the presence of chimeric ligand for LecA
and pili, and pili ligand alone. Rhamnolipids are a special case in the signaling context because
they are needed for structured biofilm,79 which is of high cdG phenotype, but are also necessary
for swarming motility,80 which is of low cdG phenotype.76,80 Interestingly, both SFEG4OH and
the chimeric ligands cause about 5-fold increase in rhamnolipids production, to ~107 µM (Fig.
2.20c), which is close to rhamnolipid’s critical micelle concentration (130 µM).118 Because
pyocyanin and rhamnolipids are inversely regulated in P. aeruginosa,62 and our result shows that
pili inhibition leads to pyocyanin reduction, it is consistent that pili inhibition also lead to
increase in rhamnolipid production. Furthermore, lowering the cdG level leads to rhl quorum
sensing that increases rhamnolipid production,67,69 and lecA inhibition has been shown to
correlated to low cdG;99 thus inhibiting LecA can also promote rhamnolipids production.
Together, these results provide a signaling map identifying the phenotypes of pili and LecA
proteins, and the effects from chemical inhibition of the two proteins (Fig. 2.21, and Table 2.2).
Overall, inhibiting LecA inhibits high cdG phenotypes, whereas inhibit pili suppress low cdG
phenotypes. We note that pili appendages are also relates to drug tolerance as increasing
swarming motility is also known to lead to antibiotic tolerance.64,65
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Figure 2.21 Mapping of chemical inhibition of pili and LecA, and the correlation to their
controlling phenotypes.
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Table 2.2 Ligand correlating phenotypes and corelated receptor.
Ligand
Chimeric,

Pili only,

Inferring

3,5-diMeDβM

SFEG4OH

Receptor

Biofilm

Inhibit

No effect

LecA, not pili.

SCVs

Inhibit

No effect

LecA, not pili.

Rugose colony

Inhibit

No effect

LecA, not pili.

Pellicles

Inhibit

No effect

LecA, not pili.

Twitching

Inhibit

Inhibit

Pili onlyb

Elastase

Decrease

Decrease

Pili onlyc

Pyocyanin

Decrease

Decrease

Pili onlyc,d

Phenotype

a

EPS
High cdG
phenotypes

Swarming

Low cdG

Not LecA as low

phenotypes

cdG promote
pyocyanin.

Both high

Rhamnolipids

Increase

Increase

LecAe

and low
a

Pili, and may be

Protein receptors (Pili and Lectin A) responsible for controlling phenotypes. b low cdG

promotes motility69. c Pili surface sensing induce Vfr, which promotes quorum sensing that
results in promotion of elastase and rhamnolipids66,67,119. d low cdG promotes pyocyanin76.
cdG promotes rhamnolipids76.

Comparing to a previous set of molecules, SFβM/βC (Fig. 1) exhibited stronger
swarming inhibition, but relatively weaker biofilm inhibition than 3,5-diMeDβM/βC. The
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e

low

molecules SFβM/βC also inhibited both high and low cdG activities, including biofilm, SCV and
pellicle formation, swarming and twitching motilities, pyocyanin and elastase A levels; and
promoted rhamnolipids production. These results collectively suggested that small modifications
in hydrophobic region of chimeric ligands can give better control over high cdG phenotypes
without compromising on control over low cdG phenotypes.

2.3 Conclusions
In this work, we showed a class of molecules that bind and inhibit both Lectin A and pili
appendages, and another that inhibit pili alone. We showed the selective chemical inhibition of
bacteriophage’s adsorption on pili appendages, and a label-free assay that identify direct binding
between pilin proteins and chemical ligands. The chemical inhibition of pili appendages likely
causes retraction of pili appendages and inhibits phenotypes that are associated with low cdG
levels. Chimeric ligands inhibit both LecA protein and pili appendages, and phenotypes
associated with both high and low level of cdG. The chimeric ligands also inhibit all the known
tobramycin-induced phenotypes, including enabling the killing of tolerant population and the
prevention of nascent persistent population in biofilm, and the small colony variants that are
specific to tobramycin-stress. Being able to selectively inhibit only pili, and inhibit both pili and
LecA, these chemical tools delineate that pili appendages is important for low cdG phenotypes,
whereas LecA is important for high cdG phenotypes. Overall, these results suggest an adjuvant
approach for existing antibiotics by inhibiting the virulent phenotypes, and a structural
consideration for new drug development. The ligands for pili also present opportunities for
inhibiting horizontal gene transfer and related drug resistance. Finally, the label-free bacterial
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motility-enabled binding assays can be explored for identification and studying new ligandreceptor interactions.

2.4 Synthesis and Spectral Data
The synthesis of 3,5-diMeDβM and 3,5-diMeDβC was performed by fellow graduate student Dr.
Felicia Burns. The generous amount of pure products were supplied to me for further biological
assays.
Materials
3,5-dimethylcyclohexanone (mixer of isomers) 1 and β-D-Maltose octaacetate 9, α-D-cellobiose
octaacetate 8 were purchased from Sigma Aldrich. Standard solvents and reagents were purchased
from commercial sources (Sigma-Aldrich, Fisher, Acros) and used as received. Solvents were
removed in vacuo using Bűchi rotary evaporator below 40⁰C. EMD silica gel 60 F254 pre-coated
plates (0.25-mm thickness) were used for TLC. Unless otherwise stated, TLC visualization was
done using ceric ammonium molybdate (CAM) stain.
1

H-NMR spectra were recorded in deuterated NMR solvents at 400 MHz (1HNMR) and 100 MHz

(13CNMR) Bruker instruments, respectively. 1H chemical shifts are reported in ppm relative to
CDCl3 δ ppm 7.26, CD3OD δ ppm 3.31. 13C chemical shifts are reported relative to CDCl3 δ ppm
77.23 and CD3OD δ ppm 49.0.
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To a solution of 1 (2.78 g, 22 mmol) in dry acetonitrile (6 mL) triethylamine (11.5 mL),
trimethylchlorosilane (4.1 mL) and sodium iodide (4.63 g, 30.9 mmol) dissolved in acetonitrile (29
mL) were added successively. The reaction mixture was stirred at room temperature. After 4 h,
cold water (37 mL) was added and the aqueous solution extracted with cold hexane. The organic
layers were combined and evaporated in vacuo to give 2 as a brown oil. Crude product was
assessed by NMR and deemed pure enough use crude in next step without further purification
(81% yield).

A solution of silver trifluoroacetate (2.09 g, 9.45 mmol) suspended in dichloromethane (9 mL)
was cooled to -78 oC and Compound 2 (1.79 g, 9 mmol) was added dropwise. 1-iodohexane (2.0
g, 9.45 mmol) was then added and the reaction was allowed to warm to room temperature then
after ten minutes the reaction mixture was filtered and concentrated en vacuo. The crude product
was flash chromatographed on silica gel (hexane/AcOEt 95 : 5) to yield 3 as a colorless oil (19%
yield). 1H-NMR (400MHz, CDCl3) δ ppm: 0.87 (3H, t), 0.92-0.97 (6H, d), 1.16-1.48 (10H, m),
1.56-1.75 (2H,t), 1.61-1.90 (2H, t), 2.18-2.35 (3H, m)
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A solution of 3 (160 mg, 0.76 mmol) in dry dichloromethane (2 mL) was cooled to 0ºC and mchloroperbenzoic acid (350 mg, 2.03 mmol) was added. The suspension and trifluoroacetic acid
(0.288 mL, 3.76 mmol) was added dropwise. During this operation, the reaction flask was
protected from light. Subsequently, the solution was allowed to warm to room temperature. After
16 h, the mixture was diluted with dichloromethane (2 mL) and the organic layer was washed
successively with a 10% aqueous solution of Na2SO3 (2 mL), a saturated aqueous solution of
potassium carbonate (1 mL) and water (2 mL). Finally, the organic layer was evaporated in
vacuo and the product purified by column chromatography (9:1 hexanes: ethyl acetate) to give
lactone 4 (46% yield). 1H-NMR (400MHz, CDCl3) δ ppm: δ 0.87 (3H, t), 0.95 (3H, d), 1.00
(3H, d), 1.17-1.59 (12H, m), 1.77-1.92 (2H, d), 2.41-2.54 (2H, dd), 4.29 (1H, td).

Under nitrogen atmosphere, a solution of 4 (1.608 g, 7.58 mmol) in a 10 mM solution in
anhydrous methanol (7.1 mL) was stirred overnight at room temperature. Then, the reaction was
neutralized using H+ amberlite resins. After filtration, the filtrate was evaporated in vacuo to give
the methyl ester 5 as a clear, oily liquid (87% yield). 1H-NMR (400MHz, CDCl3) δ ppm: 0.84
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(3H, t), 0.87-0.92 (6H, d), 0.96-1.24 (13H, m), 2.14-2.19 (2H, dd), 3.45-3.55 (2H, m), 3.65 (3H,
s)

A solution of 5 (1.098 g, 0.25 mmol) in dichloromethane (1.5 mL) was stirred on ice.
Triethylamine (0.23 mL, 1.6 mmol) and mesyl chloride (655 mL, 0.51 mmol) were added. The
mixture was stirred at 0ºC. After 4 h, aqueous NaHCO3 (1N, 1.2 mL) was added and the resulting
solution extracted with dichloromethane. The organic layers were combined and evaporated in
vacuo and the product purified by column chromatography (9:1 hexanes: ethyl acetate)to give
mesylate 6 as a yellowish oil (91% yield). 1H-NMR (400MHz, CDCl3) δ ppm: δ 0.79-0.91 (9H,
m), 1.17-1.34 (13H, m), 2.17-2.39 (2H, d), 2.43 (1H, q) 3.42 (3H, s), 4.27 (1H, td).

To a suspension of LAH (63 mg, 1.7 mmol) in anhydrous diethyl ether (1 mL) at 0ºC, a solution of
6 (68 mg, 0.20 mmol) in anhydrous ether (1 mL) was added. The mixture was brought to room
temperature then refluxed for 16 h. Then, the solution was cooled to 0ºC before quenching with
water. The resulting aqueous layer was extracted with ether. The combined organic fractions were
evaporated in vacuo and the oily residue was flash-chromatographed (hexane/AcOEt 9:1) to yield
alcohol 7 as an oil (53% yield). 1H-NMR (400MHz, CDCl3) δ ppm: 0.54-0.74 (9H, m), 0.86-1.54
(18H, m), 3.32-3.40 (2H,t).
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The cellobiose octaacetate 8 or maltose octaacetate 9 was dissolved in dichloromethane (10mL)
and 7 (2 equivalents) were added. Under vigorous stirring, BF3. etherate (2 equivalents as
compared to maltose or cellobiose monohydrate) was added to this mixture and the reaction
mixture was allowed to stir at rt for 12 h. To the reaction mixture was added aq KBr (10%,
25mL) and PhMe (60mL) under stirring. The organic phase was washed twice with aq. KBr
(10%, 2×25mL), once with aq. NaHCO3 (5%, 25mL) and twice with H2O (2×25mL). Using a
gradient elution (100 % hexane to 35 % ethyl acetate in hexane) the crude product was then
purified through a silica column to yield white powder.
10 (0.20 mg, 30% yield). 1H (400 MHz, CDCl3) δ 5.16-4.98 (m, 3H), 4.85 (q, J1-2 = 8.4 Hz,
2H), 4.48-4.29 (m, 4H), 4.06 - 3.97 (m, 2H), 3.82 - 3.69 (m, 2H), 3.66 -3.50 (m, 2H), 3.44 - 3.34
(m, 1H), 2.07-1.93 (s, 7 X 3H), 1.56 -1.32 (m, 2H), 1.20 (br, s, 18 H), 0.83 (m, 9H).
11 (0.18 mg, 12% yield). 1H (400 MHz, CDCl3) 5.43-5.36 (m, 2H), 5.25 (t, 1H), 5.07 (t, 1H),
4.97-4.79 (m, 2H), 4.53-4.42 (m, 2H), 4.29-4.20 (m, 2H), 4.07-3.85 (m, 4H), 3.70-3.65 (m, 1H),
3.53-3.44 (m, 1H), 2.14-2.01 (s, 7 x 3H), 1.66-1.16 (m, 18 H), 0.89 (br, s, 9H).
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Zemplen deacetylation was used to deprotect the acetylated glycosides. Briefly, acetylated
glycosides were treated with methanolic solution of MeONa (10 mM) followed by neutralization
(pH ~ 7) over H+ amberlite resins. The product was filtered and dried under vacuum overnight to
get white powder.

12, (9.3 mg, 75%) 1H NMR (300 MHz, MeOD) δ 4.38 (d, J = 7.8 Hz, 1), 4.24 (d, J = 7.8 Hz, 1H),
3.83 (br, s, 4H), 3.62 (dd, J1-3 = 12.0 Hz, J1-2 = 5.1 Hz, 1H), 3.56-3.44 (m, 3H), 3.37-3.27 (m,
5H, overlapping with MeOD), 1.25 (br, s, 18 H), 0.86 (m, 9H). ). 13C NMR (75 MHz, CD3OD): δ
102.26, 103.23, 76.72, 76.42, 75.11, 75.04, 73.54, 73.45, 69.97, 67.86, 61.08, 60.54, 37.68, 36.56,
31.67, 29.83, 29.77, 29.65, 29.09, 26.75, 26.65, 22.32, 19.23, 18.48, 13.2.
HRMS (ESI) m/z: Calcd. (C26H50 O11)Na+: 538.68; Found: 537.327526.
13, (6mg, 97%) 1H NMR (300 MHz, MeOD) δ 5.2 (br, s, 1H), 4.27 (d, 1H), 3.95-3.92 (m, 4H),
3.88-3.43 (m, 6H, overlap with CD3OD peak), 3.27-3.20 (m, 4H), 1.79-1.13 (m, 18H), 0.90- 0.87
(m, 9H). 13C NMR (75 MHz, CD3OD): δ 101.54, 101.52, 79.98, 76.50, 75.21, 73.69, 73.35, 72.78,
70.10, 61.36, 60.81, 36.57, 31.67, 29.83, 29.77, 29.65, 29.09, 26.75, 26.65, 22.32, 19.23, 18.48,
13.2.
HRMS (ESI) m/z: Calcd. (C26H50 O11)Na+: 538.58; Found: 537.327637.
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Figure S1: Synthesis scheme for a fluroscent probe, βGal-aryl-Dansyl
4-Aminophenyl β-D-galactopyranoside (0.12 g, 1.2 mmol) in anhydrous DMF (2 mL) was added
to Et3N (0.53 g, 0.53 mmol) in anhydrous DMF (5mL) at 0 ºC. To this solution was added dansyl
chloride (0.41 g, 1.5 mmol). After stirring at 0 ºC for 2 hours, the mixture was concentrated, and
the residue obtained was subjected to the purification by column chromatography DCM:MeOH
9:1 to yield a yellow solid product (0.44 g, 72 %). 1H NMR (400MHz, CDCl3): δ 8.47 (d, 1 H,
dansyl), 8.24 (d, 1 H, dansyl), 8.20 (d, 1 H, dansyl), 7.65-7.69 (m, 2 H, dansyl), 7.39 (d, 1 H,
dansyl), , 6.92–6.81 (m, 4H, ArH), 4.75 (d, J =7.7 Hz, 1H), 4.37 (s, 2H, CH̲2NHR), 3.69 (d, J =
3.1 Hz, 1H), 3.58–3.46 (m, 5H), 2.84 (s, 6H,-CH3).
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Figure S2: 1H NMR spectrum of 3 in CDCl3
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Figure S3: 1H NMR spectrum of 4 in CDCl3
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Figure S4: 1H NMR spectrum of 5 in CDCl3

Figure S5: 1H NMR spectrum of 6 in CDCl3
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Figure S6: 1H NMR spectrum of 7 in CDCl3
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Figure S7: 1H NMR spectrum of 11 in CDCl3
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Figure S8: 1H NMR spectrum of 10 in CDCl3
64
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Figure S9: 1H NMR spectrum of 12 in MeOD
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Figure S11: 1H NMR spectrum of 13 in MeOD
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Figure S12: 13C NMR spectrum of 12 in MeOD
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Figure S13: 13C NMR spectrum of 13 in MeOD
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Figure S14: 1H NMR spectrum of βGal-aryl-Dansyl in CDCl3

Figure S15: Mass spectroscopy by - negative-ion mode electrospray ionization of 12

Figure S16: Mass spectroscopy by - negative-ion mode electrospray ionization of 13
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2.5. Experimental section
Freezer stocks of all strains (Supplementary for Bacterial strains) were stored at -80 oC in
lysogeny broth (LB) with ~20% glycerol. All strains were grown in LB (10 g/l tryptone, 5 g/l
yeast extract, and 10 g/l NaCl) or Mueller-Hinton Broth MHB (beef infusion solids, 2.0 g/l.
casein hydrolysate, 17.5 g/l. starch, 1.5 g/l) at 37 oC with shaking at 250 rpm. All biofilm
inhibition, dispersion assays were performed in LB or MHB medium, and plates were incubated
at 37 oC under static conditions. Stock solutions of 10 mM of 3,5-diMeDβM, 3,5-diMeDβC,
SFEG4OH, and 10 mg/ml of tobramycin sulfate were prepared in sterile (autoclaved) water.
Stock solutions of agent (3,5-diMeDβM, and 3,5-diMeDβC), and non-autoclavable reagents
were further filtered through cellulose acetate syringe filter (0.2 µm pore, Millipore). All
overnight cultures of bacteria were grown in Lysogeny Broth, Miller (LB-Miller, 10 g/l tryptone,
5 g/l yeast extract, 10 g/L NaCl). All biofilm assays were performed by immersing the pegs of a
modified polystyrene microtiter lid of MBEC™ plates (Innovotech, Alberta, Canada) in M63
medium. All the optical density/absorbance measurements were carried out on Biotek ELx800™
absorbance microplate reader (BioTek Instruments, Inc. Winooski, VT).
Blood agar for revealing small colony variants: To prepare the blood agar gel containing
our agents for visualizing small colony variants (SCVs), 1.75 g of premixed powder (Thermo
Scientific™ Oxoid™ Columbia Blood Agar Base) containing peptone mixture 25.1 g/l, soluble
starch 1.0 g/l, sodium chloride 5.0 g/l, agar 12.0 g/l was mixed and autoclaved with 100 mL of
sterile water. The solution was cooled briefly without solidifying and followed by adding 5 mL
of sheep blood (Hemostat) and mixed gently by swirling. Portions of 20 mL of this solution was
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poured into a 50 mL falcon tube, followed by adding 170 µL of a stock solution of agents 3,5diMeDβM/βC (10 mM) to obtain gel solutions containing 85 µM of 3,5-diMeDβM/βC. The 20
mL gel solutions were poured into petri dishes (10-cm diameter) and solidified for inoculation
and visualizing colonies of SCVs.
Strain

Number

Source

P. aeruginosa PAO1 wild

Dr. Guirong Wang

type

(Upstate Medical University)

PAO1-EGFP

Dr. Guirong Wang
(Upstate Medical University)

ΔpilA knock out mutant

Dr. Rob Lavigne
(Katholieke Universiteit Leuven)

pilT transposon mutant

PA0395

PAO1 transposon mutant library
(Manoil lab)

LecA transposon mutant

PA2570

PAO1 transposon mutant library
(Manoil lab)

P. aeruginosa pili source

PA1244N3

Dr. Castric (Duquesne University) &

strain

(pPAC46)

Dr. Horzempa (Liberty University)

PAO1k, phage sensitive

Dr. Rob Lavigne

strain

(Katholieke Universiteit Leuven)

wt PAO1
Lytic Phage ϕKMV specific

Dr. Rob Lavigne

for PAO1k

(Katholieke Universiteit Leuven)

2.5.1 Bacterial strains and bacteriophage used in studies
Table 2.3 Bacterial strains and bacteriophage used in these studies.

72

Here, we describe experiments in this work that are new or modified from literatures.
2.5.2 In vitro Small colony variants assay71
Overnight cultures (100 µL) of wt PAO1 was diluted 10 mL of LB containing 0.3 µg/ml
tobramycin with and without 85 µM 3,5-diMeDβM/βC and incubated at 37°C without shaking
for 6 h. These cultures were serially diluted (105-107) in LB medium and spread on Columbia
blood agar plates (Thermo Scientific™ Oxoid™ Columbia Blood Agar Base (Dehydrated)
supplemented with 5% sheep blood) containing 85 µM 3,5-diMeDβM or 3,5-diMeDβC agar
plates were incubated at 37°C for 1 day.
2.5.3 Bacterial Swarming assay80
The soft gels for swarming motility were prepared by autoclaving 0.5 wt% Bacto Agar in M8
medium (0.6 % Na2HPO4, 0.3 % KH2PO4 and 0.05 % NaCl). The gel solution was cooled to ~60
ºC, supplemented with filtered 0.2 % glucose, 0.5 % casamino acid, and 1 mM MgSO4 (0.22 µ
filter). The gel solutions were poured into a Falcon tube for 20 mL portions, followed by adding
aliquots of (1-20 µL) of 3,5-diMeDβM or 3,5-diMeDβC stock solutions to achieve the desired
concentrations. The falcon tubes were closed, the agar solution was mixed by gently rocking, and
then poured into polystyrene petri dishes (10 cm-diameter). The agar solution was solidified by
cooling and air-drying in a laminar hood for 1 h. Bacterial culture of wild-type PAO1 (3 µL) with
an OD600 between ~0.4–0.6 was inoculated on the center of the surface of the soft agar gel. These
“swarm plates” were incubated at 37 oC for 12 h and then incubated for additional 12 h at room
temperature. After a total of 24 h, pictures of the swarming plates were taken.
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2.5.4 Bacterial motility enabled binding assay
For soft gel prepared for swarming motility (see above), 100 μL of 1 mg/ml pilin, LecA, or BSA
protein was introduced onto the center of the agar gel and immediately spread over the surface of
the ger using a sterile cell spreader. The proteins were prepared in NaPB (4 mM, pH 7.2), TrisHCl (0.1 M Tris-HCl, pH 7.5 and 6 μM CaCl2) and Tris buffer (2 mM Tris, 7 mM NaCl, pH 7.5).
The agar gel spread with protein solution was dried for an additional 30 min. A bacterial
subculture (3 μL, 0.6 OD600) was inoculated on the center of the soft gel (10-cm diameter plate).
The bacteria on the soft gel were incubated 12 h at 37oC and an additional 12 h at room
temperature.
2.5.5 Persistent population isolation assay85,86
An overnight culture (100 µL) of bacteria in LB was diluted in 10 mL of M63 and incubated to
reach an OD600 value of ~0.1. Aliquots (150 μL) of the subculture were added into the wells of
96-well MBEC™ microtiter plate with and without 0.3 µg/ml tobramycin, 85 µM 3,5diMeDβM/βC. MBEC™ pegs were immersed in the bacterial culture and further incubated at 37
°C without shaking for 24 h, to form biofilms. The MBEC™ peg lid was then removed, and pegs
were washed with 0.9% saline to remove unattached or loosely attached bacteria and antibiotic.
The biofilm mass was quantified by crystal violet (CV) dye assay for 6 pegs. The 10 unstained
pegs were cut with sterile plier and suspended in saline water. The saline solution with pegs were
sonicated 15 minutes at 30 kHz (Symphony VWR Internationals Ltd.). Pegs were removed, and
the solutions were centrifuged at 6000 rpm for 10 minutes, to collect the bacteria. The collected
pellets were resuspended and supplemented with 20 μg/ml tobramycin (20×MIC) in MHB
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medium and incubated at 37 ℃ with shaking at 250 rpm for 8 h, to isolate persistent population.
The sample was then centrifuged at 8000 rpm for 10 min at room temperature, to collect the
persister pellet. The supernatant was discarded, the bacterial pellet was washed twice with 0.9%
saline. The number of persistent bacteria w then quantified by counting CFU on MHB agar plate.
2.5.6 Chemical inhibition of bacteriophage adsorption ϕKMV on P. aeruginosa strains111,112
Bacteriophage adsorption assay were adopted as described previously,112 with addition of our
agents. An overnight culture (100 µL) of wt P. aeruginosa strain PAO1k that is ϕKMV sensitive,
knockout mutant ΔpilA, and transposon mutant pilT mutant (pilT::Tn) were diluted with 10 mL
of LB supplemented with 10 mM MgSO4 (LB‐Mg2+) and subcultured to OD600 around 0.6 at
37°C with shaking at 250 rpm with and without 85 µM 3,5-diMeDβM/βC, or 60 uM SFEG4OH.
The bacteria subculture (100µL) was mixed with 900 μL of LB‐Mg2+/ml ϕKMV phage. The titer
of added phage was individually determined for every experiment from the phage stock solution.
Following incubation for 10 min at 37 °C with shaking at 100 rpm, bacteria were removed by
centrifugation (10,000 g, 5 min at 4°C), and 900 μL of the supernatant was transferred to an
Eppendorf tube. The plaque‐forming units (PFU) in the supernatant with and without the added
agents was determined by the top agar overlay method with PAO1k. The percentage of phage
bound to bacteria was calculated as [(titer of added phage − titer in supernatant)/(titer of added
phage)] × 100.
2.5.7 Crystal violet dye-based biofilm assay120
An overnight culture (100 µL) of bacteria in LB was diluted in 10 mL of M63 and incubated to
reach an OD600 value of ~0.1. The bacterial culture (150 µL) was added to the wells of MBEC™
microtiter plate, followed by predetermined volumes of 3,5-DiMeDβM/βC stock solution for
targeted concentrations (6 wells/concentration). The MBEC™ plates were incubated under
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stationary conditions at 37 ℃ for 24 h. After incubation, the pegs were transferred and immersed
into 96 wells containing sterile water (200 µL) twice to briefly rinse the biofilms to remove
unattached or loosely attached bacteria and were dried at 37 ℃ for 30 min. The peg-attached
biofilms were immersed into 96 wells containing crystal violet (CV) dye solution (150 µL, 0.1%)
at ambient temperature for 30 min, to stain the biofilms. The CV-stained pegs were then washed
twice with sterile water (200 µL). To solubilize the CR stains, 150 µL of 30% acetic acid
solution was added to wells, and the pegs was immersed in the wells, the plates were shake on a
microplate mixer (Scilogex MX-M) at 100 rpm for 15 min. The amount of biofilms was inferred
and quantified by measuring the OD600 of the 150 µL acetic acid solution on plate reader. The
absorption from stained pegs containing just M63 medium was subtracted from pegs treated with
agents.

2.5.8 Confocal microscopy of biofilms and image acquisition55,81
In a 24-well microtiter plate, biofilms were grown by placing 100 µL of wt PAO1 culture with
and without tobramycin, and with and without 85µM 3,5-diMeDβM/βC, on polystyrene coupons
(roughly 3/8 in. × 3/8 in.) that were cut from a polystyrene petri dish. The Saran-wrapped plate
was then incubated at 37 oC without shaking. Each polystyrene coupon was then washed gently
by immerging into saline twice and then placed on a microscope cover glass (50 x 24 mm, No. 2,
Fisher Scientific, Pittsburgh, PA). All microscopy images were acquired using a Zeiss LSM
confocal laser scanning microscope (Carl Zeiss, Germany) for monitoring Green Fluorescent
protein (GFP) and propidium iodide (PI) fluorescence.

2.5.9 Colony morphology assay99
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Overnight cultures of wt PAO1 (100 µL) was diluted with 10 mL MHB medium containing 0.3
ug/ml tobramycin with and without 85 µM of 3,5-diMeDβM or 3,5-diMeDβC and cultured
further for 6 h. These cultures (10 µL) were inoculated on a 1 wt% LBNS agar gels containing
0.3 µg/ml tobramycin with and without 85 µM of 3,5-diMeDβM or 3,5-diMeDβC. The agar
plates were incubated at 37°C for 3 days, and images of the colonies were taken. The agar gels
were prepared by autoclaving 1 wt% bacto agar in LBNS medium. The gel solution was cooled
to about 60 ºC, and poured into Falcon tubes for 20 mL, and supplemented with filtered solutions
of Congo red (40 µg/ml), Coomassie brilliant blue dye (20 µg/ml), and tobramycin (0.3
ug/ml), 3,5-diMeDβM or 3,5-diMeDβC (85 µM). The falcon tubes were closed, gently mixed,
and then the agar solution was poured into polystyrene petri dishes (10 cm-diameter,
Fisherbrand™), and solidified at room temperature.

2.5.10 Characterization of rugose and smooth colony morphology of PAO1 caused by 0.3 µg/ml
tobramycin with and without 85 µM 3,5-diMeDβM/βC121,122
The overnight culture (100 µL) of wt PAO1 was diluted in 10 mL LB medium and treated with
and without 0.3 µg/ ml tobramycin with and without 85 µM 3,5-diMeDβM/βC 37 oC with
shaking at 250 rpm for 6 h. The 10 µL of these cultures were spotted on 1 % bacto agar plates
containing 20 mL colony morphology assay medium (1% tryptone; Bacto), with 40 µg/ml Congo
red (CR) and 20 µg/ml Coomassie brilliant blue dyes (EMB). Colonies were incubated at 37°C
for 3 days.

2.5.11 Pellicle formation and quantification122
Pellicle formation assay was adopted as previously described. Briefly, overnight culture (100
µL) of wt PAO1 were inoculated in borosilicate glass tubes (18 mm by 150 mm) containing 10
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mL of MHB supplemented with and without 0.3 µg/ml tobramycin, 85 µM 3,5-diMeDβM/βC.
Tubes were incubated without shaking at 37°C for 3 days. Pellicle formed at the air-liquid
interface was resuspended in 1.5 mL PBS buffer. Congo red stock solution (10 mg/ml) was
added to a final concentration of 40 µg/ml and incubated with shaking for 2 h at 37°C. Following
this incubation, the bacteria were pelleted via centrifugation (6000 rpm, 15 min); and the
absorbance (490 nm) of 200 uL of the supernatant was measured on plate reader. The PBS with
40 µg/ml Congo red was used as the reference to determine the amount of Congo red bound to
pellicles.

2.5.12 Quantification of biofilm bacteria and mass55,81
We quantified the killing of bacteria in biofilms under different chemical treatment (tobramycin
and 3,5-diMeDβM/βC) by CFU counting, and measured biofilm mass by CV dye assay. An
overnight culture (100 µL) of bacteria in LB was diluted in 10 mL of M63 and subcultured to
reach an OD600 value of ~0.1. The bacterial culture (150 µL) was added to the wells of MBEC™
microtiter plate, followed by predetermined volumes of 3,5-diMeDβM/βC stock solution for
targeted concentrations (6 wells/concentration). The 24 h-old biofilm on pegs were transferred to
wells of saline briefly, and then transferred to wells containing 150 µL of fresh M63 medium
containing of tobramycin, 3,5-diMeDβM or 3,5-diMeDβC with targeted concentrations and were
incubated for an additional 0-24 h at 37 oC. The pegs were washed with saline and clipped with
sterile plier. Each condition consisting of 6 pegs was sonicated in 5 ml of saline and serially
diluted in saline followed by plating on LB agar plates for 24 hours for counting colony forming
units. The amount of the biofilms on pegs were measured by using the crystal violet staining
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method described in biofilm inhibition assay. The bacterial count (CFU/ml) was normalized by
amount of biofilm.

2.5.13 Hemolysis assay123
Single donor Human Red Blood Cells (Innovotech) suspension (300 µL) was mixed with
different volumes of 3,5-diMeDβM/C to reach final concentrations of 0-500 µM in PBS buffer,
respectively. mix 300 µL of RBC suspensions with of 30 µL of Triton X (1%) and PBS,
respectively as Positive and negative controls After incubation at 37℃ with 100 rpm shaking for
1 hthe samples were then centrifuged for 2 min at 2000 rpm. The absorbance of 200 µL
supernatant was recorded at 540 nm. % Hemolysis was calculated as (ODsample − ODnegative
control)/(ODpositive control−

ODnegative control) × 100%. Experiments were performed in triplicate.

2.5.14 Critical Aggregation Concentration (CAC) assay124
A 3,5-diMeDβM/βC stock solution (10 mM) was diluted in PBS buffer at various concentrations
(0-200 µM). An ethanol solution (1 μL) of Nile red (2.5 mM) was added to 1 mL assay solution,
and the fluorescence emission was measured on a using Synergy 2 multimode microplate reader
an excitation wavelength of 550 nm after 20 minutes of incubation at 37℃. Fluorescence
intensity was recorded at 635 nm. Experiments were performed in triplicate.

2.5.15 Bacterial Growth as 3,5-diMeDβM as the sole carbon source125
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Wild type P. aeruginosa strain was grown on 1.5 % agar gel containing modified M9 minimal
salts, 3.5 g of NaNH4HPO4·4 H2O, 7.5 g of K2HPO4·3H2O, 3.7 g/liter KH2PO4, and 0.1%
(vol/vol) trace salts solution. One liter of trace salts solution contained 2.86 g of FeCl3·6H2O,
1.98 g of MnCl2·4H2O, 3.31 g of CoCl2·6H2O, 1.47 g of CaCl2·2H2O, 0.17 g of CuCl2·2H2O,
and 0.61 g of ZnCl2. Combinations of either 85µM of 3,5-diMeDβM or 2% glucose were
provided as the sole carbon source. Growth of bacterial colonies was monitored at 37°C for 1-3
days.
2.5.16 Twitching assays126,127
Subsurface twitching assays were modified from previously reported procedures. Briefly, 100 µL
of overnight culture of PAO1-EGFP was diluted in 900 μL of Luria Bertani broth without NaCl
(LBNS). Sterile pipette tips (10 µL) were dipped in this LBNS suspension and were then stabbed
through a one-day-old 1% LBNS agar, with and without 85 µM of 3,5-diMeDβM or 3,5diMeDβC, to inoculate bacteria at bottom of the agar gel. Plates were incubated upright (not
inverted) in an incubator at 37 ℃ for 5 days, and images of the plates were taken under
ultraviolet light (Accuris™ E3000 UV Transilluminator - 302nm) in dark room.
2.5.17 Gel electrophoresis of sheared surface proteins from wild type P. aeruginosa110
The levels of pili on bacterial surface were analyzed by gel electrophoresis as described
previously with slight modifications110. The wt PAO1 and transposon mutant pilT::Tn were
streaked on LB agar plates with and without 85µM 3,5-diMeDβM/βC and incubated at 37 °C for
~ 16 h. The bacterial cells were scraped from the agar gels with glass coverslips and resuspended
in 5 mL of phosphate buffered saline, pH 7.0, with and without 85µM 3,5-diMeDβM/βC,
respectively. The solutions were centrifuged at 6000 rpm for 15 min to collect bacterial cells.
The collected bacterial pellet was resuspended in 1 ml PBS buffer, and vortexed for 30 s to shear
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surface proteins from suspended bacterial cells. The suspensions were transferred to three
separate 1.5 ml Eppendorf tubes and centrifuged at 11,688 x g for 5 min to pellet the bacterial
cells. The supernatant was transferred to fresh tubes and centrifuged at 11,688 x g for 20 min to
further pellet remaining cells. The supernatants were collected in new tubes, mixed with 1:10
volume of 5 M NaCl and 30% (w/v) polyethylene glycol (PEG 8000; Sigma-Aldrich), and
incubated on ice for 90 min, to precipitate the surface proteins. The solutions were centrifuged at
11,688 x g for 20 min, to collect the aggregated proteins. The protein pellets were resuspended in
100 μL PBS buffer and the amount of total surface sheared protein was determined by Bradford
assay that resulted for 120 µg/ml protein mass for wt PAO1 without 3,5-diMeDβM/βC treatment,
and 136 µg/ml for wt PAO1 with 3,5-diMeDβM/C treatment, which were diluted to 120 µg/ml;
and 470 µg/ml for transposon mutant pilT::Tn without 3,5-diMeDβM/βC treatment, which was
diluted to 321 µg/ml, and 321 µg/ml for transposon mutant pilT with 3,5-diMeDβM/βC
treatment. The protein samples (80 µL) were mixed with 150 μL of 1X sodium dodecyl
sulfate (SDS) sample buffer (125 mM Tris, pH 6.8, 2% β-mercaptoethanol, 20% glycerol, 4%
SDS and 0.001% bromophenol blue), and boiled for 10 min, cooled to room temperature; 20 µL
of the sample were loaded to for separation on 15% SDS–polyacrylamide gel
electrophoresis (SDS–PAGE) gels. Proteins were visualized by staining with Coomassie brilliant
blue.

2.5.18 Quantification of phage titer, plaque forming unit (PFU), by top overlay method112
All phage counts were quantified by phage titer using top overlay method to report the plaque
forming units.112 Top agar preparation. Mix 3 mL of warm top agar solution (7 g/l agar, 0.5 g/l
sodium chloride, 10 g/l tryptone, 5 g/l yeast extract in sterile water) and 200 µL of LB culture of
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PAO1k (OD 0.6); spread this mixture solution on 1.5% LB agar plate (LB-Miller, 10 g/l
tryptone, 5 g/l yeast extract, 10 g/L NaCl ,15 g/l agar, 10-cm in diameter). Cool for 15 min in
biosafety level 2 hood to solidify the gel. Serial dilutions of supernatant of containing phage
were prepared in LB-Mg2+. Nine or six drops of 10 µL of the diluted supernatant were placed on
the top agar plates to observe plaques formation on bacterial lawn after 12 h. The number of
plaques were counted and reported as plaque forming units per ml of sample.

2.5.19 Lysis of bacterial cells by bacteriophage ϕKMV112,128,129
The overnight culture (100 µL) of (PAO1k, ΔpilA, pilT::Tn ) was diluted in 10 mL LB medium
with MgSO4 (10 mM) and was grown to mid-log phase (OD=0.5) with and without 85 µM 3,5diMeDβM or 3,5-diMeDβC at 37℃ at 250 rpm. These cultures (OD600 = 0.5) were infected with
φKMV phage (PFU/ml = 3.4×109). The optical density (OD600) of bacterial culture was
monitored over 12 h. The clear bacterial lysate (OD < 0.1) is considered as the end point for lysis
experiment.

2.5.20 Direct binding of fluorescent ligands to LecA114
The fluorescent ligand (βGal-aryl-Dansyl) were dissolved in water to a final concentration of 3
mg/ml. 2 mg LecA (Sigma) was dissolved in 1 mL of 0.1M Tris-HCl pH 7.5 supplemented with
CaCl2 (6 µM). The solution of fluorescent ligand (βGal-aryl-Dansyl, 200 nM) is mixed with
different concentrations of LecA solution (0-100 µM). After incubation for 1 h at room
temperature in dark, fluorescence polarization was measured by using Edinburgh FLS9801
Spectrometer, with the samples being illuminated with vertically polarized light at 330 nm (for
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βGal-aryl-Dansyl). The vertical and horizontal fluorescence components of emission 570 nm
were recorded, and the fluorescence polarization was calculated and data were analyzed using a
four-parameter fit model.

2.5.21 Competitive binding of ligands to LecA114
To a solution of LecA (final concentration: 20 μM) and fluorescent ligand (final concentrations
of βGal-aryl-Dansyl: 200 nM) in 0.1M Tris-HCl pH 7.5 supplemented with CaCl2 (6 μM), serial
dilutions (0.1 μM to 140 μM) of test compounds (SFβM/C, rhamnolipids, SFEG4OH and 3,5diMeDβM/βC) were done. The mixture samples were incubated for 6 hours at room temperature.
The fluorescence polarization was measured using Edinburgh FLS9801 Spectrometer. During
measurement, the samples were illuminated with vertically polarized light at 330 nm (for βGalaryl-Dansyl) and vertical and horizontal fluorescence components were measured, and the
fluorescence polarization was calculated and data were fitted with four parameter variable slope
model.

2.5.22 Elastase assay126,130
Elastase activity in P. aeruginosa culture was determined by an elastin Congo red (ECR) assay
with modifications126,130. Briefly, 100 µL of bacteria from overnight cultures in MHB were
diluted in fresh MHB to an OD600 of 0.01 with and without 3,5-diMeDβM or 3,5-diMeDβC,
SFEG4OH (final concentration: 85 µM). After culturing for 18 h at 37°C with shaking, culture
supernatants were filtered (0.45-µm pore-size filter). Triplicates of culture filtrates (100 µL)
were added to 1 mL of Tris buffer (0.1 M Tris, pH 7.2, 1 mM CaCl2) containing 20 mg of
Elastin-Congo red (Sigma Aldrich). The glass tubes were incubated for 6 h at 37°C with shaking
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at 100 rpm and were added with 0.1 ml of 0.12 M EDTA and placed on ice. Insoluble ECR was
removed by centrifugation at 16,000 rpm and the OD495 of the supernatant was measured.
The elastase activity was reported as OD495 (with agent) - OD495 (without agent).

2.5.23 Rhamnolipid assay118
Quantification of rhamnolipids in planktonic cultures of P. aeruginosa was determined by
methylene blue-rhamnolipid complex assays by an established assay.118 In this assay, the
positively charged methylene blue form noncovalent complex preferentially with negatively
charged surfactants, and does not bind to nonionic surfactants. The methylene blue bound with
negatively charged surfactants has an increased partition into the chloroform phase bought in
contact with the aqueous solution. The methylene blue in the chloroform phase were measured
for its UV absorbance, which infers the amount of negatively surfactants. Briefly, 100 µL
bacteria from overnight cultures in MHB were diluted in fresh MHB to an OD600 of 0.01 with
and without 3,5-diMeDβM or 3,5-diMeDβC, SFEG4OH (final concentration: 85 µM). After 18 h
at 37°C with shaking, culture supernatants were filtered with 0.45-µm pore-size filter (SCBT,
USA). The filtrate pH was first adjusted to 2.3 ± 0.2 using 1 N HCl. The acidified sample was
then extracted with five-fold volume of chloroform. The chloroform extract (4 mL) was
transferred to put in contact with 5 mL of a freshly prepared methylene blue aqueous solution (40
µg/ml, pH pre-adjusted to 8.6 ± 0.2 by adding the 50 mM borax buffer). The pH of this aqueous
solution of methylene blue had been pre-adjusted to 8.6 ± 0.2 by adding the 50 mM borax buffer
(~15 μL). After being vigorously mixed for 4 min, the samples were left to stand for 15 min. The
chloroform phase was transferred into a cuvette and the absorbance was measured at 638 nm
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with a UV/Vis spectrophotometer with a reference of blank chloroform. The absorbance values
were converted to rhamnolipid concentrations using a calibration curve.

2.5.24 Pyocyanin assay131
An overnight culture of PAO1 (100 µL) was added to 10 mL fresh LB medium, 5 mL of which
were grown with and without 85 µM 3,5-diMeDβM, or 3,5-diMeDβC, SFEG4OH for 12 h. The
absorbance of bacterial culture was measured at 600 nm (A600), and then centrifuged to remove
bacterial pellet. Supernatant (5 mL) was extracted with 3 mL chloroform. The pyocyanincontaining chloroform layer was acidified with 2 mL of 0.1 N HCl to give a pink solution, the
absorbance at 520 nm of 200 µL of the solution was measured. The absorbance reading at
520 nm was converted into µg/ml of supernatant with standard curve reported in literature.
Pyocyanin levels were expressed as µg/ml of supernatant/A600 of culture where A600 is
absorbance of bacterial culture.
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Chapter 3 Chemical control over Asialo-GM1: A dual ligand for Pili and
Lectin A that activates swarming motility and facilitates adherence of
Pseudomonas aeruginosa.
3.1 Background and Significance
The bacterium Pseudomonas aeruginosa is one major opportunistic pathogen that
contribute to a wide range of infection conditions, including burnt wounds, nosocomial bacterial
infections 132 cystic fibrosis lung infection 133, and other immune compromised illnesses 134. The
initial contact and adherence to either a host cell surface or any abiotic surfaces is facilitated by
surface bound proteins, and appendages 100,135-144. For P. aeruginosa, type IV pili and lectin
proteins are one of the commonly employed adhesins proteins 137,142. This bacterium interacts
with different small molecules on human epithelial cells, including glycosphingolipids, including
globotriaosylceramide (Gb3) and ganglio-N-tetraosylceramide (asialo-GM1), as well as
receptors protein, such as transmembrane conductance regulator of cystic fibrosis lungs 145-152.
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Type IV Pili of P. aeruginosa are often involved initial attachment to surfaces 136,139,140 and
facilitate transition between motility and irreversible attachment 136. For host infection, pili
recognizes asialo-GM1, asialo-GM2 and related gangliosides present in epithelial cell membrane
and initiate subsequent virulence factors 145-147,153. Surprisingly, P. aeruginosa mutants lacking
pili still adhere to epithelial cells after extended exposure 154 suggesting that additional non-pilus
adhesins on bacterial surfaces are involved in stabilizing host-pathogen interactions, and that
lack of pili may only prevent initial short-term interaction with host cells 141,154.
Another adhesin protein Lectin (LecA) exhibits preferential binding affinity for α-Dgalactosylated glycans and has been shown to interact with wide range of ganglioside molecules
149-151,155

. The interactions between LecA and ganglioside molecules like globotriaosylceramide

(Gb3) leads to the bending of mammalian cell membrane and the entry of bacteria into the cells
are crucial for initiating bacterial infection 149. These findings suggest that LecA and pili may
complement each other for the attachment to and the entry into mammalian cells. As LecA has
binding affinity towards various galactose and glucose terminated lipids 100,155,156, we believe that
LecA can also interact aGM1 and function as a non-pilus adhesin. The adherence of bacteria
caused by pili, are known to lead to a wide range of phenotypes, including motility of twitching
and swarming, as well as biofilm formation 66,136. Furthermore, both pili and LecA have been
shown to act as invasion factor damaging host epithelial cells 138,149. Pili lead to epithelial cell
injury followed by bacterial internalization 157 while LecA induce permeability and growth
defect in epithelial cells 149,158. Considering that bacteria can use more than one adhesin protein
for adherence, controlling multiple adhesin’s binding is important for both understanding the
chemical signaling and phenotypes, and for therapeutic developments.
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Our past studies show that disaccharides tethered with different aliphatic chain structures
can control both swarming motility and biofilm formation of the bacterium Pseudomonas
aeruginosa81,82 81,82. Interestingly, the control of these two bioactivities is extremely sensitive to
the structural changes in the aliphatic chains, and tolerate changes in disaccharide structures
(maltoside or cellobioside) 81. Furthermore, for a multivalent glycopeptide dendrimer binding to
LecA, hydrophobic spacer adjacent to anomeric center of saccharide enhanced binding of the
molecule to LecA, suggesting that hydrophobic regions adjacent to the galactose are also
important for binding 102,117,151. To that end, the artificial liposomes offer a model for studying
ligand-receptor binding on a lipid bilayer that resembles the basic structure of host cell
membrane 159-161. In this model, the contribution of the aliphatic chains to ligand-receptor
binding may be revealed by the change of liposomal membrane structural integrity. Because of
their ability to compartmentalize dye molecules in the internal aqueous environment, liposomal
systems are used to study integrity of membrane 160,161.
In this work, we propose and demonstrate that lectin LecA is also a receptor protein for
ganglio-N-tetraosylceramide (aGM1). We show that aGM1 displaces a synthetic fluorescence
ligand molecule from LecA to solution. Surprisingly, we find that on hydrated gel surface, aGM1
activates swarming motility of a non-swarming rhlA transposon mutant, of Pseudomonas
aeruginosa. In contrast, on solid surfaces, aGM1 facilitates P. aeruginosa’s adherence that is
mediated by binding to LecA or pili protein. A novel bacterial motility enabled binding assay
shows direct binding between unlabeled LecA and pilin to aGM1, for which externally added
proteins (LecA and pilin) inhibit the swarming motility activated by aGM1. We further
demonstrate a class of synthetic dual ligands comprised of saturated farnesol derivatized with
disaccharide (Fig. 1) for LecA and pili appendages inhibits the adherence of wild type P.
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aeruginosa, and mutant strains with no LecA protein (but still has pili), and with no pili protein
(but still has LecA), on aGM1-coated surfaces. We also explored the potential contribution of
the lipid aliphatic chains, by incorporating a small percentage of aGM1 into artificial liposomes
of 1,2-dioleoyl-sn-glycero-3-phosphocholine: cholesterol (DOPC:Chol 65:30 w/w) and studied
the effect of LecA and pili’s binding to aGM1 on the leakage of fluorescent dye, Sulforhodamine
B encapsulated in liposomes.

Figure 3.1 Chemical structures of dual ligands targeting both lectin LecA and pilin of P.
aeruginosa: Asialo-ganglioside-monosialic acid (asialo-GM1), saturated farnesol-β-cellobioside
(SFβC), saturated farnesol-β-maltoside (SFβM) and synthetic fluorescent lectin LecA ligand
βGal-aryl-Dansyl.
3.2 Results and Discussion
Gangliosides, and asialo gangliosides, including asialo-GM1 in general consist of four
sugar moieties, with three galactose at the terminus 151,162. Because LecA has a binding affinity
for galactose, we explore the binding of aGM1 by LecA by five different methods, including a
fluorescence polarization assay that measure the displacement of a fluorophore from LecA by
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aGM1, a label-free bacterial motility enabled binding assay that examine the effect of direct
binding between a protein spread on the surface of hydrated gel, and aGM1 molecules prepared
in the gel, a liposome leakage assay that characterize the effect of LecA on aGM1-loaded
liposome; and the bacterial adhesion and inhibition of a lecA transposon mutant lecA::Tn and a
pili mutant (ΔpilA). Asialo-GM1 on a host mammalian cell is known to bind to pili appendages
and facilitate bacterial adherence 157,163. However, the bacteria’s motility on the surface caused
by the aGM1-mediated adherence is not addressed. Here, by including the aGM1 in hydrated
gels, we examine that effect of aGM1 on the swarming motility of the bacteria. By incorporating
the aGM1 in an artificial liposome, we also examine the effect on pili binding on the leakage of
liposome.
3.2.1 Asialo-GM1 is a specific ligand for Lectin A.
We have reported molecules of disugar tethered with methyl-substituted aliphatic chains
that inhibit swarming and biofilm formation 81. We propose that these molecules bind to both
LecA and pili appendages, as a class of synthetic dual ligands for both proteins. Here, we use
fluorescence polarization to demonstrate a specific binding between LecA and aGM1, SFβM and
SFβC. An efficient one-step synthesis resulted in a fluorescently labeled ligand βGal-aryl-Dansyl
that binds to LecA. Direct titration with increasing amounts of LecA to 200 nM βGal-arylDansyl, caused an increase in the fluorescence polarization of the dye with a transition to plateau
of signals indicative of a binding constant of 10.7 µM between the fluorescent ligand and LecA
(Fig. 3.2). A half maximal inhibitory concentration (IC50) of our synthetic molecules against
βGal-aryl-Dansyl were determined by competitive binding assay, in which small molecule ligand
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candidates displace the fluorescent ligand, resulting in increasing the tumbling motion of the
dissociated fluorescent ligands, and a decrease in fluorescent polarization signal.

Figure 3.2 βGal-aryl-Dansyl binds to Lectin A. Titration of βGal-aryl-Dansyl with increasing
Lectin (LecA) and bovine serum albumin (BSA) proteins. Dissociation constants were obtained
from four parameter fitting procedure to the dose-dependent increase in fluorescence
polarization. βGal-aryl-Dansyl showed binding to LecA (Kd = 10.7 ± 0.8 µM) while showed no
binding to bovine serum albumin (BSA) protein.
The ligand candidates, aGM1, SFβM and βC, were titrated into a mixture of βGal-arylDansyl (200 nM) and LecA (20 μM). We found that SFβM and SFβC caused a decrease of
fluorescence polarization indicative of an apparent IC50 of 17 µM and 16 µM, respectively,
whereas aGM1 showed apparent IC50 of 42 µM, against β-Gal-aryl-Dansyl-LecA complex (Fig.
3.3). Detailed studies of the fluorescence polarization for LecA protein revealed that the IC50
values for galactoside ligands varied between 10 -100 µM and are highly sensitive to both the
ligand structures of galactose derivatives, and to the fluorescent probe structures tethered on the
galactose 114,155. Thus, comparing two IC50s reflect a relative binding strength of two ligand
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molecules to LecA, but does not necessarily reflect the impact on the LecA folding structure and
thus on its bioactivities.

Figure 3.3 Binding of asialo-GM1, SFβM and SFβC to Lectin A protein. The fluorescent probe
β-Gal-Dansyl-LecA displacement assay with asialo-GM1, SFβM and SFβC. 100 µL of LecA (20
µM) and β-Gal-Dansyl (200 nM) versus different concentrations of ligand asialo-GM1, SFβM
and SFβC. Error bars indicate the standard deviations of means of triplicates.
3.2.2 aGM1 activates swarming motility, which is inhibited by LecA and Pilin spread on gel
surfaces
The type IV pili is responsible for two types of motilities in P. aeruginosa viz. twitching
and swarming. These pili mediated motilities were important for P. aeruginosa cytotoxicity
against epithelial cells and for virulence in vivo 164 . Rhamnolipids, a class of self-secreted small
molecule by P. aeruginosa 79,80, is necessary for swarming motility; mutant with impaired
rhamnolipid production does not swarm 79,80. When exogenous rhamnolipids are added to
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hydrated gel, the swarming motility of nonswarming mutant rhlA is reactivated

79,80,82

. Here, we

evaluate the effect of aGM1 on swarming motility of this bacterium. We discovered that aGM1
activates and modulates the swarming motility of rhlA mutant as a function of concentration in
the hydrated agar gel (Fig.3.4 and Fig. 3.5A). At 10 µM, aGM1 started to activate swarming
motility and swarm area was increased from 1.5 to 5.3 cm2. As concentration increased to 20-60
µM, aGM1 caused more tendrils formation with an increase in swarm area from 8.12 to 34.22
cm2 (Fig. 3 and Fig.S2). At 80 µM, aGM1 resulted in defined and dense tendrils with a similar
swarming area of 34.42 cm2 (Fig. 3.4).

Figure 3.4 Asialo-GM1 activates and modulates swarming of P. aeruginosa rhamnolipid
deficient rhlA mutant. Swarming motilities rhlA mutant on semisolid gel (~0.5% agar) with
different concentrations of aGM1 in DMSO was observed after 24 h. The swarming area was
estimated by measuring diameter of swarm area on agar gel and plotted against respective
concentration of aGM1 used in swarm gel. The average of two independent experiments was
plotted and error bars representing standard error from the mean.
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This result is consistent with possibility that both aGM1 and rhamnolipids are specific
ligands for pili appendages, and binding of both small molecules activate swarming motilities,
but with different characteristics. Rhamnolipids prepared in the hydrated gel start to activate
swarming motilities at 5 µM and inhibit swarming motilities as the concentration increases to
about 30 µM. The patterns of the swarming bacteria activated by rhamnolipids are radial and
without formation of tendrils. Asialo-GM1 activates swarming motility around 10 µM and
causes formation of increasingly large tendrils as concentration increases. We believe that the
tendrils are caused by the formation of two different phenotypes, the hyper swarming, and lazy
swarming phenotypes, while the original normal swarming phenotype is abolished. This subject
is of our current research. To corroborate the binding hypothesis, we apply a label-free bacterial
motility-enabled binding assay to examine the effect of direct binding interaction between aGM1
prepared in gel and protein (LecA or pilin) spread on the gel surface on the swarming motility.
We propose that when a protein (spread on the gel surfaces) selectively recognizes the ligand
molecules from the gel surfaces, their binding may sequester the ligands molecule, and deplete
their presence on and near the gel surfaces, because, in a gel, the diffusion is slow, and replenish
the molecule from the bulk to surface is ineffective. In the absence of ligand molecules, the
swarming motility is abolished.
We observed that while the swarming motility of rhlA mutant was activated on gels
containing 10 µM of aGM1, spreading Pili or LecA (100 µL of 1 mg ml-1), about 626 and 780
nmol, respectively, on the gel surfaces (10-cm in diameter) abolished the swarming motility (Fig.
3.5B). This result is consistent with pilin and LecA bind and sequester aGM1 on the gel surface,
depleting their availability for pili appendages on bacteria, and thus abolishing the swarming
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motility of rhlA mutant. Spreading a solution of bovine serum albumin (BSA) protein has no
effect on swarming motility of mutant in the presence of aGM1. This set of results indicates a
direct interaction between the lecA or pilin protein with aGM1, for which the swarming motility
activated by aGM1 is inhibited.

Figure 3.5 Swarming motility assays. Asialo-GM1 activates and modulates swarming of P.
aeruginosa rhamnolipid deficient rhlA mutant.(A) Swarming motility assay; The representative
images of swarming motilities rhlA mutant on semisolid gel (~0.5% agar) with different
concentrations of asialo-GM1 in DMSO after 24 h. The concentrations are indicated between the
images. (B) Asialo-GM1 binds to Lectin A protein and Pilin. Images of swarming patterns of
rhlA mutant (18 h) on the soft gel (0.5% agar in LB) with the gel containing 10 µM of aGM1 and
having 100 µl of 1 mg ml-1of pilin, LecA or BSA spread on gel surface.
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As pili are necessary for twitching motility in P. aeruginosa 92,164,165, we also examined
the effect of aGM1 on twitching motility. Asialo-GM1 (10 µM) promoted twitching motility by
about 14 % based on the sub-surface twitch zone area (Fig. 3.6). This result is consistent with
aGM1 binds to pili of the bacterium, and likely promote the extension-retraction dynamics of the
pili appendages on the bacterium. In P. aeruginosa, twitching motility is required for the initial
attachment and pathogenesis 165. This result showed that pili binding to aGM1 does not just
facilitate adherence, but can also initiate twitching or swarming motility, and lead to virulence
signaling related to motilities 66,166,167.

Figure 3.6. Asialo-GM1 and SFβM/βC affects pili-mediated twitching motility. aGM1 promotes
twitching motility while SFβM and βC inhibit twitching motility. LB agar plates (1%) were stab
inoculated with a toothpick to the bottom of the plate and incubated for 48 h at 37 ° C with and
without 10µM aGM1 or 20 µM SFβM or βC. The light haze of growth, the twitch zone, at the
agar-plate interface is a measure of twitching motility (red dashed circle). Twitch zone is
measured as area of red circle. The smaller, denser zone represents colony growth. Images were
taken under UV lights.

3.2.3 Synthetic ligand and aGM1 reduces phage adsorption on pili
Pili appendages are the key receptor protein for the adsorption of bacteriophage and lysis
of bacteria 112. Lytic bacteriophage ϕKMV requires specifically type IV pili of P. aeruginosa for
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adsorption 112. Here, we studied the effect of aGM1 and SFβM and βC on the adsorption of
bacteriophage ϕKMV to a known phage sensitive P. aeruginosa strain, PAO1k 112. We found
that mixing bacteriophage ϕKMV (1.6×106 PFU ml-1) with excess of PAO1k (2.0 x107 CFU ml1

) for 8 min and removing the bacteria and adsorbed phage from the culture, the remaining phage

titer in supernatant was reduced to 1.2×105 PFU ml-1, indicating that ~93% of the phage was
adsorbed on PAO1k (Fig. 3.7). In contrast, culturing bacteria in the presence of 20 µM of SFβM
or βC, the phage count in solution was 1.2×106 PFU ml-1, indicating that only ~25 % of phage
was adsorbed on pili of PAO1k. This result indicated that SFβM or βC (20 µM) inhibited phage
adsorption on pili appendages by 73%. Presence of aGM1 (10 µM) showed weaker impact on
phage adsorption (82% of phage was adsorbed on PAO1k). While SFβM or βC showed a strong
inhibition of phage adsorption (and twitching, swarming motility), aGM1 had a weak impact on
phage adsorption, and promoted twitching motility, modulated swarming motility. These results
are consistent with the notion that both molecules bind to pili appendages but have an opposite
effect on the pili-mediated activities.
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Figure 3.7 Phage adsorption assay. aGM1 and SFβM or βC binds to pili aGM1. aGM1 has no
effect on phage adsorption while SFβM or βC inhibit phage adsorption. Percentage of ϕKMV
(~106 PFU ml-1) phage adsorbed on PAO1k (wt PAO1 strain that is sensitive to ϕKMV) over 10
min in LB containing 10 µM aGM1, or 20 µM of SFβM or βC. Error bars indicate the standard
deviations of means of triplicates. *P < 0.05; **P < 0.01 vs control, Student’s t-test.

3.2.4 LecA and pilin monomer cause leakage of aGM1-loaded liposomes.
Both the binding strength study of galactose derivatives by fluorescence polarization114
and the development of multivalent ligands to LecA 156 indicated that nonpolar groups attached
to the galactose have a substantial impact at increasing the binding to LecA protein. To explore if
aGM1’s lipid aliphatic chains also contribute to binding to Pili and LecA proteins, we conducted
the binding by incorporating aGM1 into artificial liposomes 159. Substantial interaction between
fatty hydrocarbons and proteins such as lipoproteins can results in compromise membrane and
leakage of the liposome causing the encapsulated molecules to escape from the interior aqueous
compartment of the liposome 168. We prepared liposomes consist of 1,2-dioleoyl-sn-glycero-3phosphocholine:cholesterol (DOPC:Chol 65:30 w/w) with and without 5% asialo-GM1 as
membrane component 161. The soluble dye Sulforhodamine B (50 mM) was encapsulated in the
liposomes, in which the fluorescence was inhibited by self-quenching 161. When the liposomes
containing 5 % of aGM1 were treated with LecA and pili proteins (1 mg ml-1) for 1 hour, 70%
and 55% leakage of Sulforhodamine B, respectively, was observed (Fig. 5). Without aGM1 in
the liposome, the same treatment with pili and LecA, only 10% of leakage of Sulforhodamine B
was observed (Fig. 5). Here, we used 0.1% triton X-100, a nonionic surfactant, to lyse the
liposome, and treat this lysis-caused leakage as 100 % as the basis for comparing the effect by
protein binding to aGM1 on liposomes 159,160. These results indicate that pili and LecA recognize
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and bind asialo-GM1 component from lipid membrane of liposomes and cause a leakage in the
membrane. Gangliosides like GM1,GM3 exhibit a non-uniform distribution and forms clusters in
artificial liposomes 169-171, and receptor protein binding are known to interact with gangliosides
and cause changes in membrane curvature which may lead to transient leakage 159,172-174. Thus,
the leakage of membrane system can be the result of receptor protein binding induced
restructuring of lipid bilayer, or clustering of ligand, or partial extraction of the ligand molecules
from lipid membrane. Interestingly, antibodies against aGM1 and BSA only resulted in minimal
leakage (12-15%) (Fig. 5). This result implies that binding does not necessarily lead to disruption
of lipid membrane and adhesin proteins binding to aGM1 possibly involves changes in
membrane curvature.
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Figure 3.8 Pili and LecA proteins bind to asialo-GM1 and interact with asialo-GM1 from
liposomes membrane. 100 µL saline solution of liposomes (w/ and w/o aGM1 as part of the lipid
bilayer) encapsulating 100 mM Sulforhodamine B, was mixed with a. 100 µl of 0.1 mg ml-1
(pilin or LecA) and 0.5 mg ml-1 BSA and anti-asialo-GM1 antibody for 1 h at room temperature.
The mixture was incubated in dark at ambient temperature for 1 h. The fluorescence
measurement was made at λex 565nm; λem 585 nm. As a control for 100% of liposome lysis and
leakage, 0.1% Triton-X was used. Percentage of (%) of liposome leakage was calculated as
(fluorescence after incubation – fluorescence before incubation) / fluorescence after incubation
with 0.1% Triton-X ×100.
3.2.5 Synthetic inhibitors for LecA and pili reduce bacteria adherence on aGM1-coated surfaces
With aGM1 binding to LecA and pili proteins, we examined the adherence of wild type
P. aeruginosa (wt PAO1), lecA transposon mutant, and knockout pilA mutant on aGM1-coated
surfaces. These two mutants provide means to study the impact of each adhesin protein on aGM1
mediated adherence. as the pilA mutant still has LecA protein; and the lecA mutant still has
surface pili. Here, we also study the inhibition of the adherence of these strains on aGM1-coated
surfaces by small molecule ligands, SFβM and SFβC. We cultured ligand-pretreated bacterial
cultures in aGM1-coated wells for 1 h followed by rinsing to remove unadhered bacteria. The
residual adhered bacteria were resuspended in fresh LB media by sonication and then
enumerated by Colonies Forming Units (CFU) counting on LB agar plates. We found that about
6.2×105 CFU ml-1 wt PAO1 adhered on aGM1-coated wells, whereas for lecA and pilA mutants
substantially lesser adherent bacteria were observed, about 3.4×104 and 5.2×103 CFU ml-1,
respectively. These results indicate that both LecA and pili protein contribute the bacterial
adherence on aGM1-coated surfaces.
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Figure 3.9 Bacterial adherence assay. Number of bacteria (CFU ml-1) adhered on 2 µg ml-1 (100
μL) asialo-GM1 coated 96 well plate surface. The bacterial strains wt PAO1, pili, and LecA
mutants (CFU ml-1 = 107) were cultured with and without 20 µM SFβM or βC for 1 h, and the
cultures were incubated in wells coated with aGM1 for 1h. The adhered bacteria were counted by
colony forming units on LB agar plates. For antibody adherence assay, the aGM1-coated wells
are incubated with a PBS buffer containing 0.5 mg ml-1 anti-asialo-GM1 IgG antibody for 15
min. The wells were rinsed and added with bacterial culture (wt PAO1, pili, and LecA mutant
CFU ml-1 = 107) for 1 h.
To study the chemical inhibition of bacterial adherence, we first examined the effect of
blocking the aGM1-coated well surface with the anti-asialo-GM1 antibody (100 μL, 0.5 mg ml101

1

). We found that the adherence of wt PAO1 was reduced to about 2.2×102 CFU ml-1 (from 6.2 x

105 CFU ml-1). In comparison, when the wt PAO1 was pretreated with SFβM or βC (20 µM), the
bacterial adherence was reduced nearly to 8.8×102 and 1.2×103 CFU ml-1, respectively (Fig. 3.9).
These results indicated blocking the aGM1 by its antibody reduced the bacterial adherence by
1000 times, whereas bacterial pretreatment with dual ligand of SFβM or βC, reduced the
adherence by about 100 times. For lecA and pilA mutants, pretreatment with SFβM (or βC)
further reduced the bacterial adherence by 100 and 10 times, respectively (Fig. 3.9). These
results indicated that lecA and pilA, each mutant exhibits considerable adherence to aGM1coated surface, and these adherences can be further inhibited by the dual synthetic ligand SFβM
and SFβC.
3.2.6. Binding, and inhibition, of LecA and pilin proteins to aGM1-coated surface
We studied the direct binding between LecA and pilin proteins, and aGM1 coated on
microplate surface 175, and the chemical inhibition of this binding by the synthetic dual ligands,
SFβM and βC. The commercially obtained LecA and expressed pilin monomer protein were
modified by PEGylated biotin 150,175. First, to validate direct binding of LecA protein and pilin
protein to aGM1, we incubated aGM1-coated surfaces (100 µl, 2 µg ml-1 in chloroform,
overnight) with solutions of biotin-tagged LecA or biotin-tagged pilin (100 µL, different
concentrations from 0.1 to 5 µg ml-1 in PBS buffer) for 1 h. The wells were rinsed with PBS to
remove unbound proteins and treated with 4'-hydroxyazobenzene-2-carboxylic acid (HABA)bound avidin, which exhibit a strong absorbance in solution. When HABA-bound avidin bind to
biotinylated proteins on surface, the chromophore HABA is displaced into solution by biotinavidin binding. Upon dissociating from the avidin, the free HABA exhibit a low absorbance. We
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found that saturation of binding curves were obtained when the concentration of both LecA and
pilin monomer reached ~ 1.0 µg ml-1 (Fig. 3.10). The binding curves also suggested that aGM1
may have a stronger binding constant for LecA (Kd of 0.44 µg ml-1) than that for pilin monomers
(Kd of 0.82 µg ml-1). These results are consistent with LecA being more effectively interacts with
aGM1 than pilin monomers from aGM1-loaded liposomes.

Figure 3.10 Asialo-GM1 is ligand for Pili and LecA. Aliquots of (A) biotinylated pili or (B)
LecA were added to the aGM1-coated wells (100 µL per well) to reach different concentrations
(0.1 to 5 µg ml-1) and were incubated for 1 h at 37ºC. The amount of adhered biotinylated
proteins was measured by HABA-Biotin assay (Pierce™ Biotin Quantitation Kit).

To evaluate the binding of synthetic ligands SFβM or βC to LecA and pilin monomer, we
incubated biotinylated LecA or biotinylated pilin with different concentration of SFβM or βC for
1 h. The aGM1-coated wells were then treated with these protein-ligand commixture for another
1 h. The amount of bound biotinylated proteins was estimated by HABA-avidin solution as
described previously. We found that SFβM (or βC) inhibited the binding of biotinylated LecA
and biotinylated pili binding to aGM1-coated surfaces by IC50s around 15 (17) µM and 24 (26)
µM, respectively (Fig. 3.11). These results demonstrated that SFβM and βC are synthetic dual
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ligands for pili and LecA and are consistent with their excellent ability to inhibit aGM1 mediated
bacterial adherence.

Figure 3.11 SFβM and SFβC inhibit pilin monomer and LecA binding to aGM1-coated black 96
wells. % inhibition of binding of biotinylated pilin (A) and biotinylated LecA (B) against
concentrations of ligands SFβM and βC. The two proteins were incubated with the ligands for 1
h, and the mixture of ligand-proteins were introduced to the aGM1-coated wells and incubated
for another 1 h (see experimental for details).

In this work, we note four findings and their implications. First, aGM1 activate the
swarming motility and promote twitching motility of P. aeruginosa. Bacteria respond and
counter to external stimuli by emergence of phenotypes that are associated with either high or
low levels of a global messenger small molecule 3',5'-cyclic diguanylic acid (cdG)

176

. Both

swarming and twitching motilities are governed by low cdG levels and associated signaling,
whereas adherence of bacteria often leads to biofilms formation which is governed by high cdG
signaling. Thus, aGM1 can demonstrate dual functions: facilitating motilities or supporting
adherence. Second, aGM1 also bind to LecA protein. LecA mediates adhesion of bacterial cells
to the epithelial tissue surface resulting in colonization, which may subsequently lead to biofilm
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formation 100. LecA protein appears to associate only with high cdG levels and related signaling
pathways 99. The LecA is positively correlated to biofilm formation 99,100. The mutant that
overproduces LecA forms more biofilms, whereas the mutant of lacking LecA has low level of
cdG and form weak/loose biofilm 100. Thus, bacteria likely can utilize the expression levels of
LecA and pili to tune and determine the outcome of adherence or motility. Third, besides
adherence and motilities, bacteria are known to enter the host cells. Such entry is often initiated
by adhesins binding to specific host cell receptors followed by internalization, or by bacteria
secreting and injecting proteins that mimic or hijack specific host cell factors to trigger the
bacterial uptake process 177. Our results here demonstrate that both LecA and pili can selectively
bind aGM1 from the lipid bilayers in an artificial liposome system. This binding may serve as an
important step for either of the two mechanisms of bacteria’s entry into the host cells. At the
molecular level, we believe that aliphatic chains of aGM1 likely contribute to its binding to LecA
and pilin. Finally, as aGM1 is dual ligand for LecA and pili, the binding sites of the proteins to
ligands share certain common features. Here, we demonstrate that a class of strong synthetic
ligands for LecA and pili can inhibit the function of both proteins and provide an effective
inhibition for bacterial activities over a broad level of cdG signaling.
3.3 Conclusions
While aGM1 is known to bind pili, here we showed that aGM1 also bind to LecA. We
demonstrated that aGM1 activates and modulates the swarming motility of non-swarming rhlA
mutant, promotes sub-surface twitching motility of wild type P. aeruginosa, and has a weak
effect on the adsorption of pili-specific bacteriophage on PAO1k. These results suggested that
aGM1 binding to pili can cause different bioactivities. A label-free bacterial motility-enabled
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binding assay revealed that both pilin and LecA proteins can sequester aGM1 from hydrated gel
surface and abolish aGM1 activated swarming motility. Both pilin and LecA proteins caused
leakage of artificial liposomes containing aGM1 as a lipid component, whereas BSA and antiasialo-GM1 antibody did not show a similar effect. These results showed that both pilin and
LecA bind to aGM1, and likely also recognize the aliphatic chains of aGM1, and cause leakage
of aGM1-loaded liposomal system. Synthetic dual ligands, SFβM or βC for pili and LecA
inhibited phage adsorption on pili appendages. These synthetic molecules inhibit swarming
motility, also inhibit the surface adherence of P. aeruginosa that is mediated by either LecA or
pili appendages, providing an opportunity for therapeutic development.
3.4 Experimental section
All overnight cultures of bacteria were grown in Lysogeny Broth-Miller (LB-Miller, 10 g
L-1 tryptone, 5 g L-1 yeast extract, 10 g L-1 NaCl). All the optical density/absorbance
measurements were carried out on Biotek ELx800™ absorbance microplate reader (BioTek
Instruments, Inc. Winooski, VT). The asialo-GM1 (98%), Sulforhodamine B dye was purchased
from Sigma Aldrich and dissolved in chloroform: methanol (1:1) mixture and PBS buffer
respectively for microtiter plate and liposomal assays. FITC tagged polyclonal rabbit anti-asialoGM1 IgG was purchased from Wako Pure Chemicals (Osaka, Japan). Cholesterol and DOPC
lipids were purchased from Avanti Polar Inc. For swarming assay and fluorescence polarization
assay, aGM1 was dissolved in dimethyl sulfoxide filtered through cellulose acetate syringe filter
(0.2 µm pore, Millipore).
P. aeruginosa LecA protein was purchased from Sigma Aldrich. Pili protein was
expressed and purified according to literature.178,179 EZ-Link NHS-PEG4-Biotin and Slide-ALyzer™ G1 Dialysis Cassettes, 1K MWCO were purchased from ThermoFisher Scientific. The
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fluorescent ligand βGal-aryl-Dansyl and SFβM/SFβC were synthesized as per literature with
slight modifications 81. Stock solutions of 10 mM of SFβM, SFβC and βGal-aryl-Dansyl were
prepared in sterile (autoclaved) water. Stock solutions of agents and non-autoclavable reagents
were further filtered through cellulose acetate syringe filter (0.2 µm pore, Millipore).
3.4.1 Competitive binding of ligands to LecA by fluorescent polarization
To a solution of LecA (final concentration: 20 μM) and fluorescent ligand (final concentrations
of βGal-aryl-Dansyl: 200 nM) in 0.1M Tris-HCl pH 7.5 supplemented with CaCl2 (6 μM), serial
dilutions (0.1 μM to 140 μM) of test compounds (SFβM and SFβC) were done. The mixture
samples were incubated for 6 h at room temperature. The fluorescence polarization was
measured using Edinburgh FLS9801 Spectrometer. During measurement, the samples were
illuminated with vertically polarized light at 330 nm (for βGal-aryl-Dansyl) and vertical and
horizontal fluorescence components were measured, and the fluorescence polarization were
fitted with four parameter variable slope model 114.
3.4.2 Bacterial Swarming assay
The soft gels for swarming motility were prepared by autoclaving 0.5 wt% Bacto Agar in M8
medium (0.6 % Na2HPO4, 0.3 % KH2PO4 and 0.05 % NaCl). The gel solution was cooled to ~60
ºC, supplemented with filtered 0.2 % glucose, 0.5 % casamino acid, and 1 mM MgSO4 (0.22 µ
filter). The gel solutions were poured into a Falcon tube for 20 mL portions, followed by adding
aliquots of (1-20 µL) of SFβM or βC stock solutions to achieve the desired concentrations. The
falcon tubes were closed, the agar solution was mixed by gently rocking, and then poured into
polystyrene petri dishes (10 cm-diameter). The agar solution was solidified by cooling and airdrying in a laminar hood for 1 h. Bacterial culture of rhlA mutant strain (3 µL) with an OD600
between ~0.4–0.6 was inoculated on the center of the surface of the soft agar gel. These “swarm
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plates” were incubated at 37 oC for 12 h and then incubated for additional 12 h at room
temperature. After a total of 24 h, pictures of the swarming plates were taken.
3.4.3 Bacterial motility enabled binding assay
For soft gel prepared for swarming motility (see above), 100 μL of 1 mg ml-1 pilin, LecA, or
BSA protein was introduced onto the center of the agar gel and immediately spread over the
surface of the ger using a sterile cell spreader. The proteins were prepared in NaPB (4 mM, pH
7.2), Tris-HCl (0.1 M Tris-HCl, pH 7.5 and 6 μM CaCl2) and Tris buffer (2 mM Tris, 7 mM
NaCl, pH 7.5). The agar gel spread with protein solution was dried for an additional 30 min. A
bacterial subculture (3 μL, 0.6 OD600) was inoculated on the center of the soft gel (10-cm
diameter plate). The bacteria on the soft gel were incubated 12 h at 37oC and an additional 12 h
at room temperature to develop the swarming pattern.
3.4.4 Quantification of phage titer, plaque forming unit (PFU), by top overlay method
All phage counts were quantified by phage titer using top overlay method and reported as the
plaque forming units (PFU). Top agar preparation. Mix 3 mL of warm top agar solution (7 g L-1
agar, 0.5 g L-1 sodium chloride, 10 g L-1 tryptone, 5 g L-1 yeast extract in sterile water) and 200
µL of LB culture of PAO1k (OD 0.6); spread this mixture solution on 1.5% LB agar plate (LBMiller, 10 g L-1tryptone, 5 g L-1 yeast extract, 10 g L-1 NaCl ,15 g L-1 agar, 10-cm in diameter).
Cool for 15 min in biosafety level-2 hood to solidify the gel. Serial dilutions of supernatant of
containing phage were prepared in LB-Mg2+. Nine or six drops of 10 µL of the diluted
supernatant were placed on the top agar plates to observe plaques formation on bacterial lawn
after 12 h. The number of plaques were counted and reported as plaque forming units per ml of
sample.
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3.4.5 Adsorption of bacteriophage ϕKMV on P. aeruginosa strains
Bacteriophage adsorption assay were adopted as described previously 112, with addition of our
ligands. An overnight culture (100 µL) of wt P. aeruginosa strain PAO1k that is ϕKMV sensitive
was diluted with 10 mL of LB supplemented with 10 mM MgSO4 (LB‐Mg2+) and subcultured to
OD600 around 0.6 at 37°C with shaking at 250 rpm with and without 20 µM SFβM and βC or
aGM1. The bacteria subculture (100µL) was mixed with 900 μL of LB‐Mg2+ ml-1 ϕKMV phage.
The titer of added phage was individually determined for every experiment from the phage stock
solution. Following incubation for 10 min at 37 °C with shaking at 100 rpm, bacteria were
removed by centrifugation (10,000 g, 5 min at 4°C), and 900 μL of the supernatant was
transferred to an Eppendorf tube. The plaque‐forming units (PFU) in the supernatant with and
without the added agents was determined by the top agar overlay method with PAO1k. The
percentage of phage bound to bacteria was calculated as [(titer of added phage − titer in
supernatant)/(titer of added phage)] × 100.
3.4.6 Liposomes preparation
Large liposomes were prepared using reported methods with slight modification 161. The
liposomes were prepared with 30 mol% cholesterol, 65 mol% 1,2-dioleoyl-sn-glycero-3phosphocholine (DOPC) (Avanti Polar Lipids) and 5 mol% asialo-GM1. A mixture of lipids
consists of 30 mol% cholesterol, 65 mol% 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPE)
and 5 mol% asialo-GM1 were dissolved in chloroform: methanol (2:1) and evaporated on rotary
evaporator under high vacuum at room temperature. Thin films so formed were dried overnight
under high vacuum. Dried lipid thin films were rehydrated with 100 mM Sulforhodamine B in
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saline (0.9w/v% NaCl in water). The resulting liposome solution was dialyzed with 5K Dalton
dialysis tube to remove free Sulforhodamine B that was not entrapped in liposomes.
3.4.7 Liposome Leakage assay
The liposome encasing the Sulforhodamine B dye in saline (10 µL) were resuspended in PBS
buffer (1 mL), followed by adding 100 µL of pili (1 mg ml-1), LecA (1 mg ml-1), anti-asialoGM1 antibody (0.5 mg ml-1), BSA (0.5 mg ml-1), or Triton X-100 (1 mg ml-1). The liposome and
proteins solution were incubated in dark for 6 h. The fluorescence of leaked Sulforhodamine B
into the solution containing liposomes was measured at excitation wavelength λex 565nm and
emission was measured at wavelength λem 585 nm over a period of 0-6 h. The Triton X-100 was
used as 100% lysed/leakage control.

3.4.8 Bacterial adhesion assay
The wells of the black microtiter plate were coated with 100 µL of 2 µg ml-1 solution of asialoGM1 dissolved in chloroform: methanol (1:1). The plate was kept in BSL-2 hood for overnight
to evaporate solvent and form asialo-GM1 coating. The wells were rinsed with 200 µL PBS
buffer once and each well was added with 150 µL of 50 µg ml-1 of BSA solution and incubated
for 1 h in at 37 ℃ to passivate the surfaces. The wells were washed with PBS containing 0.05%
(w/v) BSA (Buffer A). Overnight cultures (100 µL) of wt PAO1, ΔpilA, and lecA::Tn - in LB
medium were diluted in 10 mL of LB. When the OD600 of the sub-cultures reached ~0.6, an
aliquot of the sub-culture (200 µL) was transferred to the asialo-GM1-coated wells in black
microtiter plate, The black microtiter plate was wrapped in plastic cling wrap and incubated at
37ºC for 1 h. The bacterial cultures were then discarded by pipetting, and each well was washed
once with saline water (0.85 w/v% aqueous NaCl). An aliquot of fresh LB (200 µL) was then
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added to the wells and sonicated for 5 min (10 L water bath cooled with ice, 40 kHz). The
suspended bacteria were enumerated by colony forming units (CFU ml-1) on LB agar plates.
For antibody assay, aGM1-coated surfaces were treated with anti-asialo-GM1 antibody (100 μL,
0.5 mg ml-1) for 15 min prior to addition of bacteria. For competitive inhibition assay, bacteria
were cultured with SFβM or βC.

3.4.9 Synthesis of fluorescent probe, βGal-aryl-Dansyl
4-Aminophenyl β-D-galactopyranoside (0.12 g, 1.2 mmol) in anhydrous DMF (2 mL) was added
to Et3N (0.53 g, 0.53 mmol) in anhydrous DMF (5mL) at 0 ºC. To this solution was added dansyl
chloride (0.41 g, 1.5 mmol). After stirring at 0 ºC for 2 hours, the mixture was concentrated, and
the residue obtained was subjected to the purification by column chromatography DCM:MeOH
9:1 to yield a yellow solid product (0.44 g, 72 %). 1H NMR (400MHz, CDCl3): δ 8.47 (d, 1 H,
dansyl), 8.24 (d, 1 H, dansyl), 8.20 (d, 1 H, dansyl), 7.65-7.69 (m, 2 H, dansyl), 7.39 (d, 1 H,
dansyl), , 6.92–6.81 (m, 4H, ArH), 4.75 (d, J =7.7 Hz, 1H), 4.37 (s, 2H, CH̲2NHR), 3.69 (d, J =
3.1 Hz, 1H), 3.58–3.46 (m, 5H), 2.84 (s, 6H,-CH3).

3.4.10 Direct binding of fluorescent ligand to LecA114
The fluorescent ligand (βGal-aryl-Dansyl) were dissolved in water to a final concentration of 3
mg ml-1 . 2 mg ml-1 LecA (Sigma) and bovine serum albumin (Sigma) was dissolved in 1 mL of
0.1M Tris-HCl pH 7.5 supplemented with CaCl2 (6 µM). The solution of fluorescent ligand
(βGal-aryl-Dansyl, 200 nM) is mixed with different concentrations of LecA solution (0-100
µM). After incubation for 1 h at room temperature in dark, fluorescence polarization was
measured by using Edinburgh FLS9801 Spectrometer, with the samples being illuminated with
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vertically polarized light at 330 nm (for βGal-aryl-Dansyl). The vertical and horizontal
fluorescence components of emission 570 nm were recorded, and the fluorescence polarization
was calculated and data were analyzed using a four-parameter fit model.

3.4.11 Twitching motility assay180
Subsurface twitching assays were modified from previously reported procedures. Briefly, 100 µL
of overnight culture of PAO1-EGFP was diluted in 900 μL of Luria Bertani broth without NaCl
(LBNS). Sterile pipette tips (10 µL) were dipped in this LBNS suspension and were then stabbed
through a one-day-old 1% LBNS agar, with and without 10 µM of aGM1 or 20 µM SFβM or βC,
to inoculate bacteria at bottom of the agar gel. Plates were incubated upright (not inverted) in an
incubator at 37 ℃ for 2 days, and images of the plates were taken under ultraviolet light
(Accuris™ E3000 UV Transilluminator - 302nm) in dark room.

3.4.12 Synthesis of biotinylated Pili and LecA proteins 175,181
The 500 µL of pili (0.5 mg ml-1) or LecA (0.5 mg ml-1) were biotinylated with 1 ml solution of
EZ-Link NHS-PEG4-Biotin (1 mg ml-1) in 1 ml carbonate-bicarbonate buffer (pH 9.2). The
reaction was carried out at 37 ℃ for 4 h under 100 rpm shaking condition. The resultant mixture
was pipetted into Slide-A-Lyzer™ G1 Dialysis Cassettes, 1K MWCO and stir for 24 h in
distilled water. The dialyzed proteins were lyophilized to obtain biotinylated pili or LecA. The
extent of biotinylating reaction was accessed by Pierce™ Biotin Quantitation Kit (ThermoFisher
Scientific).
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3.4.13 Protein binding, and inhibition, to aGM1 on surfaces 175,182
The wells of the microtiter plate were coated with 100 µL of 2 µg ml-1 solution of asialo-GM1
dissolved in chloroform: methanol for overnight in biosafety level-2 hood. The excess sites in the
wells were blocked with a 5% (w/v) BSA solution (150 µL per well) for 1 h in a 37 ℃ incubator
for drying. The wells were washed with PBS containing 0.05% (w/v) BSA (Buffer A). Aliquots
of biotinylated pili or biotinylated LecA were added to the wells (100 µL per well) to reach
different concentrations (0.1 to 5 µg ml-1) and incubated for 1 h at 37℃. The plate was washed
three times with Buffer A. The amount of biotinylated pili and biotinylated LecA bound on
aGM1-coated wells were characterized by the 4’-hydroxyazobenzene-2-carboxylic acid
(HABA)-Biotin assay (Pierce™ Biotin Quantitation Kit, ThermoFisher Scientific). The
absorbance of HABA at 500 nm was measured and plotted against concentration of pili or LecA
proteins. The hyperbolic curve model was fitted by using non-linear regression program in
Mathcad and binding constant Kd was extrapolated from model.
For inhibition assay, we used 1 µg ml-1 of biotinylated pili and biotinylated LecA as 1 µg
ml-1 concentration provides a near full binding of aGM1 on surfaces as depicted in previous
protein binding studies. The 1 µg ml-1 protein solutions are mixed with different concentrations
of SFβM or βC (final concentrations 0.1 to 120 µM) for 1 h, and the mixture were added to
aGM1-coated wells for 1 h. The binding of biotinylated pili/LecA was measured same as above.
The inhibition of binding of biotinylated pili/LecA was plotted against concentrations of ligands
SFβM or βC. The half-maximal inhibition concentration (IC50) was calculated from standard
dose-response curves using Dr-Fit software.
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Chapter 4 Antibacterial agents that inhibit tolerance, persistence, and
resistance: receptor identification and mechanism
4.1 Background and significance
The chemical action of killing bacteria by traditional antibiotics always cause the bacteria
to develop certain resilient phenotypes that survive. All these resilient phenotypes have the
characteristic of either drug tolerance, drug persistence, or drug resistance, and are manifested in
the form of increased biofilm formation183 and motility,30,46 over production exopolymers,183
formation of small colony variants.36,184 All clinically approved antibiotics promote biofilm
formation, by a sub-lethal concentration in laboratory setting, and by less well-defined conditions
on an infection site. These biofilms host high populations of drug tolerant, drug persistent, or
drug resistant population, which overall requires thousands fold of concentration of antibiotics to
kill in comparison to bacteria in a planktonic form.185-188 More intriguing cases are where,
bacteria respond to the same antibiotic treatment with different resilient phenotypes under
different conditions.
4.1.1 Antibiotic leads to tolerance, persistence, and resistance.
Use of antibiotics on bacteria readily causes the bacteria to be tolerant to the antibiotics in
a matter of minutes to hours.21 This tolerance causes the requirement of a high dosage or a longer
treatment time to kill bacteria.21 In addition, this tolerance transition to persistence for some
small population of the bacteria under antibiotic treatment. These bacteria do not grow and do
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not get killed during the antibiotic treatment; but once the antibiotics are removed, these bacteria
revitalize to a population of bacteria that are mostly susceptible, with some small percentage of
persistent bacteria. These small percentage of persistent bacteria, however, is larger than that
before the antibiotic treatment. When drug resistance is fully formed, these population can grow
slowly in the presence of antibiotics . In the absence of antibiotics, the gene mutations for drug
resistance are usually stable.
4.1.2 Antibiotic tolerance and persistence facilitate resistance.
While the development of drug resistance is due to spontaneous gene mutation, which is
random in nature; under the stress of antibiotic treatment, the mutation that cause resistance is
under the natural selection for survival by the antibiotic treatment.22,23,189,190 Thus, the repeated
applications of a conventional antibiotic on a bacterial population promotes both drug tolerance,
and drug resistance. In a batch culture, both developments occur. A recent study by Balaban and
coworkers reveals the relation between the two develop.23,189-192 In a batch culture, the tolerance
mutation and resistance mutation does not occur independent of each other. Rather, the resistant
population carry both mutation responsible for drug resistance and drug tolerance, whereas the
tolerant population carry only mutated gene relevant to tolerance. This important result illustrates
an important genetic dependence (epistasis) of the development of tolerance for the development
of resistance. The resistance mutations establish significantly faster for drug tolerant and
persistent bacteria. Theoretical analysis suggests that, for example, ampC mutations for
resistance are often lost during antibiotic treatment. With a tolerance background, the probability
of lost or reversal of resistance mutation is lowered. One plausible explanation is that tolerance
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arises from many mutations, and stable resistance typically requires several important mutations.
Thus, mutations for tolerance facilitates mutations for stable resistance (Fig. 4.1).

Figure 4.1 Scheme of development of resistance under antibiotic stress (steps a to e). a.
Antibiotic treatment caused tolerance mutation.189-191 b. Tolerance and persistence facilitate
resistance mutation.25,191 c. Tolerance transitions to persistence.21,23 d. Generational gene
transfer.193,194 e. Horizontal gene transfer.24,195,196
Interestingly, it is also mentioned that at low concentrations of antibiotics, fully resistant single
step mutants can occur without a priori developed tolerance.
4.1.3 Horizontal or lateral gene transfer for propagating the resistant genes.
The above describes diverse types of drug resistance mechanisms.24,193-196 Once the
resistant mutant forms, their genes can be transferred by the different ways. First, generational
gene transfer causes the daughter bacterium to carry the gene from the parent gene. Second, a
common mechanism of gene transfer for bacteria is the direct physical contact between two
bacteria causing the transfer of DNA from one to the other: or the release of DNA materials into
the environment by one bacterium and be taken up by another. These gene transfers does not
involve a bacterium’s replication and multiplying, but horizontally between bacteria of the same
species or between different species, and thus are called horizontal gene transfer (HGT).
116

Horizontal gene transfers (HGT) result in genetic variation in bacteria and are a major
contribution to the spread of antibiotic resistance genes.
There are three mechanism of horizontal gene transfers196-198. 1. Conjugation: Two
bacteria can pair up and connect through structures in the cell membranes and then transfer DNA
from one bacterial cell to another. 2. Transformation: Some bacteria can take up pieces of DNA
directly from the environment around the cell. 3. Transduction: There are viruses called
bacteriophages that can infect bacteria. These viruses sometimes bring along genes that they
picked up during infection of another bacterium. These genes may then be incorporated into the
DNA of the new bacterial host.
Any gene has the potential to be transferred between bacteria by HGT, including
antibiotic resistance genes.196 The transferred genes may be integrated into the DNA genome of a
recipient bacterium or may exist as a circular plasmid DNA. Foreign DNA can be harmful to a
bacterium, and there are machineries in place that degrades incoming DNA. However, these
systems are not always 100% efficient. If the incoming DNA is incorporated into the recipient
genome and provides a benefit for the bacterium, the integrated DNA is more likely to be
maintained. For example, if a bacterium picks up an antibiotic resistance gene and is
subsequently exposed to that antibiotic, this bacterium can proliferate.196
4.1.4 Our advances in inhibition of resilient phenotypes and design of antibacterial agents that
inhibit resistance.
We believe that the fundamental issue we face for development of antibiotics is that
primary or only goal in the tradition approach to develop antibiotics is to kill the bacteria with
high potency. Here, we first develop agents to inhibit broadly all the resilient phenotypes, and
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then modify the structure so that the molecules kill the bacteria while retaining the ability to
inhibit the formation of resilient phenotypes.
We showed a broad class of disugar-derivatized hydrocarbons that inhibit both biofilm
formation and swarming motility of P. aeruginosa bacteria. Our past studies revealed that two
most active molecules among these dual synthetic inhibitors are saturated farnesol-β-cellobioside
or -β-maltoside (SFβC and SFβM).81,199 Early structural studies indicated that the methyl
substitution in the aliphatic chains is important: linear C12-aliphatic chain does not exhibit
strong bioactivity, whereas the 3,7,11-trimethyl substituted aliphatic chain does. In search for
more potent molecules through synthesis of structural variants, we explored new methyl
positions on the C12-alphatic chain resulting in new molecules 3,5-diMeDβM and 3,5diMeDβC. These molecules inhibits tolerance and prevents formation of new persistent
populations in P. aeruginosa. To introduce bactericidal or bacteriostatic activities into these
chimeric agents, we note a recent development of dodecyl triazole cellobioside (C12TC, Fig. 4.2)
that has exhibited antibacterial activities. This molecule showed mild bacteriostatic activity
against wild type P. aeruginosa.
To understand structure activity relationship between antibacterial activity and structural
elements of dodecyl triazole cellobioside (C12TC), we designed following variants of Dodecyl
triazole cellobioside (C12TC). We have previously showed that saturated farnesol derivatized
control bioactivities in P. aeruginosa and hence we designed farnesol triazole cellobioside (FTC)
(Fig. 4.2) and saturated farnesol triazole cellobioside (SFTC). To understand importance of sugar
moiety, we designed farnesol derivatized tetra ethylene glycol with click chemistry. The fatty
acids/long chained alkyl groups play role in biological system hence to understand role of
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hydrophobic alkyl group in antibacterial activity we designed short chained trimethyl hexyl
triazole cellobioside (triMeHTC).
We found that SFTC and FTC (Fig. 4.2) showed bactericidal activities against P.
aeruginosa while other molecules showed bioactivities like inhibition of swarming motility,
biofilms against P. aeruginosa but lacked antibacterial activity. These results hinted us towards
significance of triazole and sugar moieties in antibacterial activities against P. aeruginosa. Hence
to test this hypothesis we designed Farnesol oxadiazole cellobioside (FOC) which contains
farnesol and sugar (cellobioside) but lack triazole moiety. We introduced oxadiazole as
heterocycle linker in place of triazole.
4.1.5 Journey from adjuvant agents to design of antibacterial agents with no resistance.
We showed a broad class of disugar-derivatized hydrocarbons that inhibit both biofilm
formation and swarming motility of P. aeruginosa bacteria.81,199 Our past studies revealed that
two most active molecules among these dual synthetic inhibitors are saturated farnesol-βcellobioside or -β-maltoside (SFβC and SFβM).81,199 Early structural studies indicated that the
methyl substitution in the aliphatic chains is important: linear C12-aliphatic chain does not
exhibit strong bioactivity, whereas the 3,7,11-trimethyl substituted aliphatic chain does. In search
for more potent molecules through synthesis of structural variants, we explored new methyl
positions on the C12-alphatic chain resulting in new molecules 3,5-diMeDβM and 3,5diMeDβC. These molecules inhibits tolerance and prevents formation of new persistent
populations in P. aeruginosa. To introduce bactericidal or bacteriostatic activities into these
chimeric agents, we note a recent development of Dodecyl triazole cellobioside (C12TC). that has
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exhibited antibacterial activities. This molecule showed mild bacteriostatic activity against wild
type P. aeruginosa.
We found that SFTC, FTC showed bactericidal activities against P. aeruginosa while other
molecules showed bioactivities like inhibition of swarming motility, biofilms but lacked
antibacterial activity.
These results hinted us towards significance of triazole and sugar moieties in antibacterial
activities against P. aeruginosa. Hence to test this hypothesis we designed Farnesol oxadiazole
cellobioside (FOC) which contains farnesol and sugar (cellobioside) but lack triazole moiety. We
introduced oxadiazole as heterocycle linker than triazole.

Figure 4.2 Structures of Farnesol triazole cellobioside (FTC), Saturated farnesol triazole
cellobioside (SFTC), Farnesol oxadiazole cellobioside (FOC), Dodecyl triazole cellobioside
(C12TC) and farnesol triazole tetraethylene glycol (FTEG4OH), 3,5,5-trimethylhexyl triazole
cellobioside (3,5,5-triMeHTC)
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4.2 Farnesol Triazole Cellobioside is active against both planktonic and biofilm bacteria
The failure of existing antibiotics because of the development of drug tolerance and drug
resistance is increasingly severe worldwide. While bacteria are usually sensitive to antibiotic in
planktonic cultures, bacteria form biofilms under almost all conditions. In biofilms, it has
become clear, bacteria is more difficult to kill by antibiotics, resulting in relapse and recurrence
of infections190,191,200. Bacteria evade antibiotics treatments by three different phenotypes, drug
tolerant, drug persistent, and drug resistant populations22,26,189-192,200-202. The resistance is often
defined as intrinsic or acquired genetic process that leads bacterial survival under antibiotic
treatment. Biofilms show enhanced tolerance to antibiotics and harbor persistent populations
which are precursor to resistance under prolonged antibiotic exposure189,190. In fact, all current
antibiotics are known to promote biofilm formation by bacteria33,34. As higher dose of
antibiotics are necessary to eradicate biofilms,34,38 vicious circles are created that increase the
overuse of antibiotic and the drug tolerance, and persistence. In general, this overuse of
antibiotics often leads to resistance202.
In our past studies, we have identified a class of adjuvant molecules that are specific
ligands to two proteins Lectin A and pili. When combined with an existing antibiotic tobramycin,
this class of chimeric ligands enables tobramycin to kill drug tolerant population and prevents the
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formation of nascent persistent populations. Based on the structures of the chimeric ligands, we
have developed a class of antibacterial molecules with no resistance that is able to kill a wide
range of bacteria strains, include both gram-positive and gram-negative (see previous section
4.1). Here we present the effectiveness of this class of molecules at killing the planktonic
bacteria by evaluating the minimum inhibitory concentrations (MIC), and at killing biofilm
bacteria by minimum bactericidal concentration (MBC). In the next section, we will characterize
the effectiveness of this class of molecules at inhibiting the inhibiting and killing tolerant and
persistent populations
4.2.1 FTC is active against both gram-negative and gram-positive pathogens in planktonic
cultures.
First, we established the growth curves of wild type Pseudomonas. aeruginosa (wt
PAO1) and Staphylococcus aureus (S. aureus) in the presence of FTC (1 - 100 µg/ml). The P.
aeruginosa and S. aureus are common pathogens for many infection conditions, such as in the
lung of cystic fibrosis patients and the sites of burnt wounds. For both wt PAO1, and S. aureus,
we found that FTC significantly reduce the growth of both strains at around 10 µg/ml (Fig. 4.3).
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Figure 4.3 Representative growth curves of wild type P. aeruginosa (wt PAO1) and
Staphylococcus aureus (S. aureus) in the presence of different concentrations of FTC (1 – 100
µg/ml). P. aeruginosa PAO1 in Luria–Bertani broth media. Staphylococcus aureus (S. aureus) in
Tryptic soy broth (TSB) OD600 = 0.01 were grown with different concentrations of FTC ((1 –
100 µg/ml) or without FTC (control) at 37°C for 24 hours under 250 rpm shaking.

4.2.2 Inhibiting growth of planktonic bacteria : Minimum inhibitory concentration (MIC)
To characterize the killing of the bacteria in planktonic culture, minimum inhibitory
concentration (MIC) – the lowest concentration of FTC that prevents visible growth of bacteria
(cloudiness of the culture) is determined by microtiter broth dilution method as described by
Eloff according to the Clinical and Laboratory Standards Institute (CLSI) guidelines203,204. The
FTC molecule was diluted serially on 96-well plates, in cultures with an initial optical density
(OD600) of ~0.01 of gram-negative strains, including Pseudomonas aeruginosa PAO1 and PA14,
E. coli; and gram-positive strains, including Staphylococcus aureus, Bacillus subtilis,
Staphylococcus epidermidis, Nontuberculous mycobacteria (NTM) of Mycobacterium avium and
Mycobacteroides abscessus. The MIC values are displayed in Table 4.1.
4.2.3 Killing planktonic bacteria: Minimum bactericidal concentration (MBC)
The MBC is identified as the lowest concentration of antibacterial agent that reduces the
viability of the initial bacterial inoculum by a pre-determined reduction of ≥99.9%. MIC test
demonstrates the lowest level of antimicrobial agent that greatly inhibits growth, the MBC
demonstrates the lowest level of antimicrobial agent resulting in microbial death.204
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FTC showed most promising activity against gram positive bacteria Staphylococcus
aureus, Bacillus subtilis and Staphylococcus epidermidis and Mycobacterium avium. FTC was
bactericidal against Staphylococcus aureus with MIC of 2 µg/ml and MBC of 8 µg/ml. FTC
showed bactericidal activity against Bacillus subtilis with MIC of 1 µg/ml and MBC of 4 µg/ml.
FTC was more potent against Staphylococcus epidermidis with MIC of 1.5 µg/ml and MBC of 4
µg/ml. FTC was active against Mycobacterium avium with MIC of 8 µg/ml. FTC showed very
mild activity against multidrug resistant Mycobacteroides abscessus with MIC of 64 µg/ml
(Table 4.1).
FTC exhibited mild bactericidal activity against all the gram-negative strains (Table 4.1).
FTC was bactericidal against P. aeruginosa strains PAO1 and PA14 with MIC of 4 µg/ml/MBC
of 48 µg/ml and MIC of 12 µg/ml and MBC of 64 µg/ml. FTC was active against E. coli with
MIC of 8 µg/ml and MBC of 72 µg/ml.
Table 4.1 Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration
(MBC) of FTC against different gram-negative and gram-positive bacteria.
Bacterium strain

MIC (µg/ml)

MBC (µg/ml)

Gram-negative
Pseudomonas aeruginosa (PAO1) 4-8

48

Pseudomonas aeruginosa (PA14)

12

64

E. coli

8

72

Gram-positive
Staphylococcus aureus
Bacillus subtilis
Staphylococcus epidermidis
Mycobacterium avium***
Mycobacteroides abscessus***

2
1
0.5
8
64

8
4
4
-
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Two different strains are used for P. aeruginosa *wild-type Pseudomonas aeruginosa reference
strain PAO1. **PAO1 isolated form lungs of cystic fibrosis patients. *** NTM strains are
evaluated by Seattle Children’s Hospital.
Table 4.2 The MIC values of commercially available antibiotics on PAO1 and S. aureus.
Antibiotic

PAO1 (MIC µg/ml)

SA (MIC µg/ml)

Tobramycin

1

0.125-1

Aztreonam

3205-207

Inactive

Colistin

1205-207

>100205-207

Imipenem

2205-207

0.05

Ceftazidime

2205-207

Inactive

Ciprofloxacin

0.25205-207

0.2

Moenomycin A

32

0.5

*FTC

4-8

2

* relisted from Table 4.1
4.2.4 Antibacterial activities of FTC against P. aeruginosa clinical strains from cystic fibrosis
patients.
Bacteria extracted from patients, clinical isolates, or strains, always exhibit high
tolerance, sometimes, resistance to treatments of conventional antibiotics. During early
infections, P. aeruginosa is typically in a planktonic, non-mucoid form and can be easily killed
by repeated antibiotic exposure. However, during chronic infections P. aeruginosa forms
biofilms and becomes more tolerant to antibiotics. The repeated exposure to higher antibiotic
concentrations leads tolerant and persistent clinical isolates in cystic fibrosis patients.208-211 The
clinical isolates are known to exhibit persistent phenotypes like mucoid production, hyper
adherent, and small colony variants. We used three clinical isolates of P.
aeruginosa characterized as non-mucoid (SMC1587, SMC1595 and SMC1596) and three
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characterized as mucoid (SMC5450, SMC5451 and SMC1585) obtained from Dr. George
O’Toole laboratory.208-213 Clinical P. aeruginosa isolates SMC1585, SMC1587, SMC1595,
SMC1596, SMC5450 and SMC5451 were collected from the sputa of CF patients by the clinical
microbiology laboratory at the Dartmouth-Hitchcock Medical Center (DHMC). Preliminary
biofilms study with these phenotypes revealed that these strains form more biofilms than wild
type PAO1. SMC1587 and SMC1585 cause small colony variants under tobramycin and
aztreonam treatments, and the other four strains did not. Mucoid strains overproduce exopolymer
alginate, and often cause cultures with slims. This phenotype, when populate in patients’ lung,
causes patients’ difficulty in beathing. We also studied a clinical, hyper-mucoid P. aeruginosa
strain PA2192. This strain overproduces mucoid and is considered highly virulent because
patients show poor clinical outcome despite having a heightened immune response.54,214-216
Mucoid PA 2192 was obtained from Dr. Joanna B. Goldberg (Emory University, Atlanta
GA).214,217,218
Here, we examined planktonic minimum inhibition concentration (MIC) of FTC on three
nonmucoid strains and four mucoid strains. We found that FTC is effective against all clinical P.
aeruginosa strains. FTC showed bactericidal activity against non-mucoid SMC1587, SMC1595
and SMC1596 with MIC <16 µg/ml. FTC also showed excellent activity against resilient mucoid
strains (Table 4.3). For SMC1585, SMC5450 and SMC5451, the MICs are 8 µg/ml. The clinical
cystic fibrosis isolate of P. aeruginosa PA2192, produces visibly slimier (alginate) than other
mucoid strains, which cause the significant increase of viscosity of culture. The MIC for this
strain is lower than 16 µg/ml.
Table 4.3 MIC of Farnesol Triazole Cellobioside against clinical isolates of P. aeruginosa.
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Clinical strain
Nonmucoid

Mucoid

MIC (µg/ml)

Note

SMC1587

8<MIC <16

Colistin resistant

SMC1595

8<MIC <16

SMC1596

16<MIC <32

SMC1585

4<MIC <8

SMC5450

4<MIC <8

SMC5451

4<MIC <8

Mucoid PA2192

8<MIC <16

β-lactam resistant

During MIC assay, we made a surprising discovery that SMC1587 appeared to be
resistant to colistin (10 µg/ml, MIC for wt PAO1 : 1 µg/ml) (Fig. 4.4). We further validated this
colistin resistance by subculturing SMC1587 in the presence of 100 µg/ml colistin and observed
that the growth if this strain was as fast as if there was no colistin in the culture. Interestingly,
FTC showed activity against colistin resistant SMC1587 with MIC = 16 µg/ml.

Figure 4.4 Typical 96-well plates for determination of MIC values. Specific examples here for
examining FTC against clinical strain SMC1587 (A) and SMC1595 (B) Column 1 contains no
agent Column 11 to 2 contain, 256, 128, 64, 32, 16, 8, 4,2, 1, 0.5 µg/ml of FTC. Column 12
contains 10 mg/ml of colistin. Strain SMC1587 showed resistance to colistin, while strain
SMC1595 was susceptible to colistin.
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Figure 4.5 Antibiotic susceptibility tests of non-mucoid and mucoid P. aeruginosa strains by disc
diffusion method showing zone of inhibition. 10 µL of 3 µg/ml AZT and 8 µg/ml FTC was
dropped on discs , incubated for 24 h at 37oC. *wt PAO1 laboratory strain has been obtained
from multiple antibiotic abuse.
We compared antibacterial efficacy of FTC with aztreonam antibiotic by disc diffusion
assay. As clinical strains are more resistant to aztreonam, we increased concentrations of
aztreonam from 3 µg/ml (the reported MIC against wt type for AZT is 3 µg/ml219) to 6 µg/ml and
to 8 µg/ml. At these two concentrations (6 µg/ml and 8 µg/ml, 10 µL on the disks), inhibition
zones were observed for clinical strains, except for SMC 5451. This result suggests that SMC
5451 is resistant to aztreonam, which is consistent with O’Toole and coworkers reported finding
that that SMC5451 is tolerant to aztreonam in planktonic culture with a MIC >256 µg/ml208.
Overall, with MIC values, we believe that these MIC values suggest that FTC is potent enough
for an immediate exploration for therapeutic applications. The most significant finding here is
that FTC is active against aztreonam- and colistin-resistant clinical strains.
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Figure 4.6 FTC is active against aztreonam resistant strain of P. aeruginosa SMC5451.
Antibiotic susceptibility tests of wild type PAO1 and SMC5451 by disc diffusion method
showing zone of inhibition. 10 µL of 6 µg/ml, 8 µg/ml AZT and 8 µg/ml FTC was dropped on
discs; incubated for 24 h at 37oC.

Table 4.4 Minimum Biocidal Concentration (MBC) of antibiotics on wild type P. aeruginosa
Antibiotic

MBC µg/ml 220,221

Tobramycin

2

Aztreonam

8

Colistin

1

Imipenem

4

Ceftazidime

8-12

Ciprofloxacin

0.5-1

FTC

48*

*FTC is done by us. All other values are from literature.
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4.2.5 FTC against Biofilms: Minimal biofilm-eradication concentration (MBEC)
The MBEC is defined as the lowest concentration of antibiotic required to eradicate the biofilm
or, the lowest concentration of antimicrobial agent that prevents visible growth in the recovery
medium used to collect biofilm cells.203,204,222,223 We tested efficacy of FTC against 1- day old
biofilms of wild type P. aeruginosa PAO1 and S. aureus grown on peg surface by Calgary
devices (MBEC Assay® Biofilm Inoculator). FTC reduced viability of biofilm bacteria in both
PAO1 and S. aureus. FTC was active against PAO1 with MBEC of 48 µg/ml and MBEC of 16
µg/ml against S. aureus (Table 4.4).
Table 4.4 Minimal biofilm-eradication concentration (MBEC) and Biofilm bactericidal
concentration (BBC) of FTC against biofilms of gram-negative and gram-positive bacteria.
Bacteria

MBEC (µg/ml)

BBC (µg/ml)

48

64

16

32

Gram-negative
Pseudomonas aeruginosa (PAO1)
Gram-positive
Staphylococcus aureus

Table 4.5 Minimal biofilm-eradication concentration (MBEC) and Biofilm bactericidal
concentration (BBC) of different antibiotics against biofilms of wild type PAO1.
Antibiotic

Type/receptor

MBEC µg/ml

BBC µg/ml

220,221

220,221,224

Aztreonam

β-lactam/PBP

1028

-

Imipenem

β-lactam/PBP

256

256

Ceftazidime

β-lactam/PBP

64

1024

Colistin

Polymyxin/outer membrane

32

64

LPS
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Tobramycin

Amino glycoside/ribosome

4

64

Ciprofloxacin

Fluoroquinolone/topoisomerase

4

64

48*

64*

FTC

4.2.6 FTC against Biofilms: Biofilm bactericidal concentration (BBC)
The BBC is defined as lowest concentration of an antibiotic producing a 99.9% reduction of the
CFUs recovered from a biofilm culture as compared to the growth control203,204,222,223. We tested
efficacy of FTC against bacteria in 1- day old biofilms of wild type P. aeruginosa PAO1 and S.
aureus grown on peg surface by Calgary devices (MBEC Assay® Biofilm Inoculator). FTC
reduced viability of biofilm bacteria in both PAO1 and S. aureus. FTC was active against PAO1
with BBC of 64 µg/ml and BBC of 32 µg/ml against S. aureus (Table 4.5).
We demonstrated killing of both planktonic and biofilm bacteria; for a wide range of
bacterium species, including both gram-positive and gram-negative strains. FTC is indeed broadspectrum antibiotic. The activity against nontuberculous mycobacteria (NTM) is promising as
recently there has been a considerable rise in pulmonary infections caused by NTM. These
mycobacteria species have developed resistance to conventional antibiotics leading to treatment
failure. FTC has showed better anti-biofilm activity than existing antibiotic used in clinical
settings220. β-lactam antibiotics like aztreonam, Imipenem and ceftazidime showed MBEC of
512 µg/ml, 1028 µg/ml, and 64 µg/ml, respectively against wild type PAO1 biofilms while FTC
showed MBEC of 48 µg/ml.
We showed that FTC is bactericidal against and gram-negative and positive bacteria. The
MIC values of FTC range from 2 µg/ml to 4 ug/ml for gram positive, and from 4 ug/ml-16ug/ml
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for gram negative. These MIC values suggest that FTC is more potent for planktonic grampositive than gram negative bacteria. The clinical isolates of P. aeruginosa are showed to be
tolerant to antibiotic treatments.208 FTC showed activity towards to 7 clinical isolates of P.
aeruginosa, both mucoid and non-mucoid phenotypes. The bactericidal concentration for FTC
was higher than other antibiotics. However, all current antibiotics are reported to promote
biofilms in both laboratory settings and in patients. We showed that even though FTC exhibit
higher MIC or MBC than conventional antibiotics, FTC do not promote biofilm formation. It is
important to note that, at least for aztreonam, the planktonic MIC does not correlate with
tolerance in biofilms. In fact, SMC5451 biofilm is reported to be susceptible to aztreonam, while
SMC5451’s planktonic MIC is reported to >256 µg/ml.208
However, in a collaboration with O’Toole, results indicate that FTC is more potent than
aztreonam for wt PAO1 biofilms formed on airway cells conducted an in vitro experiment.
Many conventional antibiotics exhibit strong activity for planktonic bacteria, as
illustrated by the relatively low minimum inhibitory concentration (MIC) and minimum
bactericidal concentration(MBC), see Table 4.2 and Table 4.3. However, these antibiotics exhibit
disappointingly low activities against biofilm bacterial, as shown in minimum biofilm
eradication concentration (MBEC) that measure the inhibition biomass, and biofilm bactericidal
concentration (BBC) that measures the killing of biofilm bacteria. These values against biofilms
are 100 to 1000 times less potent than the values against planktonic values. While these
measurements are in vitro data, the clinical treatment of infections related to biofilms are even
worse, requiring dosage of antibiotics 1000 times or more than that for planktonic
bacteria.34,187,225
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In contrast, for FTC the activities against planktonic bacteria (MIC: 4-12 µg/ml) and
activities biofilms (MBEC: 48 µg/ml) are not so many magnitudes different. This sharp contrast
between FTC and all conventional antibiotics is interesting and likely therapeutically valuable.
We believe the reason for the activity of FTC is rooted in the fact that FTC inhibit biofilm
formation, and disperse already formed biofilms, whereas all conventional antibiotics promote
biofilm formation.
The mechanisms for FTC against biofilm and killing bacteria will be studied in the
following sections with following sequence. First, we will explore FTC’s effect at causing, in
fact not causing, drug tolerance and drug resistance; in comparison with other conventional
antibiotics that are all known to rapidly cause drug tolerance, and over repeated exposure, drug
resistance. Second, we will identify the protein receptors for FTC that are related to bacterial
signaling that inhibit the formation of biofilms and the emergence of drug tolerance, as well as
the spread of drug resistance.
Table 4.6 Structural Activity correlation between different molecules.
Bacteriostatic Biofilm inhibition

Swarming inhibition

FTC

Yes

Yes

Yes

SFTC

Yes

Yes

Yes

FOC

No

-- not done

-- not done

C12TC

Yes

Yes

--not done

FTEG4OH

No

No

Yes

3,5,5-triMeHTC

No

No

No ??

C12TC showed mild antibacterial activity against wild type P. aeruginosa with MIC of 32
µg/ml. The MBC for C12TC was 256 µg/ml. According to CLSI, antibacterials with MBC/MIC >
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4 are defined as bacteriostatic, hence C12TC is bacteriostatic. Though C12TC showed biofilm
inhibition with MBEC = 128 µg/ml, C12TC could not eradicate 24-h PAO1 biofilms.
Summary
We found that MIC value for FTC against P. aeruginosa against planktonic culture is higher than
antibiotics used to treat pseudomonal infections. But FTC has excellent activity against P.
aeruginosa biofilms. When existing antibiotics fail against (higher MBEC and BBC) biofilms,
we found that FTC is better than existing antibiotics.
Clinical strain SMC1587 isolated from CF patients showed resistance to colistin which is last
resort antibiotic for treatment of pseudomonal infections. FTC showed bactericidal activity
against this clinical strain. In cystic fibrosis patients, antibiotic therapy includes both a betalactam (Aztreonam) and an aminoglycoside antibiotic (tobramycin, gentamicin). This
combination therapy help prevent or delay the emergence of resistance which is often observed
with single-drug therapy.226 But it has been shown that clinical isolates of P. aeruginosa are
resistant to aztreonam like SMC5451. 210
FTC is active against aztreonam resistant strain of P. aeruginosa SMC5451. FTC can be used in
combination with tobramycin against P. aeruginosa and can be better alternative to aztreonam.
Experimental section
4.2.7 MIC Determination by Broth Microdilution Method
On a sterile 96-well plate, 100 µL of Cation-adjusted Mueller-Hinton broth (MHB-2) was
introduced to 8 wells of 12 columns. The 100 µL of stock solution FTC (1.024 mg/ml) was
introduced to column 11 to generate a concentration of 1/2 of the stock conc., then 100 µL from
column 11 was introduced to column 10 to generate ¼ of stock conc., repeated pass of 100 µL
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down the columns generated 1/8, 1/16, 1/32, 1/64, 1/128, 1/512, 1/1024, 1/2048, of the stock
conc. For the 12th column, 10 µL of colistin stock solution (10 mg/mL) was introduced to the
eight wells as positive control. All bacteria including clinical strains, nonmucoid, mucoid were
cultured overnight in MHB-2, 200 µL of the overnight culture was mixed 20 mL of MHB-2.
Then, 100 µL of this mixture was introduced to all 12 columns. For 12 column, 10 µL*10 µg/uL
*(1/210) = 10/21 µg/uL = ~0.5 mg/mL colistin (MIC =1 µg/mL). For 11th to 2nd column, ¼, 1/8,
1/16, 1/32, 1/64, 1/128, 1/512, 1/1024, 1/2048, 1/4096 of the stock conc (1024 µg/mL) of FTC,
corresponding to concentrations (µg/mL) of 256, 128,64, 32, 16, 8, 4,2, 1, 0.5, respectively. The
1st column contains no agents or antibiotics and serves as negative (growth) control. The plate
was incubated at 37oC without shaking for 24 hours. The MIC was determined by the minimum
concentration for which there was no visible bacterial growth.
4.2.8 Antibiotic susceptibility by Disc diffusion test
A suspension of the desired P. aeruginosa strains following overnight growth was made to equal
a 0.5 MacFarland Standard, or approximately 108 CFU/ml. Using a sterile swab, a lawn of the
inoculum was made on Mueller Hinton agar by covering the entire surface of the plate. The
Mueller Hinton agar was stamped with antibiotic discs within 15 minutes of the inoculated
preparation and incubated in a 37oC incubator for 24 hours. Using calipers, the diameters of the
zone of clearing were measured and the zone sizes recorded and interpreted according to CLSI
procedures.
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4.3 Inhibition of tolerant and persistent phenotypes by Farnesol Triazole Cellobioside
Dr. Alexander Fleming, who discover the first antibiotic penicillin in 1928, described rather
clearly in his Nobel lecture in 1945 on development of drug resistance by microbes: “It is not
difficult to make microbes resistant to penicillin in the laboratory by exposing them to
concentrations not sufficient to kill them, and the same thing has occasionally happened in the
body. The time may come when penicillin can be bought by anyone in the shops. Then there is
the danger that the ignorant man may easily underdose himself and by exposing his microbes to
non-lethal quantities of the drug make them resistant.”
This development of antibiotic resistance by bacteria has become increasingly more
severe over time since their discoveries, as predicted by Dr. Fleming. Since then, three different
phenotypes that all seem to be resistant are better defined, drug tolerant bacteria require a high
dose or longer drug treatment time to kill; drug persistent bacteria are not killed during drug
treatment periods but revitalize to be a population mixture of majorly susceptible bacteria and a
small percentage of persistent bacteria; and drug resistant bacteria grow slowly in the presence of
antibiotic.192,227-229 In addition, biofilms are discovered to be a major lifestyle besides planktonic
form.192,225 In general, biofilms host bacteria with low metabolic rates, and are the host all three
types of resilient phenotypes, drug tolerant, persistent, and resistant population.40,230,231 We not
that there always exist a small percentage of persisters in a bacterial population, which does not
get killed and does not grow during drug treatments and revitalize to become a population of
mainly susceptible and with a small percentage of persisters when drug treatment is removed.227
At sub-lethal concentration (such as <MIC in lab), almost all commercially used
antibiotics actually promote biofilm formation.30,231 Treatment of a biofilms with antibiotics
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causes increase in drug tolerant population in minutes and increase in persistent population in
perhaps hours to days. There are two types of drug resistant population of a strain of bacterium,
the acquired drug resistance and intrinsic drug resistance.21,186,190,232 Natural resistance may be
intrinsic (always expressed in the species), or induced (the genes are naturally occurring in the
bacteria, but are only expressed to resistance levels after exposure to an antibiotic).190
Acquisition of genetic material that confers resistance is possible through all of the main routes
by which bacteria acquire any genetic material: transformation, transposition, and conjugation
(all termed horizontal gene transfer—HGT); plus, the bacteria may experience mutations to its
own chromosomal DNA. The acquisition may be temporary or permanent.186,232 Intrinsic
resistance may be defined as a trait that is shared universally within a bacterial species, is
independent of previous antibiotic exposure, and not related to horizontal gene transfer.186,232 We
will address resistance in the next section.
Bis-(3′-5′)-cyclic dimeric guanosine monophosphate (c-di-GMP, cdG) plays an important
role in biofilm formation and motility of gram-negative bacteria.233-236 Bacterial intracellular cdG
levels controlled by diguanylate cyclases (DGCs) that catalyze the formation of cdG and
phosphodiesterases (PDEs), which degrade c-di-GMP.234 When intracellular cdG levels are
high, bacteria halt motility and switch to biofilm formation. In contrast, biofilm cells when
needed increase their motility and disperse from biofilms by reducing cdG levels.234,236 C-diGMP signaling can be triggered by stress conditions immune attack or antimicrobial exposure.236
The impact of cdG on mediating stress response by microbial communities during both
planktonic and biofilm modes of growth remains unclear. Elevated levels of cdG contribute to
antimicrobial tolerance in Pseudomonas aeruginosa.237 It is well known that higher cdG
contribute to antibiotic tolerance in P. aeruginosa by enhancing biofilm formation, high cdG can
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also leads to biofilm independent increased antibiotic tolerance.238 The reasons for the biofilm
tolerance are multiple, including slow growth or the presence of an extracellular matrix.239
Over the years, different anti-biofilm strategies are employed as means to eradicate
biofilms and hence biofilm-related antibiotic tolerance. 228,230,240-244 2-Aminoimidazole/triazoleconjugated compounds can induce the dispersal of bacterial biofilms.243,244 2Aminoimidazole/triazole showed to inhibit bacterial signaling (quorum sensing).244 Most of the
anti-biofilm compounds act as anti-virulence agents and has no effect on bacterial growth.
Antimicrobial peptides (AMPs), specifically lytic peptides are used against bacterial biofilms.242
Combinatorial therapy of anti-biofilm agents with antibiotics look promising but suffer potential
rise of motile lifestyle for bacteria. Motility especially swarming motility leads to enhanced
antibiotic tolerance in P. aeruginosa.245-247 Swarming bacteria move in multicellular groups and
exhibit adaptive tolerance to multiple antibiotics.246 Swarming bacteria also have increased
virulence which can add to antibiotic tolerance.245 To counter swarming motility, researchers
have developed swarming inhibitor compounds but detailed mechanisms underlying swarming
inhibition remain unknown. P. aeruginosa swarming motility is inhibited by several compounds,
including branched-chain fatty acid anteiso-C15:0, cranberry proanthocyanidins and other tannins,
and several amino acids, such as arginine.248-250
Another important resilient phenotype, small colony variants phenotype (SCV) on semisolid surfaces are linked to elevated cdG levels.27,35,37,251 SCVs are hyperpiliated, showed
increased twitching motility and capacity for biofilm formation. SCVs were found to be multidrug tolerant.37
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Tolerance unlike resistance, that's a growth of the drug concentration for bacteria can grow,
tolerance is an extension of the time frame that bacteria can live under high concentrations of an
antibiotic (regularly way greater than MIC).
We divide tolerance into two major types: biofilm dependent tolerance and biofilm
independent tolerance. Biofilm dependent tolerance can be easily evaluated as reduction in
biofilms and biofilm related phenotypes. Although research into defining planktonic tolerance is
ongoing, direct measurement techniques are also lacking and limited. There are numerous
mechanisms probably underlying planktonic tolerance recently for example, tolerance to βlactams can be done via way of means of a reduced cell wall synthesis, and tolerance to
fluoroquinolone consequences from a reduced DNA replication. The standard method used to
evaluate tolerance is by performing time-kill measurements. In this method, bacteria are exposed
to a higher antibiotic concentration, and viable counts are plotted against time. Recently, Balaban
group have termed this parameter the minimum duration for killing a certain percentile of the
population (MDK), with the percentile added as an index—thus, MDK99 is the minimum
duration for killing 99% of the population. A comparatively high MDK suggests that bacterial
killing requires more time, i.e., corresponds to high tolerance.
4.3.1 Inhibition and dispersion of P. aeruginosa biofilms.
Biofilms are strongly correlated to antibiotic tolerance.34,252 P. aeruginosa forms biofilms which
consists of three main polysaccharides: Psl, pel and alginates.31,32 The Pel plays protective role in
the biofilm matrix of Pseudomonas aeruginosa and pel overproduction leads aminoglycoside
antibiotic tolerance.31,32 Alginate production leads mucoid biofilms which exhibit antibiotic
tolerance. P. aeruginosa biofilms harbor tolerant and persister cells which can survive transient
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antibiotic treatments and revive after in the absence of antibiotic treatment.31,32 Interestingly,
sub-lethal antibiotic causes biofilm formation in P. aeruginosa.33,34 Antibiotics can have two
opposing effect on biofilms: enhancing biofilm formation or disrupting existing biofilms.33,34
We first tested effect of different concentrations of FTC on biofilm formation of P.
aeruginosa wild type PAO1 and PA14. We found that FTC inhibits biofilm formation in PAO1
and PA14 with half maximal inhibition (IC50) of 0.5 µg/ml and 0.8 µg/ml, respectively. At
1µg/ml, FTC completely (>95% inhibition) inhibits biofilm formation in both PAO1 and PA14.
We then evaluated effect of sub-MIC of FTC on dispersion of 24-h old biofilms. We found that
FTC was capable of dispersing 24-h old PAO1 and PA14 biofilms with half maximal dispersion
(DC50) values of 1 µg/ml and 1.5 µg/ml, respectively (Table 4.7).

Table 4.7 Inhibition and dispersion of P. aeruginosa biofilms by farnesol triazole cellobioside
(FTC).
Strain

Biofilm Inhibition

Biofilm Dispersion

(IC50) µg/ml

(DC50) µg/ml

PAO1

0.5

1

PA14

0.8

1.5

We compared biofilm inhibition and dispersion efficacy to previous generation anti-biofilm
adjuvants SFβM/ βC and 3,5-diMeDβM/βC. SFβM/βC showed biofilm inhibition with IC50 = 15
µg/ml and biofilm dispersion with DC50 = 54 µg/ml. The 3,5-diMeDβM/βC showed better anti140

biofilm activity than SFβM/βC. 3,5-diMeDβM/βC showed biofilm inhibition with IC50 = 9 µg/ml
and biofilm dispersion with DC50 = 32 µg/ml. We believe antibacterial effect of FTC
synergistically increases biofilm inhibition and biofilm dispersion.
4.3.2 Inhibition of the formation of small colony variants.
P. aeruginosa forms small colony variants (SCVs) as adaptive response to antibiotic
treatments.35-37 SCV are a phenotypic subset of the bacterial population surviving in biofilms.37
SCVs are persistent phenotype, which is dormant, hyper adherent, exhibit enhanced biofilm
formation and slow, auto-aggregative growth.35-37 Antibiotics like aminoglycosides leads SCVs
formation.
We tested effect of sub-lethal concentrations of FTC on small colony formations in P.
aeruginosa. We grew 24-h PAO1 biofilms in the presence of sub-MIC of FTC and cultivated,
visualized biofilms bacteria on Columbia blood agar. We found that sub-MIC concentrations of
FTC does not promote SCVs formations in PAO1 biofilms. We previously showed that
tobramycin induced SCVs in P. aeruginosa. Here, we tested effect of combination of tobramycin
and FTC on SCVs formation in biofilms. We also tested effect of aztreonam, well known
combination antibiotic used with tobramycin in cystic fibrosis on SCVs formation in biofilms.
We found that sub-MIC of tobramycin induces SCVs in P. aeruginosa biofilms. Aztreonam does
not prevent induction of SCVs by sub-MIC of tobramycin. Tobramycin -FTC combination
prevented formation of SCVs in 24-h biofilms (Fig. 4.7).
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Figure 4.7 Colony morphology assay. Images of biofilm bacterial colonies (37 ℃, 24 h) on
MHB agar plates. Scale bar = 2 cm. wt PAO1 was treated with sub-MIC concentrations of FTC
or Tobramycin or aztreonam or combination and inoculated in MBEC peg plates to form
biofilms for 24 h and then biofilm bacteria were obtained and plated on MHB agar plates for 24
h. TOB- tobramycin, AZT-aztreonam, FTC-farnesol triazole cellobioside; For assay
concentrations of antibiotics used are, 0.3 ×MIC for TOB, 0.5 × MIC for AZT, 0.5 × MIC for
FTC.

4.3.3 Tolerance Detection test (TDtest).
We used a simple modification of the standard Kirby-Bauer disk-diffusion assay
(Tolerance Detection/TDtest) which allows the semi-quantitative evaluation of tolerance to
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antibiotic.253-256 TDtest enables the detection of tolerant and persistent bacteria by promoting the
growth of the surviving bacteria in the inhibition zone once the antibiotic has diffused away.
Using the TDtest, we can detect different levels of antibiotic tolerance in different bacteria. In
typical Kirby–Bauer disk diffusion method, gradient of antibiotic prevents the growth of bacteria
creating an “inhibition zone” around the disk. The TDtest enables the detection of tolerant strains
by overcoming the nutrient depletion that occurs in the Kirby–Bauer disk diffusion method. The
surviving bacteria in the inhibition zone are then recovered by replacing the antibiotic disk with a
new disk impregnated with nutrients like glucose. As nutrients diffuse away from the new disk,
they now promote the growth of tolerant bacteria that can form detectable colonies in the
inhibition zone. We found that aztreonam showed tolerant bacteria while FTC had almost no
tolerant bacteria in zone of inhibition. Furthermore, a qualitative evaluation of tolerance can be
done by the number of colonies inside a typical inhibition zone. Makarova et.al has used TD test
to identify cross tolerance of Salmonella enterica to herbicide.256 Kotkova et.al has successfully
used TD test to detect persistent or tolerant bacterial cells in clinical isolates of Staphylococcus
aureus.255
We found that wild type PAO1 showed medium tolerance to aztreonam (medium
tolerance: 10 to 100 colonies in inhibition zone) while low or no tolerance to FTC (Fig. 4.8). We
also tested if colonies grown inside zone of inhibition are all tolerant or mixture of tolerant and
resistant. We picked single colony from inside zone of inhibition and regrew in fresh medium in
the presence of antibiotic. We found that none of the colonies survive antibiotic treatment
indicating that all those colonies were tolerant (Fig. 4.9).
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Figure 4.8 TDtest for direct visualization of tolerance/persistence strains of wild type PAO1.
FTC showed low tolerance while Aztreonam showed high tolerance/persistence. We first
exposed wt type PAO1 to antibiotic (8×MIC for AZT and 10×MIC for FTC) for 24 h and then
followed by 24 h exposure to glucose disk. Colonies inside the inhibition zone after the second
step (please see experimental section) of the TDtest shows tolerant/persistent strains. Disk
diameter: 6 mm.

Figure 4.9 Bacterial growth assay. The large majority of colonies growing inside the inhibition
zone after the second step of TDtest are not resistant. The single colony inside zone of inhibition
was regrew with and without antibiotic AZT (8×MIC) and FTC (10×MIC) for 24 h to observe
visible bacterial growth.
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4.3.4 FTC causes low or no antibiotic-tolerance in planktonic culture.
In this method, bacteria are cultured with a higher concentration (higher than MIC, 1015×MIC) of antibiotic, and number of viable bacteria (CFU/ml) are plotted against time. When
the killing curve is exponential (not biphasic) the killing rate can be used to quantify tolerance.
Balaban group used parameter the minimum duration for killing (MDK) a certain % (e.g. 99%)
of the population; MDK99.9 is the minimum duration for killing 99.9% of the population. A
comparatively high MDK suggests that bacterial killing requires more time, i.e., corresponds to
high tolerance257,258.
Planktonic P. aeruginosa, wt PAO1, was cultured with and without higher concentrations
of aztreonam or FTC for 8 h. The concentration of aztreonam was 45 µg/ml (15xMIC), and that
of FTC was 80 µg/ml (10xMIC); at these concentrations, the frequency of mutants was less than
10−11.. The residual live bacteria were isolated from the entire culture volume by centrifugation
and rinse with fresh LB medium to remove the antibiotics. The bacteria were then cultured
overnight again to obtain an ancestral (without antibiotic) and evolved (with antibiotic) bacterial
population.
We first validated if these ancestral and evolved strains are not resistant strains because
resistance is described as a shift in the MIC to higher drug concentration. We determined MIC
of aztreonam and FTC against ancestral and evolved strains by disk diffusion test. We found that
under aztreonam treatment, evolved strain showed same zone of inhibition (11±1.5 mm) as
ancestral strain (12±0.5 mm). For FTC, evolved strain showed same zone of inhibition (9±1 mm)
as ancestral strain (9±0.5 mm) (Fig. 4.10).
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Figure 4.10 Kirby-Bauer disk diffusion susceptibility test on ancestral and evolved wild type
PAO1 grown on Mueller-Hinton agar plates with 4 µg/ml Aztreonam and FTC. The zones of
clearing (zone of inhibition) are measured to determine susceptibility to aztreonam and FTC.
The ancestral, and AZT/FTC-evolved population (106 CFU/ml) were cultured again with
FTC (10xMIC) and AZT (15xMIC); and the survival population were monitored (by colony
forming units) over 0,3,6, 8, 12, 24 h; and the MDK99 was obtained (Fig. 4.11).

Figure 4.11 Time-kill curves under FTC and aztreonam treatment of two population ancestral
and evolved with different tolerance levels. The tolerant population (evolved) was obtained from
the ancestral strain under intermittent antibiotic exposure (8h). The ancestral, and AZT/FTCevolved population (106 CFU/ml) were cultured again with FTC (80 µg/ml) and AZT (45
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µg/ml); and the survival population were monitored (by colony forming units) over time. From
killing curve, tolerance is reflected in the terms of MDK99, i.e., the time to kill 99% of the
population, or Survival = 10−2.
Table 4.8 The minimum duration for killing (MDK99) of ancestral and evolved population of
wild type PAO1 under the treatment of FTC and aztreonam.a

a

Antibiotic

Ancestral

Evolved

FTCb

~6 h

~6 h

Aztreonamc

~5 h

~15 h

8 h culture with high concentrations of antibiotics. bFTC conc. 80 µg/ml (10xMIC). cAztreonam conc. 45

µg/ml (15xMIC).

We found that MDK99 for ancestral and evolved population of PAO1 after FTC
treatments were both about 6 h (Table 4.8). We found that MDK99 for ancestral and evolved
PAO1 after FTC treatments were 6 h. The similar MDK99s between the ancestral and evolved
PAO1 suggest that high concentrations of antibiotic FTC (10xMIC) did not cause a tolerant
phenotypes after an 8 h treatment of FTC. For aztreonam, one exposure cycle caused an increase
in MDK99 from 5 h to 15 h, suggesting that the tolerant bacteria population has evolved.
4.3.5 Inhibition swarming motility while killing P. aeruginosa.
Bacteria exhibit activities with complex high cell density in swarming motility, which is
regarded to protect bacteria against antibiotic exposure.30,245-247,259 Swarming bacteria are
believed to be more tolerant to antibiotics.246,259 Interestingly, antibiotic of aminoglycoside
(tobramycin) also promotes the swarming motility in P. aeruginosa.30
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We evaluated effect of FTC on swarming motility of wild type P. aeruginosa strains
PAO1 and PA14. We found that FTC inhibits swarming of both PAO1 and PA14 below
minimum inhibitory concentration (12 µg/ml). We found that concentrations range (0.5 – 4
µg/ml) FTC could inhibit swarming motility in PAO1 and PA14 without affecting viability
(clearly visible under UV light). At concentrations higher than 4 µg/ml, FTC cause both
swarming inhibition and killing in PAO1 and PA14

148

Figure 4.12 (A) FTC inhibits swarming motility in P. aeruginosa strains. Swarming motility
assay; The representative images of swarming motilities wt PAO1 and PA14 on semisolid gel
(~0.5% agar) with different concentrations of FTC after 24 h. Images were with and without
365/254nm UV irradiation. The concentrations are indicated over the images. (B) Detail
examination of the swarming pattern of PA14 in the presence of FTC (0.5, 1.0, 2.0 ug/ml).
Because FTC kills bacteria, whether FTC also inhibits swarming motility need a close
examination. We studied effect of different concentrations of FTC prepared in the hydrated gel
for swarming motility for PAO1 and PA14 (Fig. 4.12). At higher concentrations, 6-16 ug/ml the
inoculation spot of the bacteria fade out, indicating that the bacteria was killed. For low
concentrations, 0.5-4 ug/ml, the area of swarming bacteria reduces, which can be attributed to
either killing of the bacteria or inhibiting the swarming motility of the bacteria, or both. Close
examination of swarming patterns of PA14 suggest that the tendrils of the swarming pattern
reduced more than the area in the center. This result suggests that swarming motility is likely
also inhibited in addition to killing of bacteria. If only killing is occurring, then the swarming
tendril pattern likely will be maintained, and both the tendril and the center of the swarming
pattern should fade to a similar extend (Fig. 4.12).
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To validate FTC does inhibit swarming at low concentrations, we evaluated effect of FTEG4OH
on swarming motility of wild type PAO1. FTEG4OH is structural variant of FTC which has no
bactericidal activity. FTEG4OH and FTC both share structural features needed for pili inhibition.

Figure 4.13 Farnesol triazole tetraethylene glycol (FTEG4OH) inhibits swarming motility in P.
aeruginosa. Swarming motility assay; The representative images of swarming motilities wt
PAO1 on semisolid gel (~0.5% agar) with different concentrations of FTEG4OH after 24 h. The
concentrations are indicated over the images.
We found that FTEG4OH inhibits swarming motility of wild type PAO1 at
concentrations higher than 30 µM (Fig. 4.13).

Discussion
These results suggest that FTC inhibits biofilm formation in P. aeruginosa. Previously, we
showed that sub-lethal concentrations of antibiotics promote biofilm formations but sub-lethal
concentrations of FTC inhibits biofilms in P. aeruginosa. FTC does not induce small colony
variants in biofilms unlike other antibiotics like tobramycin, gentamicin. Collectively, we
showed that FTC inhibit biofilm dependent tolerance in P. aeruginosa.
FTC and FTEG4OH inhibit swarming motility in P. aeruginosa. Antibiotics have been shown to
promote swarming motility in P. aeruginosa30 and swarming bacteria are more tolerant to
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antibiotics245-247. FTEG4OH and FTC both have C12 branched hydrocarbon as structural moiety.
These results are consistent with previous finding that branched chain hydrocarbons are
important for swarming inhibition.81,199,249 We believe that branched chain hydrocarbon inhibit
pili, appendage needed for swarming motility and hence inhibit swarming motility in P.
aeruginosa. The branched chain hydrocarbon structural feature of FTC gives antibiotic
advantage at inhibiting swarming motility.
Summary
We showed that FTC inhibits swarming motility and biofilm formation in PAO1 and
PA14. FTC does not promote swarming motility or biofilm formation unlike other antibiotics.
We believe that FTC eradicates swarming and biofilm-induced antibiotic tolerance. FTC also
does not induce SCVs formation in P. aeruginosa. FTC inhibits tobramycin induced SCV
formation in P. aeruginosa. The mechanism of inhibition is still not clear. Inhibition of biofilm,
swarming, and SCV are inhibiting tolerance, and inhibition of swarming is likely due to
inhibition of pili, which we will elaborate in the receptor identification section.
Experimental section
Freezer stocks of all strains were stored at -80 oC in lysogeny broth (LB) with ~20% glycerol.
All strains were grown in LB (10 g/l tryptone, 5 g/l yeast extract, and 10 g/l NaCl) or MuellerHinton Broth MHB (beef infusion solids, 2.0 g/l. casein hydrolysate, 17.5 g/l. starch, 1.5 g/l) at
37 oC with shaking at 250 rpm. All biofilm assays were performed by immersing the pegs of a
modified polystyrene microtiter lid of MBEC™ plates (Innovotech, Alberta, Canada) in M63
medium. All biofilm inhibition, dispersion assays were performed in M69 medium, and MBEC
peg plates were incubated at 37 oC under static conditions.
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4.3.6 Crystal violet dye-based biofilm assay260
An overnight culture (100 µL) of bacteria in LB was diluted in 10 mL of M63 medium and
incubated to reach an OD600 value of ~0.1. The bacterial culture (150 µL) was added to the wells
of MBEC™ microtiter plate, followed by predetermined volumes of FTC stock solution for
targeted concentrations (6 wells/concentration). The MBEC™ plates were incubated under
stationary conditions at 37 ℃ for 24 h. After incubation, the pegs were transferred and immersed
into 96 wells containing sterile water (200 µL) twice to briefly rinse the biofilms to remove
unattached or loosely attached bacteria and were dried at 37 ℃ for 30 min. The peg-attached
biofilms were immersed into 96 wells containing crystal violet (CV) dye solution (150 µL, 0.1%)
at ambient temperature for 30 min, to stain the biofilms. The CV-stained pegs were then washed
twice with sterile water (200 µL). To solubilize the CR stains, 150 µL of 30% acetic acid
solution was added to wells, and the pegs was immersed in the wells, the plates were shake on a
microplate mixer (Scilogex MX-M) at 100 rpm for 15 min. The amount of biofilms was inferred
and quantified by measuring the OD600 of the 150 µL acetic acid solution on plate reader. The
absorption from stained pegs containing just M63 medium was subtracted from pegs treated with
agents. For dispersion assay, biofilms were grown for 24 hours and then treated with different
concentrations of FTC for 24 hours. The amount of biofilm mass was determined by same CV
dye method described previously.

4.3.7 Disk diffusion test261,262
The 100 µL bacterial strain of interest (0.6 OD, ~106–107 CFU/ml ) was spread onto a Mueller–
Hinton agar plate. The antibiotic disks (Whatman® Antibiotic Assay Discs , diam 6 mm, Sigma
Aldrich) were used. The 5 µL of antibiotics were dropped on disks and incubated for 24 h at
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37oC. After 24-h incubation, zone of inhibition was measured and efficacy of antibiotic was
expressed as diameter of zone of inhibition.
4.3.8 TDtest for visualization of tolerance/persistence253
The TDtest consists of two steps: Step I: similar to reference disk diffusion assay, with the
following exceptions: 100 µL of wt PAO1 bacteria (0.6 OD, ~106–107 CFU/ml) were plated on
LB agar plate, with diffusion disks containing 5 µL of AZT and FTC with concentrations 24
µg/ml (8×MIC) and 80 µg/ml (10×MIC), respectively. The disk/agar was incubated for 24 h at
37oC. The amount of antibiotics in the disks was adjusted low enough (still multiple of MICs) so
that the glucose diffusion ring will cover the abx/agents ring, and not generate spontaneous
mutation. Multiple trials indicate that the optimal amount of antibiotic for this TDtest is 24 µg/ml
(8×MIC) for AZT and 80 µg/ml (10×MIC) for FTC.
Step II: The antibiotic disks were replaced with a fresh blank disk, and applied 5 μl of 40%
sterile glucose solution, and were incubated for an additional 24 h. The tolerant strains can grow
in the inhibition zoom in this experiment because glucose gradients is introduced to replace the
24-h old antibiotics disks.
4.3.9 Planktonic tolerance assay258
The overnight cultures of wt PAO1 was diluted to OD=0.01 in MHB medium and then was
cultured to OD=0.6. We treated wt PAO1 (10 mL) with a high concentration of FTC
(80µg/ml;10×MIC) and aztreonam (45µg/ml;15×MIC). These two values 10xMIC and 15xMIC
for FTC and AZT, respectively, are determined by the single step resistance assay, for which the
frequency of mutants that were resistant to these concentrations of antibiotics was less than 10-11.
After 8 h of exposure to these antibiotics, the cultures were washed to remove the drug,
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resuspended in fresh MHB medium, and grown for total 24 h. After 24 h, we got four
populations, two for each of ancestral and evolved by FTC/AZT. We measured MDK99 (the
minimum duration for killing 99% of cells) may be defined to quantify tolerance. (See procedure
below). We will also find out susceptibility of these strains to AZT and FTC by disk diffusion
assay to show validate these strains are not resistant.
4.3.10 MDK99 assay258
We cultured wt PAO1 ancestral and evolved strains in MHB medium and adjusted to ~106
CFU/ml. We supplemented 106 CFU/ml bacterial cultures with high concentrations of FTC
(80µg/ml ,10×MIC) and aztreonam (45µg/ml, 15×MIC) for 24 h. The bacterial viability was
determined by colony forming units on LB agar plate every 3, 6, 9, 12 and 24 hours. We plotted
% survival bacterial population vs time and calculate MDK99 as the time to kill 99% of the
population, or survival = 10−2.
4.3.11 Bacterial Swarming assay263
The soft gels for swarming motility were prepared by autoclaving 0.5 wt% Bacto Agar in M8
medium (0.6 % Na2HPO4, 0.3 % KH2PO4 and 0.05 % NaCl). The gel solution was cooled to ~60
ºC, supplemented with filtered 0.2 % glucose, 0.5 % casamino acid, and 1 mM MgSO4 (0.22 µ
filter). The gel solutions were poured into a Falcon tube for 20 mL portions, followed by adding
aliquots of (1-20 µL) of FTC, FTEG4OH stock solutions to achieve the desired concentrations.
The falcon tubes were closed, the agar solution was mixed by gently rocking, and then poured
into polystyrene petri dishes (10 cm-diameter). The agar solution was solidified by cooling and
air-drying in a laminar hood for 1 h. Bacterial culture of wt PAO1/PA14 (3 µL) with an OD600
between ~0.4–0.6 was inoculated on the center of the surface of the soft agar gel. These “swarm
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plates” were incubated at 37 oC for 12 h and then incubated for additional 12 h at room
temperature. After a total of 24 h, pictures of the swarming plates were taken.
4.3.12 Examination of SCV formation and inhibition251
An overnight culture (100 µL) of wt PAO1 bacteria in LB was diluted in 10 mL of M63 medium,
and sub-cultured to reach an OD600 value of ~0.1. The sub-culture (150 µL) was added to the
wells of MBEC™ microtiter peg plate and supplemented with (and without) tobramycin (0.3
ug/ml ), and aztreonam (0.5 ug/ml) or FTC (0.5 ug/ml). Each condition is duplicated in 6 wells
and incubated under at 37 ℃ without shaking for 24 h. The pegs were then transferred and
immersed into 96 wells containing sterile water (200 µL) twice to briefly rinse the biofilms to
remove unattached or loosely attached bacteria. The 6 pegs were cut with sterile plier and put in
saline in a test tube. The saline solution with pegs were bath sonicated 15 minutes at 30 kHz
(Symphony VWR Internationals Ltd.). Pegs were removed, and the solutions were centrifuged at
6000 rpm for 10 minutes, to collect the bacteria. The collected pellets were resuspended in 1 mL
saline, which were serially diluted (105-107) in LB medium, spread on Mueller Hinton Agar
plates, and incubated at 37°C for 1 day.
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4.4 Inhibition of drug resistance development
Antibiotics disrupt the essential structures or processes in bacteria, which either kills the
bacteria or stops them from multiplying.185-188,225,264-266 In response, bacteria have evolved to
develop many types of resistance to withstand the actions of antibiotics.185-188,225,264-266
Generally, the major mechanisms of bacteria used to counter antibiotic attack can be classified
into intrinsic, acquired and adaptive resistance. The intrinsic resistance of bacteria includes low
outer membrane permeability, expression of efflux pumps that expel antibiotics out of the cell
and the production of antibiotic inactivating enzymes. The acquired resistance of P. aeruginosa
can be achieved by either horizontal transfer of resistance genes or mutational changes.
The primary mechanism for drug resistance development is spontaneous mutation, which
is random and rare. Under stress of a drug treatment, however, the natural selection of cause the
selected mutant that survived the mutation to multiply and populate. Such a natural selection is
not random. There are ways by which the drug resistant mutants pass on their genes. First, by
generational gene transfer that the resistant gene is passed on to the daughter bacteria when the
bacteria replicate and multiple and proliferate. Second, by horizontal gene transfer, for which the
bacteria can release their genes to the environment and be picked up another; or the bacterium
can directly make direct physical contact with another bacterium and transfer the genes to the
other bacterium.
The gene mutations that resist the effects of an antibiotic cause one of the two
effects;188,264-266 one, to reduce antibiotic concentration by pumping the drug out or by
chemically destroying or modifying the drugs; or two, to modify or bypass the drug target, which
are often enzymes in bacteria, that the antibiotic acts on.188,266 Bacteria produces protein pumps
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that sit in their membrane or cell wall. These so-called efflux pumps are very common in
bacteria and can transport a variety of compounds such as signal molecules and toxins. Gene
mutation can cause bacteria produce more of a certain pump or make certain pumps more
effective at pumping the antibiotics out of the bacterium lowering the antibiotic concentration
inside the bacterial cell, resulting in drug resistance, for which the bacteria grow slowly in the
presence of drugs.188,264-266 Gene mutation can also decrease the permeability of the bacterial
membrane. This change decreases the amount of antibiotics getting into the bacteria, resulted in
drug resistance and growth. Gene mutation can also make enzymes that are more effective at
destroying or modifying certain antibiotics, making the antibiotics not being able to bind to the
protein targets. One example is β-lactamase that destroys the β-lactam ring of penicillin, the first
and most used antibiotics for treating human infections. Over the years, bacteria evolve to
produce many different β-lactamases. These bacteria form a class called extended spectrum betalactamases (ESBL)-producing bacteria, has become a major health issue. These bacteria can
degrade a wide spectrum of β-lactam antibiotics, sometimes also the last resort drugs like
aztreonam for infections with these bacteria.185,187 Gene mutation can also change the
composition or the structure of the drug target (often enzymes) in the bacterium. The
modification render the antibiotics missing the target, and the biology and livelihood unchanged.
Gene mutation can also cause the making of alternative proteins to replace the drug targets. For
example, the bacterium Staphylococcus aureus can acquire the resistance gene mecA and
produce a new penicillin-binding protein. The new penicillin-binding protein has low affinity to
β-lactam antibiotics and is thus resistant to β-lactam treatment. This type of resistance is the
basis for methicillin-resistant Staphylococcus aureus (MRSA). Gene mutation can also
reprogram or modify the structures of the target molecules (nonprotein). For example,
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Vancomycin-resistant bacteria make a different cell wall lipid structures compared to susceptible
bacteria. The antibiotic is not able to interact as well with this type of cell wall185,187.Some
bacteria are naturally resistant to certain antibiotics. Imagine for example an antibiotic that
destroys the cell wall of the bacteria. If a bacterium does not have a cell wall, the antibiotic will
have no effect. This phenomenon is called intrinsic resistance. When a bacterium that was
previously susceptible to an antibiotic evolves resistance, it is called acquired resistance264,265.
Both serial passage assay and single step mutation assay are used to evaluate the “resistance”
development by bacteria under antibiotic treatment in a laboratory settings. Often both assays are
studied together267,268.269 Serial passage assay are believed to allow cumulation of multiple
mutations, each with incremental survival benefit; and single step mutation assay causes drug
resistance in a single step.18,267,269

Inhibition of acquired drug resistance, and mechanism:
4.4.1 Serial multi-passage assay:
Serial Passage: This assay develops resistance in bacteria by continuously passaging bacteria
grown in sub-MIC (sub-inhibitory) concentrations of antimicrobial agent. For serial passage
assay, the bacterial culture were treated with a range of doubling MIC concentrations of the wild
type, such as 0.5x MIC, 1x MIC, 2x MIC,…,etc., for 12h. The lowest concentration that causes
no visible bacterial growth are regarded at the new MIC. The culture with high concentration that
shows visible bacterial growth is diluted and cultured with a new series of doubling
concentration of the NEW MIC for the next passage. It is important to note that in between each
passage, the bacteria are not culture without antibiotics. Thus, a series of questions are not
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answered. Is the resistance mutation in the new “resistant” population stable? In other words, if
the bacteria population is isolated and cultured again, is the entire population of the bacteria
resistant to drugs, or some of new generation will be susceptible? More importantly, will some
of the initial “resistant” population, cultured without antibiotic, revert back to susceptible? If
some of the initial “resistant” population revert back to susceptible, then these bacteria are really
tolerant rather than resistant. For the latter case, it is not clear if the increased MIC due to
multiple passages will or will not revert back to a lower value if the bacteria are cultured again
without antibiotics.
Illustration of serial passage assay was done in Fig.4.14 A parent culture is prepared and used to
inoculate a serially diluted series of antimicrobial compound.

Figure 4.14 Schematic representation of multi-passage assay.

The culture is incubated and on day 1 the MIC concentration is determined to be the
lowest concentration in which no growth is observed. The sub-MIC concentration culture is used
to inoculate a second serially diluted series of antimicrobial compound and incubated overnight.
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The next day the MIC (which may remain the same or increase) is determined and the sub-MIC
concentration culture from the latest passage is used to inoculate a new series of diluted
antimicrobial compound. The process continues for up to 21 days or until a predetermined end
point concentration is reached.

Figure 4.15 Multi-passage resistance assay for P. aeruginosa. Bacteria were serially passaged
over a 21-day period and the broth microdilution assay was used to determine the minimum
inhibitory concentration of each compound against wild type PAO1 after each successive
passage.

Examining the details for the data (Table 4.9), we note increase of MIC in the serial
passage assay is exponential over time, whereas the increase of MIC in the same assay but with
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the presence of pili inhibitor appears to be linear. This substantial suppression of antibiotic
resistance development by a non-killing agent was not known before this work and is a surprise
when pondering on the possible mechanisms.
Table 4.9 MIC values for aztreonam and FTC after each passage.
Day

AZT (µg/ml)

FTC (µg/ml)

0

3

12

1

3

12

2

6

12

3

12

16

12

12

5

24

18

6

64

16

7

32

16

8

32

16

9

32

18

10

64

18

11

64

16

12

64

32

13

128

24

14

128

24

15

256

32

16

512

32

17

512

32

18

>512

32

4
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19

-

42

20

-

42

21

-

42

Horizontal gene transfers promote drug resistance by increasing drug tolerant population.
To understand the mechanism for reducing drug resistance in a serial passage assay by
inhibiting horizontal gene transfer using pili inhibitors, we first discuss the establish background
knowledge, and then state the key question, and describe the logical answer that elucidate a
proposed mechanism. First, we note that in the presence of antibiotics, bacteria develop drug
tolerance over short period of time, in 24 h.257 Such drug tolerance is still presence even after the
antibiotic is removed, and the bacteria is cultured for another 24 h.257 Thus, the gene mutation for
tolerance is stable. Also, the MIC are the same for the ancestral and the evolved/tolerant (one
passage) bacteria.257 Second, the MIC of a bacterial population is primarily the property of
individual bacterium, meaning that, on average, each bacterium needs a higher concentration of
antibiotic to inhibit its growth for a high MIC strain than that for a low MIC. Furthermore,
measuring the MIC of a culture grown to an OD 0.8 versus the same culture diluted with LB to
an OD of 0.01 should not be greatly different. Third, for stable gene mutation, horizontal gene
transfer are readily possible, and HGTs merely increase the population of bacteria to carry the
mutated genes.
These establish background knowledge naturally leads to the question of how does
inhibiting horizontal gene transfers reduce or subpress the development of drug resistance as we
have seen in our results? In a series of recent seminal work, tolerance mutation is found to be the
genetic background or foundation that greatly facilitate the development of stable resistance, and
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thus tolerance is regarded as the epigenetics for resistance.23,189,191,257 These findings together
with our results deduce that horizontal gene transfers increase MIC values in the serial passage
assay by greatly increase the tolerant population, which by itself does not increase the MIC
values, but such tolerant population readily transitions into resistant one in each bacterium,
which requires a higher MIC for inhibiting their growth.
In summary, the effect of horizontal gene transfers on resistance development was not
clear before. Here, we found that the effect is significant: inhibiting HGTs not only inhibit the
drug resistance development for at least two weeks, but also change the drug resistance
development from exponential over time to apparently linear over time. Furthermore, the
mechanism suggests that, while HGTs transfer mutated genes between bacteria, HGTs suppress
the development of drug resistance by inhibiting the spread of tolerance mutation in a
population, which would have facilitated the population to be resistant that requires a high MIC
of the antibiotic.

4.4.2 Single step resistance development in P. aeruginosa and S. aureus, mechanism: unknown
Single step resistance assay causes a set of mutations that permits surviving and growing bacteria
under a single treatment (often 12 h) of a high concentration (multiples of planktonic MIC) of an
antibiotic. The mutation rate in single step resistance assay is defined as the in vitro frequency at
which detectable mutants arise in a bacterial population in the presence of a high antibiotic
concentration.268,270 It is important to note that, in this single step resistance assay, the number of
mutant bacteria are recorded as colonies, and that the number of mutation events are not yet
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characterized.270 Therefore, only the favorable mutations are recorded for the bacteria that lead to
a visible antibiotic resistance phenotype on agar plates (Fig. 4.16).

Adopted from Emery Pharma Ref: Antimicrobial Agents and Chemotherapy, Apr. 2006, p. 1228–1237 Vol. 50, No. 4, Mani et al,
In Vitro Characterization of the Antibacterial Spectrum of Novel Bacterial Type II Topoisomerase Inhibitors of the
Aminobenzimidazole Class.

Figure 4.16. Single step mutation assay: This figure illustrates the general workflow for
conducting a single-step, spontaneous mutation frequency assay. (1) Liquid agar containing a
known concentration of antibiotics (typically 4-fold or 8-fold or greater the MIC value of the
bacteria being assayed) is prepared, poured into petri dishes, and allowed to solidify. (2) A
parental bacteria culture is prepared and the bacterial density in CFU/ml is determined. (3) The
parental bacteria culture is spread onto the agar plate containing antibiotic and incubated for up
to 2 days. (4) The number of CFUs recovered is enumerated and this value is compared to the
parental bacterial density to generate a frequency of mutation.
We tested mutational frequencies of wild type PAO1 under high concentrations of
aztreonam and FTC. We found that aztreonam had resistant colonies in the presence of 4×MIC,
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8×MIC and 16×MIC with a mutation frequency of 2.8 × 10-9 at 4×MIC. FTC did not show any
resistant colonies at 8×MIC and 16×MIC, but 2 resistant colonies in the presence of 4×MIC with
a mutation frequency of 2 × 10-10 (Fig. 4.17) We also tested if the resistance of bacteria (by
aztreonam and FTC) in these resistant colonies is “stable”. We picked single colony from agar
plates containing 4 × MIC of aztreonam or FTC and cultured them in the presence of 10 × MIC
of aztreonam or FTC at 37 C with shaking (250 rpm). For both cases, the bacteria did group to
cloudiness under such high concentration of antibiotics (10x MIC of aztreonam and FTC) These
results indicated that bacteria survived in the single-step assay are stable resistant mutants.

Figure 4.17 Single step resistance assay for P. aeruginosa. For single step resistance, wt PAO1
(1010 CFU/ml) was plated on MHB containing 2×, 4×, 8× and 10 × MIC of aztreonam and FTC.
After 48 h of incubation at 37 °C, no resistant colonies were detected for FTC. Aztreonam
showed resistant colonies for high concentration (16 × MIC). mutational frequency = no. of
resistant colonies / CFU of bacteria added (1010); FTC = 2 × 10-10; aztreonam = 2.8 × 10-9
We tested mutational frequencies of methicillin susceptible S. aureus (MSSA) under high
concentrations of vancomycin and FTC. We found that vancomycin had resistant colonies in the
presence of 4×MIC, 8×MIC and 16×MIC. Vancomycin showed mutational frequency of 12 × 10165

8

in the presence of 4×MIC vancomycin. Interestingly, FTC did not show any resistant colonies at

2×MIC, 4×MIC 8×MIC and 16×MIC (Fig.18).

Figure 4.18 FTC Does Not Cause Resistance by Staphylococcus aureus (SA) while vancomycin
does after 48 h. After 48 h of incubation at 37 °C, no resistant colonies were detected for FTC.
Vancomycin showed resistant colonies for high concentration (16 × MIC). mutational frequency
= no. of resistant colonies / CFU of bacteria added (1010) Vancomycin = 12 × 10-8

Discussion
Single-step mutation assay and serial passage assay are used to study bacterial survival
under antibiotic treatments, and to characterize the development of resistance by the survival
colonies and increasing MIC, respectively. Typically, single step mutation assays only consider
situations in which bacteria acquire genetic mutations by a single high dose antibiotic treatment
that renders them practically immune to therapy.267,268,271 However, this is not the case in nature.
Bacteria undergo multiple antibiotic treatments or abuse in clinical settings. Serial passage assay
considers multi-step resistance, where the accumulation of several mutations of low individual
benefit is necessary for high-level resistance.
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For single-step mutation assay, our results showed that at 2x MIC aztreonam (at higher
concentrations than MIC) developed single-step mutants, while FTC did not show any colonies
for P. aeruginosa. The possible explanation for occurrence of aztreonam-resistant mutants are
the change in porin structures or increased efflux pump activity.272,273 The development of
resistance against FTC has yet to be elucidated, and is likely different than that of beta-lactam,274
particularly because the molecular weight cut off for hydrophilic drugs passing through different
porins is shown to be around 600 Daltons.274-276 The molecular weight of aztreonam is 435.4
Daltons while that of FTC is 627.23 Daltons, thus FTC will likely not pass through the porins to
get into the bacteria, and the resistance via porin permeability is likely irrelevant.
For S. aureus, higher number of resistant colonies were observed under one-time high
concentrations of vancomycin treatment. These results are consistent with literature that
vancomycin has high propensity to develop single-step mutations in the presence of high
antibiotics concentrations.277-279 Numerous changes related to S. aureus cell wall structure or cell
wall metabolism are shown to lead to an increased number of false binding sites for
vancomycin.277 S aureus did not show any resistant mutants in the presence of FTC.
For serial passage assay, from day 5, aztreonam MIC showed two-fold increase,
and started to increase exponentially. Multiple genes are reported to recurrently mutate in P.
aeruginosa when repeatedly passaged with aztreonam, these multiple gene mutations occurred
cumulatively, including those related efflux pumps, porins and beta lactamase, all appears to be
specific to aztreonam.273,280 FTC did not show exponential increase in MIC over days during
serial passage. We believe that exponential increase in MIC is a result of the resistant mutation
has become stable, and the spread resistance is facilitated by both generational passing
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compounded by horizontal gene transfer. Whereas the linear slow increase in MIC is a result of
unstable resistant mutation, and thus ineffective generation passing, and inactive horizontal gene
transfer. In such a case, the bacteria may be in a state of drug tolerant and drug persistent. Dr.Luk
group is working on identification of population diversity under serial passage assay under
aztreonam and FTC treatment.
Most of the antibiotics exhibit rapid drug resistance development by serial passage assay,
except the newly developed ones, such as the quaternary positively charged molecules, cationic
steroid antibiotics (CSA) and Teixobactin and a particularly peculiar case, Moenomycin A.
Moenomycin is family of antibiotics that inhibits the peptidoglycan glycosyltransferases (PGTs)
in cell wall synthesis of gram-positive bacteria and showed activity against methicillin
sensitiveS. aureus with MIC of 0.5 µg/ml, 281-284 This class of antibiotics is not active against
gram-negative bacteria. The lead antibiotic in this class, Moenomycin A failed as a drug for
human due to suboptimal pharmacokinetics. Instead, Moenomycin A is used as supplements
livestock feeds for animals to promote animal growth as well as an antibiotic.283 Surprisingly,
after decades of higher dose feed of Moenomycin A to animals, no moenomycin-resistant
bacteria have been reported to date.281,282 Single-step mutation assay showed very low mutational
frequency for moenomycin in vitro (2.2×10-10).281 Moenomycin also showed no transferable
resistance or cross resistance.283,284
Comparing the structures, FTC and Moenomycin share two key common structural
elements, both bear sugars and aliphatic chains. However, FTC is overall smaller, having two
sugars instead of 4, and the aliphatic chain is shorter. One key functional advantage of FTC is
that FTC is active against both gram-negative and positive bacteria, whereas Moenomycin is
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only active against gram positive. FTC also does not seem to develop drug resistance, just like
Moenomycin.
Experimental section
4.4.3 Multi-passage resistance assay
Multi-passage assay was adopted as described previously.269,285 To prepare the initial bacterial
culture, an overnight culture of PAO1 wild type was prepared in MHB in falcon tube at 37°C
with 250 rpm shaking. Subculture of PAO1 was prepared by diluting 100 µL of overnight culture
into 10 mL fresh MHB (1:100). For the serial passage experiment, the prepared subculture of
PAO1 was transferred into a 96-well plate with adding antibiotics (Aztreonam, FTC) stock
solution to get different final concentration (0.25 x MIC, 0.5 x MIC, 1 x MIC, 2 x MIC) in totally
200 µL culture into each well (6 replicates of each concentration were performed in the same
column). After a 24-h incubation in a static incubator at 37°C, the column of wells with the
highest concentration of antibiotics that still showed bacteria growth was sub-cultured again:
Culture from six wells of this column were taken out and combined, and 100 μL of the combined
culture was mixed with 10 mL of fresh MHB (1:100). This freshly diluted culture was transferred
into another column of 6 wells with addition of a new set of concentrations of antibiotics. The
new concentrations were adjusted such that the lowest concentration of antibiotic that showed
non-growth in column was the new MIC value, and thus 0.25 x new MIC, 0.5 x new MIC, 1 x
new MIC, 2 x new MIC, were applied.
To quantify the MIC change for PAO1, this lowest concentration of antibiotics that showed nongrowth in column was taken as the new MIC for PAO1 for each passage. The added antibiotics
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concentrations were increased for the rising MIC values. This process was repeated for 21 times
(passages).
4.4.4 Single step resistance assay
We tested single step resistance assay as described in literature.269,285 For single step
resistance, P. aeruginosa at 1010 CFU/ml was plated onto MHB containing 2×, 4×, 8× and
16 × MIC of Aztreonam and FTC. For single step resistance, S. aureus at 1010 CFU/ml was
plated onto MHB containing 2×, 4×, 8× and 10 × MIC of vancomycin and FTC. After 48 h of
incubation at 37 °C, no resistant colonies were detected for FTC in both strains. We obtained no
mutants of P. aeruginosa or S. aureus to FTC with a low dose (4 × MIC) of the compound.
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4.5 Farnesol triazole cellobioside exhibits synergy with conventional antibiotics
4.5.1 FTC showed synergy with β-lactam antibiotics in gram-negative bacteria.
In previous section, we have shown that FTC inhibits NagZ enzyme activity in P.
aeruginosa. NagZ promotes AmpC β-lactamase expression through activating AmpR and
enhances resistance to β-lactam antibiotics in P. aeruginosa286-289 and E. coli290.
These results prompted us to evaluate the efficacy of combining different class of
antibiotics with FTC for killing gram-negative bacteria. We determined Fractional Inhibitory
Concentration (FIC) index values by microdilution checkerboard analysis291. These assays
determined minimum inhibitory concentration (MIC) of different antibiotics and FTC. We
determined the impact on potency of the combination of antibiotics in comparison to their
individual activities against both bacteria.
Table.4.10 Synergistic effect of FTC with different antibiotics.
Antibiotic

Type/receptor

FIC Index*

FIC Index*

(E. coli)

( PAO1 wt)

Aztreonam

β-lactam/PBP

0.44

0.58

Imipenem

β-lactam/PBP

0.28

0.45

Ceftazidime

β-lactam/PBP

0.36

0.44

Cefoxitin

β-lactam/PBP

0.48

0.58

Tobramycin

Aminoglycoside/Ribosome

0.78

0.80

Ciprofloxacin

fluroquinolone /DNA gyrase

1.0

1.0

Colistin

Polymyxin/outer membrane/LPS

1.6

1.4

*

FICantibiotic = MICantibiotic+FTC/MICantibiotic, FICFTC = MICFTC+antibiotic/MICFTC The FIC index is the sum of

FICantibiotic and FICFTC.A FIC index of < 0.5 indicates synergism, > 0.5–1 indicates additive effects, > 1 to
< 2 indifference, and ≥ 2 is considered to be antagonism.
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We found that FTC showed synergy with β-lactam antibiotics aztreonam, imipenem,
ceftazidime and cefoxitin against E. coli and P. aeruginosa. FTC was additive with
aminoglycoside antibiotic tobramycin and fluroquinolone antibiotic ciprofloxacin against E. coli
aureus and P. aeruginosa (Fig. 4.19)
Overall, FTC showed enhanced activities of β-lactam class of antibiotics against gramnegative bacteria like E. coli and P. aeruginosa. FTC showed additive effect with other
antibiotics like aminoglycoside tobramycin, fluroquinolone ciprofloxacin. These results showed
that FTC may have synergy with β-lactam antibiotics via NagZ inhibition which targets
peptidoglycan (PG) synthesis pathway.

Figure 4.19 Biofilm eradication by aztreonam and Imipenem in the presence of FTC. The 24-h
PAO1 biofilms were subjected to different concentrations of Aztreonam and Imipenem in the
presence of 10 µg/ml for 24 h. The number viable biofilm bacteria were obtained by sonication
and enumerated by plating on LB agar plate and expressed as colony forming units.
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We found that FTC (10 µg/ml) potentiate aztreonam and imipenem (10, 40 and 80 µg/ml)
against 24-h PAO1 biofilms.
Even though extended β-lactam antibiotics are active against planktonic P. aeruginosa,
they fail against P. aeruginosa biofilms29,220,292. In P. aeruginosa , β-lactamases was associated
with strong biofilms and β-lactamases results in enhanced resistance in biofilms220.Aztreonam
and Imipenem showed higher tolerance towards P. aeruginosa biofilms than planktonic bacteria.
The MBEC for both aztreonam and imipenem against P. aeruginosa biofilms are greater than
512 µg/ml (MICAZT = 3 µg/ml; MICIMP = 2 µg/ml).

4.5.2 FTC is active against Clinical Isolate of P. aeruginosa ( Non-mucoid strain 1587) in
Biofilm
P. aeruginosa non mucoid isolates were shown to be tolerant to aztreonam.208 we tested efficacy
of aztreonam and FTC, combination against Clinical Isolate of P. aeruginosa ( Non-mucoid
strain 1587)
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Figure 4.20 Biofilm eradication of Clinical P. aeruginosa strain 1587 by aztreonam and FTC.
The 24-h PAO1 biofilms were subjected to different concentrations of 10 µg/ml Aztreonam in
the presence of 10 µg/ml for 24 h. The number viable biofilm bacteria were obtained by
sonication and enumerated by plating on LB agar plate and expressed as colony forming units.
We found that aztreonam (AZT) was moderately active against 24-h biofilms of strain 1587 and
reduced biofilm bacteria by 2 log. FTC alone showed good activity against strain 1587 and
reduced biofilm bacteria by 4 log. Aztreonam and FTC combination did not show any significant
reduction in biofilm bacterial count than FTC alone though FTC prevented formation (Fig. 4.20).
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4.6 Receptor identification and mode of action of FTC
4.6.1 Identification of Receptors and Mode of action of FTC
We showed that FTC inhibited swarming motilities in P. aeruginosa strains (PAO1 and
PA14 ) at concentrations lower than MIC. Pili are necessary for swarming motility.293-295
Previously Luk group has shown group of molecules which targets pili and inhibit pili-mediated
motilities like swarming.81,199 Previous generation of adjuvant agents like SFβC, 3,5-diMeDβC
and SFEG4OH, FTEG4OH inhibit swarming motility in P. aeruginosa. Luk group has shown that
SFβC/3,5-diMeDβC and SFEG4OH/ FTEG4OH inhibits pili mediated activities by the small
molecules direct binding to pili and causing retraction of pili (See Chapter 2). LecA play major
role in biofilm formation and inhibition of LecA leads to inhibition of biofilms in P.
aeruginosa.296-298 Luk group has shown that SFβC/3,5-diMeDβC binds to LecA. Because of this
strong similarity between the activities of the molecules that kill bacteria and the chimeric
molecule, we hypothesize that that FTC and SFTC also binds to pili and LecA, but also bind to a
new receptor protein that causes killing of the bacteria. . Binding and inhibiting pili and LecA are
responsible inhibiting a wide range of phenotypes that is controlled by both high and low level of
cdG, controlling these phenotypes inhibits the development of drug tolerance and drug
resistance.
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Table 4.11 Structure and phenotypes relation of small molecules provide receptor hypothesis.

Small molecules
FTC, SFTC

Phenotypes

Biofilm

Inhibit

SFβC81,

SFEG4OH81,

3,5-diMeDβCa

FTEG4OHb

Inhibit

No effect,
or slightly promote

Swarming

Inhibit

Inhibit

Inhibit

Killing

Yes

No

No

Protein

LecA

??

Yes

No

receptor

Pili

??

Yes

Yes

(for killing)

??

NA

NA

a.derived from chapter 2 b.Another Graduate student Yuchen Jin’s work
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Bacterial populations susceptible to antibiotics become resistant either through genetic
mutation (spontaneous) or through horizontal transfer and expression of resistance genes from
other strains.193,195,196,299 Horizontal gene transfer (HGT) is one of major cause of acquired
antibiotic resistance193,195,300. All resistance genes from the super bugs can be mobilized by HGT
mechanisms to other pathogenic and non-pathogenic bacteria. Pili also play important role in
horizontal gene transfer in P. aeruginosa299,301,302. A gene cluster encoding type IV pilus is
crucial for horizontal gene transfer.193,195 We believe that FTC prevents horizontal gene transfer
and hence prevents resistance development in P. aeruginosa.
4.6.2 Killing mechanism of FTC
The farnesol triazole cellobioside (FTC) is an amphiphilic glycolipid. The amphiphiles
are known to damage bacterial cell membrane and cause leakage causing cell leakage and lysis,
and bacterial death.303,304 To test effect of FTC on bacterial cell membrane permeability, we used
propidium iodide (PI), a fluorescent probe which exhibit fluorescence after binding to DNA.305
PI dye is not capable to cross an intact cell membrane, but only crossed compromised cell
membrane that results in DNA binding and fluorescence increases. Based on this PI dye assay,
we found that FTC has no effect on bacterial cell membrane permeability of either B. subtilis or
PAO1, suggesting that cell membrane damage is not a mechanism of killing by FTC.
To identify the protein receptor for FTC that resulted in killing of the bacteria, we first
found out that sub-inhibitory concentration of FTC (0.5×MIC) caused filament formation for
both gram-negative wild type P. aeruginosa and gram-positive B. subtilis (Fig. 4.21). This result
provides a strong entry point for identifying the protein receptors that are responsible for killing
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the bacteria. There are a few conditions that would cause bacteria to form filaments, including
inhibition of penicillin binding proteins (PBPs), undecaprenyl diphosphate synthase (UppS),
reactive oxygen species (ROS) formation under anaerobic conditions.48,49,306-309 Among these
conditions, we believe the potential protein receptor that is responsible for FTC binding and
killing of the bacteria is either penicillin binding proteins or undecaprenyl diphosphate synthase
(UppS). The reactive oxygen species (ROS) formation under antibiotic stress requires strictly
anaerobic conditions hence we ruled out ROS formation as potential mode of action. Penicillin
binding proteins (PBPs) is a critical enzyme that catalyze the cross-links in the cell walls, and
inhibition of PBP by β-lactam kill bacteria by impairing the cell wall synthesis. Undecaprenyl
diphosphate synthase (UppS) is another important enzyme in the biosynthesis of bacterial cell
wall, it catalyzes the condensation of farnesyl pyrophosphate (FPP) with eight consecutive
isopentenyl pyrophosphate units (IPP), to generate undecaprenyl pyrophosphate. UppS also
serves as a lipid carrier for peptidoglycan synthesis.309-311 Small molecule inhibitors of UppS
inhibits bacterial the growth of a variety of bacteria.309-311 Both β-lactam and UppS inhibitor at
sub-MIC concentrations cause filamentous bacteria formation. FTC showed activity against both
gram-positive and gram-negative bacteria, hence we believe that FTC kill bacteria by either
inhibition of undecaprenyl diphosphate synthase (UppS) or glycosyltransferase (GT) and
transpeptidase (TP) activities of penicillin-binding proteins (PBPs).
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Figure 4.21 Morphology of B. subtilis and P. aeruginosa under treatment of Farnesol triazole
cellobioside (FTC) at 0.5×MIC for 1 h in planktonic culture and visualized by light microscopy.
We first evaluated effect of FTC on undecaprenyl diphosphate synthase (UppS) for grampositive bacteria by using a screening platform described in literature.312-314 For Gram-positive
bacteria like S. aureus, the cell wall is made up of peptidoglycan and teichoic acid (WTA), both
are synthesized from the lipid carrier undecaprenyl phosphate (Und-P).310,312 UppS is an enzyme
responsible for synthesizing undecaprenyl phosphate (Und-P), which is the precursor WTA.312
Both Und-P and WTA are required for cell wall synthesis. Targocil is a drug that inhibit enzyme
tarG which acts on WTA, resulting in the inhibition of bacterial growth.315 Past studies by Eric
Brown group has shown that as sub-inhibitory concentration of UppS inhibitors reduces WTA
levels.312 Targocil becomes less effective as a bacteriostatic agent due to unavailability of WTA,
indicated by the increase of MIC of Targocil at inhibiting bacterial growth. This increase in MIC
of Targocil has been used as an indicator for the presence of UppS inhibitors. Our results show
that the known UppS inhibitor, Clomiphene increased Targocil’s MIC from 1.5 to 8 µg/ml
(Table 4.11). Our results showed that FTC did not change MIC of Targocil (1.5 to 2 µg/ml),
suggesting that FTC may not inhibit UppS enzyme (Table 4.12).
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For a separate experiment, we study another effect that is known for UppS inhibitors.
Presence of UppS inhibitors, such as Clomiphene, at sub-MIC concentrations increases the level
of Staphyloxanthin pigment – a yellow-to-orange pigment produced by S. aureus.312 At sub-MIC
concentration of FTC, the levels of Staphyloxanthin pigment did not change. These results
together indicated that FTC is unlikely targeting UppS.
Table 4.12 Susceptibility of S. aureus against different cell wall synthesis inhibitors.
MIC (µg/ml)
Antibiotic/Agent

by itself

with Clomiphene

with FTC

Targocil

1.5

8

2

Clomiphene

8

FTC

2

We next moved to explore another potential receptor, penicillin binding proteins (PBPs).
316-319

PBPs are members of a subgroup of enzymes called transpeptidases.316-319 The beta lactam

antibiotics inhibits penicillin binding proteins, and also causes bacteria to form filaments at subMIC concentrations.316-319 We tested effect of FTC on inhibition of transpeptidase activity of the
PBP1a from E. coli. PBPs are found in every bacterial species. E. coli, for example, has eight
well-known PBPs, named 1A, 1B, and 2-7. PBPs have molecular masses ranging from 20 to 120
kDa and are split into two categories: high molecular mass (HMM) and low molecular mass
(LMM) PBPs.16,320,321 HMM PBPs are required for bacterial survival and are –lactam antibiotics'
fatal targets, but LMM PBPs are not required for cell viability.320,321 Moreover, PB1a is
correlated to filament formation in bacteria.49 Hence we chose commercially available PBP1a as
representative protein for small molecule studies. FTC is also active against E. coli with MIC of
8 ug/ml while FTEG4OH showed no antibacterial activity against E. coli. We used microtiter
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plate-based assay for inhibitor binding to the PBPs based on competition with biotin-ampicillin
(BIO-AMP) conjugate binding. Ampicillin is a beta-lactam that has a high affinity for PBPs.316318

In this assay, purified PBP1awere immobilized onto microtiter plate wells by physical

adsorption and labeled with BIO-AMP. The amounts of the BIO-AMP labeled PBP are
determined by avidin based biotin quantification kit.322 The binding/labelling of the BIO-AMP to
PBP1a can be inhibited with different concentrations of unlabeled PBP inhibitors, in our case
FTC. We used moenomycin A antibiotic as positive control. Moenomycin A is active against
gram-positive bacteria and binds to PBP, inhibit transpeptidase activity of PBPs.281,283 We used
FTEG4OH as negative control; FTEG4OH is not bactericidal against gram-positive or gramnegative bacteria.
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Fig. 4.22 Inhibition curves of unlabeled PBP inhibitor against BIO-AMP labeled E. Coli PBP1a
The different concentration of FTC, FTEG4OH were added to 2 μg E. Coli PBP1a and then 100
μM BIO-AMP was added to mixture. After 10 min, amount of Bound biotin-Amp-PBP was
quantified by Pierce™ Biotin Quantitation Kit. % inhibition was calculated as % inhibition =
100 x [1 - (amount of BIO-AMP bound at given concentration – amount of BIO-AMP bound
with Moenomycin A)/( amount of BIO-AMP bound with no inhibitor - amount bound with
Moenomycin A)].
We found that FTC inhibited transpeptidase activity of E. Coli PBP1a enzyme while
FTEG4OH did not inhibit transpeptidase activity of E. Coli PBP1a (Fig.4.22). These results are
consistent with the bactericidal activity of FTC and FTEG4OH against E.coli. In this assay,
moenomycin A showed highest inhibition of E. Coli PBP1a which is consistent with
literature.281,283 Together , these results suggest that FTC inhibits transpeptidase activity of E.
Coli PBP1a and shows bactericidal activity against E. coli. We believe that FTC may inhibits
different PBPs proteins in gram-positive and gram-negative bacteria and showed antibacterial
activity against these bacteria.
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4.6.3 Inhibition of HGTs, conjugation, transformation, and transduction by FTEG4OH
Drug resistance can be developed by acquiring gene materials that encode for proteins
that causes drug resistance from environment or from another strain. Classically, this type of
gene transfer was thought to occur by three different mechanisms: Conjugation: the use a surface
appendages called a pilus to transfer genes between two bacteria. Transformation: naked DNA is
taken up by a bacteria. Transduction: genes are transferred using a phage particles. We
previously showed that FTEG4OH which inhibits pili and pili-mediated swarming motilities in
wild type P. aeruginosa. Here, we tested efficacy of FTEG4OH at inhibition of three
mechanisms of gene transfer.
First, we used well established Pseudomonas Aeruginosa Pathogenicity Island I (PAPI-I)
gene transfer assay between P. aeruginosa species via conjugation mode of transfer.301,302 In this
conjugation assay, we used two P. aeruginosa strains PA14-140495 (PAPI-I donor) and
PAO1CbRlacZ (PAPI-I acceptor). The P. aeruginosa PA14 carries PAPI-I gene which is absent
in wild type PAO1.301,302 PAPI-1 gene is horizontally transferable into recipient strains lacking
PAPI-I gene via conjugation mechanism by the type IV pilus.301 We found that PAPI-I gene
transferred from PA14-PAPI-I to PAO1 with transfer frequency of 1.1 ×10-5 (Fig. 4.23). In the
presence of pili inhibitor FTEG4OH, gene transfer frequency reduced to 1.6×10-6. This results
suggested that FTEG4OH inhibits pili mediated conjugative gene transfer.

183

Figure 4.23 FTEG4OH reduces PAPI-I gene transfer from PA14-PAPI-I to PAO1 by inhibition
of conjugation mechanism. PA14-140495 (PAPI-I donor) and PAO1CbRlacZ were co-incubated
for at 37°C for 48 h statically with and without 100 µM FTEG4OH. The number of
transconjugants (blue colonies) was counted on selective agar containing 75 µg/mL gentamicin,
150 µg/mL carbenicillin and 40 µg/mL X-Gal. The transfer frequency was calculated by the
total number of transconjugants (blue colonies) divided by the total recipients (CFU after 48 h
culture at 37°C).

Bacterial transformation is a process of horizontal gene transfer by which P. aeruginosa
take up foreign genetic material (naked DNA, plasmid) from the environment.323,324 To test if pili
inhibitors have effect on gene transfer mediated by transformation mechanism, we used mCherry
(TcR) plasmid as genetic material and wild type P. aeruginosa as acceptor strain. We found that
in the absence of inhibitor wild type PAO1 pick up mCherry (TcR) plasmid from cultures with
transformation frequency (expressed as number of colonies of transformants per nanogram of
plasmid per 107 CFU/ml of recipient bacteria) of 2.4. In the presence of 100 µM FTEG4OH,
transformation frequency reduced to 1.1 (Fig. 4.24). We also performed effect of different
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concentrations of pili inhibitor (FTEG4OH) on transformation frequency of wild type P.
aeruginosa. We found that transformation frequency decreased as concentration of pili inhibitor
FTEG4OH (Fig. 4.25). These results collectively suggested that FTEG4OH inhibits pili and pili
mediated transformation mechanism of gene transfer.

Figure 4.24 FTEG4OH inhibits mCherry (TcR) plasmid transfer by transformation mechanism.
wt PAO1 (107 CFU/ml) was cultured with mCherry (TcR) plasmid for 24 h under 37℃ with
shaking (250 rpm). To quantify the plasmid transfer, colony forming units (CFU) of the
transformants was counted on agar plates containing 250 µg/mL tetracycline. Transformation
efficiency was expressed in number of colonies of transformants per nanogram of plasmid per
107 CFU/ml of recipient bacteria. Error bars indicate the standard deviations of means of
duplicates. *P < 0.05; vs control without FTEG4OH, Student’s t-test.
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Figure 4.25 Transformation efficiency of FTEG4OH. wt PAO1 (107 CFU/ml) was cultured with
mCherry (TcR) plasmid for 24 h under 37℃ with shaking (250 rpm). To quantify the plasmid
transfer, colony forming units (CFU) of the transformants was counted on agar plates containing
250 µg/mL tetracycline. Transformation efficiency was expressed in number of colonies of
transformants per nanogram of plasmid per 107 CFU/ml of recipient bacteria and plotted vs
corresponding concentration of FTEG4OH.

P. aeruginosa species like PA14 which carries PAPI-I gene use transduction via
bacteriophage,325,326 and all clinical isolates have prophages in their genomes.326-330 Transfer of
phage DNA (transduction of phage followed by lysogeny) between P. aeruginosa populations
has been reported in patients with cystic fibrosis.326,330 Generalized transduction mechanism
occurs when induced phage particles by either oxidative stress or fluroquinolone antibiotics,
package plasmid DNA that deliver host DNA to new recipient P. aeruginosa strain. 325,330 To test
effect of pili inhibitor on phage mediated gene transfer, we induced phage particles in P.
aeruginosa PA14 via exposure to fluroquinolone antibiotic ciprofloxacin as reported in
literature.326,330 We used these phage particles for gene transfer into recipient P. aeruginosa
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strain (PAO1CbRlacZ). We treated PAO1CbRlacZ with supernatant containing phage particles
and selected new transductant bacteria on selective agar plates. We found that in the absence of
pili inhibitor FTEG4OH, 98 colonies of transductant. In the presence of 100 µM FTEG4OH, we
found almost no or ~3 transductant colonies. This results suggested that FTEG4OH has strong
effect on phage mediated gene transfer.

Figure 4.26 FTEG4OH Inhibits ciprofloxacin induced phage mediated PAPI-I gene transfer by
transduction mechanism. PAO1CbRlacZ (with and without 100µM) were treated with bacteria
free supernatant of PAPI-1 donor PA14-140495 (GmR) which contains ciprofloxacin induced
phage for 48 h without shaking. The transductant were counted as blue colonies on selective agar
(75 µg/ml gentamicin, 150 µg/ml carbenicillin, and 40 µg/ml X-Gal). Error bars indicate the
standard deviations of means of duplicates. *P < 0.01; vs control without FTEG4OH, Student’s ttest.
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As pili inhibitor exhibited strong inhibition of transduction mechanism of gene transfer, we
explored effect of pili inhibitor on phage adsorption and killing. We used P. aeruginosa specific
lytic phage (ϕKMV) for adsorption and killing assay. Pseudomonas aeruginosa bacteriophage
ϕKMV requires type IV pili for adsorption and subsequent killing.331 We tested effect of pili
inhibitor FTEG4OH on phage adsorption of P. aeruginosa sensitive to ϕKMV (PAO1k). We
found that mixing ϕKMV (5.8×106 PFU/ml) with excess of PAO1k (2.8 x107 CFU/ml) for 10
min, the phage titer in supernatant culture was reduced to 6.1×105 PFU/ml, indicative of ~81% of
the phage was adsorbed on PAO1k (Fig. 4.27). In contrast, culturing bacteria in the presence of
FTEG4OH (100 µM), the phage count in solution was 4.8×106 PFU/ml, indicating of only ~20 %
of phage adsorption on PAO1k.

Figure 4.27 FTEG4OH inhibits ϕKMV Phage adsorption on P. aeruginosa. Percentage of ϕKMV
phage adsorbed on PAO1k (wt PAO1 strain that is sensitive to ϕKMV) mutants over 10 min in
LB containing 100 µM of FTEG4OH. Error bars indicate the standard deviations of means of
duplicates. *P < 0.02; vs control without FTEG4OH, Student’s t-test.
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FTEG4OH (100 µM) Delays Cip induced Phage mediated PAO1k killing.

Figure 4.28 Phage plaque formation assay. FTEG4OH (100 µM) delays Cip-induced phage
mediated PAO1k killing.

Figure 4.29 Planktonic Killing assay. FTEG4OH (100 µM) delays Cip-induced phage mediated
PAO1CbRlacZ killing.
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We also tested if bacteria survived Cip-induced phage exposure with and without FTEG4OH
after 24 hours. We found that in both cases, there are survival bacteria and we selected them on
selective agar containing 75 µg/ml gentamicin, 150 µg/ml carbenicillin . In the presence of
FTEG4OH, we found that 10 times less bacteria survived.

Figure 4.30 Colony forming unit assay. 100 µL of survived bacteria after 24 h cip-induced phage
exposure was counted on selective agar containing 75 µg/ml gentamicin, 150 µg/ml
carbenicillin.
To test if Cip induced phage caused transductional gene exchange with
recipient PAO1CbRlacZ, we isolated bacteria survived after 24 h phage exposure in planktonic
culture , and prepared a bacterial lawn using these bacteria, and then introduced drops of cipinduced phage supernatant to lawn to perform the plaque formation assay. We discovered that
new transductant bacteria did not show plaques. in the presence of Cip-induced phages. This
result suggests that this phage particle are lysogenic to the survived bacteria that was infected
with cip-induced phages.
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Figure 4.31 Plaque formation assay. 100 µL of PAO1CbRlacZ (before exposure and after 24-h
exposure of cip-induced phages in planktonic culture was mixed in 1 mL of top agar and spread
on 1.5% LB agar plates for 1 h, and 10 µL of supernatant cip-induced phage from PA14-PAPI
was spotted on top agar and images were taken after 18 h.

4.6.4 Inhibition of intrinsic drug resistance to β-lactam, mechanism: FTC inhibits NagZ protein
reducing the β-lactamase production.
β-lactam antibiotics like penicillin, cephalosporins, carbapenems showed activity against
gram-negative bacteria like E. coli and P. aeruginosa.220,288,289 Even though gram-negative
bacteria acquire resistance to β-lactam antibiotics by overexpression of different β-lactamase
enzymes which degrades antibiotic, extended spectrum β-antibiotics like aztreonam, imipenem,
cefoxitin and ceftazidime tolerate some chromosomally encoded β-lactamase enzymes288,289.
These extended spectrum β-antibiotics still are not totally resistant to broad spectrum βlactamase enzymes found in clinical strains. The chromosomally encoded AmpC β-lactamase
play crucial role in increased tolerance to extended spectrum β-antibiotics in gram-negative
bacteria.
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Previously, triazolyl glycolipid derivatives increase the susceptibility of a drug-resistant
S. aureus (MRSA) to β-lactam antibiotics.332 These molecules supposedly suppress penicillin
binding protein 2a (PBP2a) which is responsible for β-antibiotic resistance in drug-resistant S.
aureus (MRSA).333,334. These triazolyl glycolipid derivatives also showed to increase cell
membrane permeability for β-antibiotics 332.
We tested effect of FTC on β-lactamase activity in gram-negative bacteria P. aeruginosa.
We found that FTC reduces expression of basal β-lactamase activity in wild type PAO1. Usually
β-lactam antibiotics induce expression of β-lactamase enzyme in bacteria resulting in increased
resistance to β-lactam antibiotics. We tested effect of FTC on induction of β-lactamase activity in
the presence of β-lactam antibiotic, Cefoxitin. Cefoxitin is potent inducer of β-lactamase and can
antagonize the activity of other β-lactams against bacteria. We found that FTC reduced βlactamase activity in the presence of Cefoxitin and increased efficacy against wild type PAO1 by
2-folds. (MIC changed from 1028 µg/ml to 64 µg/ml).
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Figure 4.32 AmpC β-lactamase activity (measured in nanomoles per minute per milligram
nitrocefin hydrolyzed) were measured by nitrocefin hydrolysis assay. Specific activity is in units
of nanomoles of nitrocefin hydrolyzed per minute (mU) per milligram of protein. Induction was
carried out by culturing PAO1 in the presence of 50 μg/ml cefoxitin for 3 h at 37°C.
β-N-Acetylglucosaminidase (NagZ), encoded by the nagZ gene, is a critical enzyme for
ampC expression in gram-negative bacteria.286,287,335Activation of AmpC is needed for blactamase production in several pathogenic Gram-negative bacteria,336,337and ampC gene
expression is regulated by cell wall peptidoglycan recycling. Hence, blocking NagZ activity with
small-molecule inhibitors has garnered interest as a therapeutic strategy to suppress AmpC
mediated b-lactam resistance. These inhibitors like O-(2-acetamido-2deoxy-Dglucopyranosylidene)amino-N-phenylcarbamate (PUGNAc) and derivatives inhibits NagZ nonselectively.336,337 NagZ offers conformational flexibility in binding pocket for inhibitor
molecules.336,337 Analogous to PUGNAc, addition of bulky substituents to the acetamido moiety
of this inhibitor also makes it selective for NagZ.337 This knowledge suggest that saccharide with
hydrophobic moiety can potentially inhibit NagZ.
We hypothesized that FTC may have inhibitory effect on NagZ enzyme activity resulting
in downregulation of β-lactamase expression286,287,335. We tested commercially available potent
non-selective NagZ inhibitor PUGNAc and FTC against NagZ enzyme activity. We found that
FTC reduced NagZ enzyme activity in wild type PAO1 by 65%.
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Figure 4.33 NagZ activity assay of wild-type P. aeruginosa in the presence of non-selective
NagZ inhibitor PUGNAc (500µM) and FTC (10µM). NagZ activity was determined from
sonicated cultures by monitoring fluorescence of 4-methylumbelliferone (4-MU) liberation at an
excitation wavelength of 360 nm and monitoring of the emission at 450 nm.

The wild-type P. aeruginosa (PAO1) were treated with and without inhibitor PUGNAc (500µM)
and FTC (10µM) for 12 h and lysate of cells of wild-type P. aeruginosa (PAO1) was assayed for
N-acetyl-β-glucosaminidase activity by using 4-methylumbelliferyl N-acetyl-β-d-glucosaminide
(4-MUGlcNAc) as the substrate. Liberated 4-methylumbelliferone (4-MU) was detected by
measurement of the fluorescence by using an excitation wavelength of 360 nm and monitoring of
the emission at 450 nm. We found that PUGNAc reduced NagZ activity by 52% while FTC
reduced NagZ activity by 65%.
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Figure 4.34 Possible schematic representation of emergence of resistance via tolerance and
persistence route. a. Antibiotic treatment caused tolerance mutation. b. Tolerance and
persistence facilitate resistance mutation. c. Tolerance transition to persistence. d. Generational
gene transfer. e. Horizontal gene transfer.
4.6.5 FTC binds to Lectin A
The galactophilic protein Lectin A (LecA) of P. aeruginosa has a significant role in
controlling biofilm formation and is positively correlated to the levels of cdG in bacteria.297,298
FTC inhibited biofilm formation in P. aeruginosa PAO1 and PA14. We believe that FTC inhibits
biofilm formation via LecA inhibition. We examined the binding of FTC to LecA (Fig. 1), by
using an established fluorescence polarization-based competitive binding assay296. For this assay,
we designed and synthesized a Dansyl fluorophore-tagged galactose ligand (βGal-aryl-Dansyl,
Fig. X) for LecA protein. As a fluorophore-tagged ligand bind to a receptor protein, its
fluorescent polarization increases as the motion and dynamics reduce in the solution. The βGalaryl-Dansyl (200 nM) showed an increase in its fluorescence polarization with increasing
concentrations of LecA (0-100 μM), with a transition indicative of a Kd ~10.7 μM, whereas for
the control protein, bovine serum albumin (BSA), no significant increase in fluorescence
polarization was observed. To estimate the binding strength of FTC to LecA protein, the
molecules were titrated into a mixture of βGal-aryl-Dansyl (200 nM) and LecA (20 μM) to
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displace the βGal-aryl-Dansyl from LecA. We found that FTC caused a decrease of fluorescence
polarization indicative of an IC50 of 20 µg/ml.

Figure 4.35 FTC binds to Lectin A. 100 uL of LecA (20 µM) and βGal-Dansyl (200 nM) versus
concentration of FTC (1-500 µg/ml). Error bars indicate the standard deviations of means of
triplicates.
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Summary
The primary mechanism is spontaneous mutation, which is random and rare. Under
stress, natural selection is not random, and cause the selected mutant to populate. There are two
possible cases of “spontaneous mutations”. A. Unprovoked, natural mutations. B. Under killing
or growth inhibition stress, the resistant strains develop from tolerant and persistent one. For
natural mutations, FTC does not show any resistant mutant. The mechanism of action is unclear.
From initial high dose of antibiotics, there are two scenarios that the resistant mutant can emerge
and populate. 1. vertical gene transfer. 2. Horizontal gene transfer. Vertical gene transfer is the
transfer of genetic information, including any genetic mutations, from a parent to its offspring.
The vertical gene transfer is hard to inhibit. The FTC and FTEG4OH inhibit pili and pili
mediated activities which are necessary for horizontal gene transfer and different mechanisms of
gene transfer. FTC also inhibits another receptor proteins Lectin A which is closely related to
global messenger c-di-GMP. The levels of c-di-GMP dictate tolerance and persistence in P.
aeruginosa and different bacteria. As tolerant and persistent bacteria are precursor to resistance
bacteria, we believe that FTC can prevent emergence of resistant bacteria over the time.
All in all, we believe that FTC can be future of antibiotics which exhibit broad spectrum activity
against different bacteria and prevent resistance development.
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Experimental section
4.6.6 Strains and Plasmids.
PAO1-mCherry (TcR) was given by George A. O'Toole’s lab (Dartmouth College). PA14
140495 (PAPI-1) and PAO1CbRlacZ were given by Stephen Lory’s lab (Harvard Medical
School). All strains were grown in LB medium supplemented with the appropriate antibiotics.
PAO1-mCherry (TcR) was served as plasmid donors, while PAO1 wild type was served as
plasmid recipient in transformation assays. PA14 140495 (GmR) and PAO1lacZ (CbR) were
served as donor and recipient in conjugation assays respectively.
4.6.7 Inhibition of transpeptidase activity of Penicillin binding proteins (PBPs)
An ELISA-like protocol was used in black-walled Costar microtiter plates (Costar #3631), with
gentle rocking at room temperature used for all steps. For PBP1a attachment, wells were treated
with 2 μg of PBP in 50 μL of PBS/20% glycerol at 25 °C for 30 min, followed by treatment (3x)
with 150 μL/well of blocking buffer (PBS/0.2% Tween-20), and then washed (3x) with 200
μL/well of washing buffer (PBS/0.05% Tween-20). To label PBP1a in initial proof-of-principle
experiments, 50 μL of 100 μM BIO-AMP in PBS was added to the wells. After 10 min the
PBP1a was denatured heating at 80 °C for 3 min followed by quick cooling on ice. The plates
were then washed (3x) with washing buffer. Bound biotin-Amp-PBP was quantified by Pierce™
Biotin Quantitation Kit.
With inhibitor: For PBP attachment, wells were treated with 2 μg of PBP1a in 50 μL of
PBS/20% glycerol at 25 °C for 30 min, followed by treatment (3x) with 150 μL/well of blocking
buffer (PBS/0.2% Tween-20), and then washed (3x) with 200 μL/well of washing buffer
(PBS/0.05% Tween-20). 50 μL of different concentration of inhibitor FTC in PBS was added to
the wells. After 1 h, 50 μL of 100 μM BIO-AMP in PBS was added to the wells. After 10 min
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the PBP1a was denatured heating at 80 °C for 3 min followed by quick cooling on ice. The plates
were then washed (3x) with washing buffer. Bound biotin-Amp-PBP was quantified by Pierce™
Biotin Quantitation Kit.
4.6.8 Inhibition of conjugation
We adopted the method of mating in static liquid culture338 with the modification that
inhibitor molecule, FTEG4OH was cultured with recipient strain (PAO1CbRlacZ), and included
in the mating mixture culture. To prepare the culture of donor strain, PA14-140495 was grown
with 75 µg/ml gentamicin in LB medium at 37℃ overnight with shaking (250 rpm). The donor
culture (50 µL, OD600 1.0) was further diluted into 1 mL of LB and incubated at 37°C for 2-h
with shaking (250 rpm). To prepare the culture of recipient strain, PAO1CbRlacZ was grown
with 75 µg/mL carbenicillin in LB medium at 37°C overnight with shaking (250 rpm).
FTEG4OH (stock 10 mM) was added to a 50 µL of recipient cultures (OD ~1.0) for a final
concentration of 100 µM, and further cultured for 3 h at 37 °C. For gene transfer by conjugation,
the prepared recipient culture (50 µL) was mixed with the prepared donor subculture (1.05 mL)
to incubate at 37°C for 48 h statically. The resulting mating culture generated observable slimy
substances, and was mixed with 1 mL of fresh LB, and then sonicated in bath for 10 min. The
diluted culture in 15 mL falcon tube was immersed a water bath in the sonicator [SRA
TruPower, UC-45D-PRO] and sonicated for 10 min with 50% power. To quantify the PAPI-1
transfer, 100 µL of the final mating mixture was poured and spread on a selective agar
containing 75 µg/mL gentamicin, 150 µg/mL carbenicillin and 40 µg/mL X-Gal. The number of
transconjugants (blue colonies) was counted after 48 h incubation. The transfer frequency was
calculated by the total number of transconjugants (blue colonies) divided by the total recipients
(CFU after 48 h culture at 37°C)
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4.6.9 Inhibition of transformation
For transformation, the plasmid donor strain, PAO1-mCherry (TcR) was cultured with or
without the pili inhibitor, FTEG4OH. The donor culture was then sonicated by a tip sonicated to
release the DNA plasmids from the bacteria, the bacteria and its debris was removed by
centrifugation and filtration. The supernatant containing mCherry (TcR) plasmid was mixed with
the recipient strain, wt PAO1 culture with the presence of FTEG4OH under stress of sub-lethal
amount of tetracycline (20 µg/ml). Sub-lethal concentrations of antibiotic promote the intake of
plasmid.50 The number of transformed bacteria was quantified by colony forming units on LB
agar plate containing 250 µg/ml tetracycline. To prepare the recipient culture, the inhibitor
molecule, FTEG4OH (10 mM stock), was added into 1 mL of PAO1 recipient subculture (OD =
0.8) to obtain final concentration of 100 µM, and further cultured for 3 h at 37℃ with shaking
(250 rpm). To prepare the supernatant of the donor strain, an overnight culture of donor strain
(PAO1-mCherry) was centrifuged to obtain pellet. Pellet was resuspended in PBS buffer and
cold sonicated using a probe sonicator at power level 1, ON for 5 sec., and OFF for 5 sec., and
repeat 6 times; the culture was then centrifuged (4185 g, 15 min) to pellet the bacterial debris.
This supernatant of donor strain was filtered with 0.22 µm syringe filter to further remove
residual bacterial cells. Plasmid DNA concentration was estimated by measuring the absorbance
at 260nm, adjusting the A260 measurement for turbidity (measured by absorbance at 320nm),
multiplying by the dilution factor, and using the relationship that an A260 of 1.0 = 50 µg/ml pure
plasmid DNA. Concentration (µg/ml) = (A260 reading – A320 reading) × dilution factor ×
50µg/ml. The Plasmid DNA yield was calculated as plasmid DNA yield (µg) = DNA
concentration × total sample volume (ml).339
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For the transfer experiment, the supernatant (5 mL) of donor culture (PAO1-mCherry) was
mixed with 1 mL of recipient culture that contained 100 µM of FTEG4OH. To this mixture
culture, 50 µL of 10 mM stock of FTEG4OH was added to maintain 100 µM in the total 6 mL
mixture. Tetracycline was also added to the mixture to get a concentration of 20 µg/mL. The
same mixed culture was also prepared without adding tetracycline as a control. The mixtures
were cultured for 24 h at 37℃ with shaking (250 rpm). To quantify the plasmid transfer, colony
forming units (CFU) of the recipient strains was counted on agar plates containing 250 µg/mL
tetracycline.
4.6.10 Chemical inhibition of bacteriophage adsorption ϕKMV on P. aeruginosa.
Bacteriophage adsorption assay were adopted as described previously,331,340 with addition of our
agents. An overnight culture (100 µL) of wt P. aeruginosa strain PAO1k that is ϕKMV sensitive,
was diluted with 10 mL of LB supplemented with 10 mM MgSO4 (LB‐Mg2+) and subcultured to
OD600 around 0.6 at 37°C with shaking at 250 rpm with and without 100 µM of FTEG4OH. The
bacteria subculture (100 µL) was mixed with 900 μL of ϕKMV phage. The titer of added phage
was determined for every experiment from the phage stock solution. Following incubation for 10
min at 37 °C with shaking at 100 rpm, bacteria were removed by centrifugation (10,000 g, 5 min
at 4°C), and 900 μL of the supernatant was transferred to an Eppendorf tube. The plaque‐forming
units (PFU) in the supernatant with and without the added agents was determined by the top agar
overlay method with PAO1k. The percentage of phage bound to bacteria was calculated as [(titer
of added phage − titer in supernatant)/(titer of added phage)] × 100.
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4.6.11 Chemical inhibition of transduction on bacterial lawns and in planktonic culture.
To prepare phage-loaded supernatant from the donor strain, an overnight culture (150 µL)
of PAPI-1 donor PA14-140495 (GmR) was diluted with 15 mL of LB and cultured at 37°C with
shaking at 250 rpm to reach an OD600 of 0.6. Ciprofloxacin (stock 1 µg/mL) was added into this
subculture to reach 0.05 µg/ml and cultured for additional 3 h at 37℃ without shaking; to
promote the production of phages. The culture was centrifugated at 4185 g for 10 min to pellet
the bacterial cells. The supernatant (10 mL) was filtered through a 0.22 µm filter to further
remove bacterial cells and treated with 0.5 µL of Universal Nuclease (10 kU stock) and
incubated for 1 h at ambient temperature; to degrade the DNA molecules in the supernatant.
To prepare the agar plate (0.7% top agar and 1.5% LB agar), 3 mL of warm top agar
solution (7 g/l agar, 0.5 g/L sodium chloride, 10 g/l tryptone, 5 g/l yeast extract in sterile water)
was mixed with 200 µL of PAO1k culture (OD 0.6), spread on 1.5% “hard” agar plate (LBMiller, 10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl ,15 g/l agar, 10-cm in diameter), and
cooled for 15 min in biosafety level-2 hood to solidify the top gel at ambient temperature. The
agar plates were incubated at 37 °C for 1 h statically. 10 µL of ciprofloxacin treated supernatant
from PA14-PAPI-more details culture was added and incubated for 24 h.
To prepare the recipient culture, an overnight culture (100 µL) of the recipient strain
PAO1CbRlacZ was sub-cultured in 10 mL LB supplemented with and without 100 µM of
inhibitor molecule, FTEG4OH (from a stock of 10 mM) at 37°C with shaking (250 rpm) to reach
an OD600 of 0.6.
On bacterial lawn. 100 µM of FTEG4OH was added onto solidified top agar layer and incubated
for 15 min in biosafety level-2 hood at ambient temperature. The agar plates were incubated at
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37 °C for 1 h statically. 10 µL of ciprofloxacin treated supernatant from PA14-PAPI-more details
culture was added onto same spot as FTEG4OH and incubated for 24 h.
In planktonic culture. Overnight culture of wild type PAO1 was diluted 100x in LB, and
subcultured (10 mL) with and without FTEG4OH (100 µM) to an OD of 0.6. Phage loaded
supernatant (1 mL, see above) was added to both subculture, and the optical density (OD600) was
monitored over 24 h.
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4.7. Synthesis and Characterization data
4.7.1 Synthesis of Farnesol Triazole tetraethylene glycol (FTEG4OH)

Figure 4.36 Synthesis scheme for Farnesol Triazole Tetraethylene glycol (FTEG4OH)
4.7.2 Synthesis of Farnesol Triazole Cellobioside (FTC)
Synthesis of Farnesol triazole cellobioside(FTC) is based on convergent synthesis that couples an
alkyne-derivatized farnesol and a protected disugar derivatized with an azide by Click chemistry,
followed by the deprotection of the hydroxyl groups of the disugar under basic conditions
(Scheme X).

Figure 4.37 The synthesis scheme for Farnesol triazole cellobioside (FTC).
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4.7.3 Synthesis of Farnesol oxadiazole cellobioside (FOC)

Figure 4.38 Synthesis scheme for Farnesol oxadiazole cellobioside (FOC).
7.4 Synthesis and characterization of intermediates for FTC,FOC and FTEG4OH
First step of the synthesis involved conversion of acetocellobioside into acetobromocellobioside
in the presence of hydrobromic acid in acetic acid and conversion of farnesol to propargyl
farnesol ether.

Figure 4.39 Synthesis of acetobromocellobioside

Figure 4.40 Synthesis of propargyl farnesol ether.
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The 1H NMR and 13C NMR both showed the compound to be pure for acetobromocellobioside.

Figure 4.41 1H NMR of acetobromocellobioside.
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Figure 4.42 13C NMR of acetobromocellobioside

Figure 4.43 1H NMR of propargyl farnesol ether.

Figure 4.44 13C NMR of propargyl farnesol ether.
The bromoacetocellobioside was converted to azidoacetocellobioside by simple nucleophilic
substitution reaction with sodium azide.
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Figure 4.45 Synthesis of azidoacetocellobioside

Figure 4.46 1H NMR of azidoacetocellobioside

Figure 4.47 13C NMR of azidoacetocellobioside
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After synthesis of azidoacetocellobioside, click chemistry was performed on farnesol propargyl
ether and azidoacetocellobioside.

Figure 4.48 Synthesis of acetylated farnesol triazole cellobioside (AcFTC).

Figure 4.49 1H NMR of acetylated FTC
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Figure 4.50 13C NMR of acetylated FTC.
The final step of the reaction was the deacetylation of the acetylated FTC by Zemplén
deacetylation using sodium methoxide solution (MeONa/MeOH).

Figure 4.51 Deacetylation of acetylated FTC.
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Figure 4.52 1H NMR of FTC

Figure 4.53 13C NMR of FTC.
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Figure 4.54 1H NMR of farnesol oxadiazole ethyl ester.
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Figure 4.55 1H NMR of aminoheptaacetocellobioside.

Figure 4.56 1H NMR of protected farnesol oxadiazole cellobioside.
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Figure 4.57 1H NMR of deprotected farnesol oxadiazole cellobioside.
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Chapter 5. Farnesol Potentiates Silver against Burn Wound Microbiome by
Inhibiting Pyocyanin and Promoting Rhamnolipids Production.
5.1 Background and Significance
5.1.1 Silver exhibit broad-spectrum antibacterial activity.
The antibacterial activity of silver has been known for known for thousands of years
dated back around 400 B.C.341,342 Since ancient Greeks utilized silver for stomach aches and
wound healing, silver was likely the most important antibacterial compound before the
introduction of antibiotics.343 It is currently utilized on hospital surfaces to minimize nosocomial
illness.344,345 It's also found in water purification systems including hospital hot water circuits,
swimming pools, and potable water distribution systems.345 Silver can also be found in Japanese
Jintan tablets, which are used to treat nausea, vomiting, hangovers, foul breath, and sunstroke,
among other things.341,342 Similarly, silver ions have been recognized as a highly effective
potentiator of different classes of antibiotics.346,347 Finally, silver nanoparticles are one of the
most commonly employed nanomaterials in medicinal, antibacterial, and electrical
applications.345
5.1.2 Silver targets multiple bacterial macromolecules.
Despite their long and widespread use, the exact mechanism of silver as antibacterial agent
remains unknown. Interestingly, metal silver has no biological function while only ionic state
(Ag+) is highly toxic to microbes. Silver ions are strongly bind to nucleic acids and form tight
complexes with DNA or RNA.348 They interact preferentially with bases rather than the
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negatively charged backbone of DNA. Ag+ toxicity arises from nonspecific binding to DNA.348
Silver ions also target thiol containing cytoplasmic proteins like enzymes and leads to
inactivation of enzymes. membrane proteins, including those associated with electron
transport.349,350 Silver ions also showed to alter cell envelope and shrinking of cell membrane.350
There is also debatable mode of action of silver ions like ROS production and perturbation of
iron homeostasis.351

Figure 5.1 General mechanisms for antimicrobial mode of action of silver ions against bacteria.
(This figure is adapted and modified from “A. Roy, O. Bulut, S. Some, A.K. Mandal, M.D. Yilmaz, Green synthesis
of silver nanoparticles: biomolecule-nanoparticle organizations targeting antimicrobial activity, RSC advances, 9
(2019) 2673-2702.”)

5.1.3 Emergence of silver resistance.
While antibacterial targeting multiple cellular targets as mode of action for killing are believed to
combat development of drug resistance, 343,349,352 silver resistance has occurred over the years.353356

Bacterial develop resistance to silver typically by gene mutation and requires changes in
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silver-binding proteins, associated efflux pumps which export the bound silver ion from the
bacterial cell.353,354 Horizontal gene transfer also showed to rise silver resistance in many
bacterial species.357,358 Recently, a novel mechanism of silver resistance was reported for the
well-known opportunistic gram-negative bacterium Pseudomonas aeruginosa. P. aeruginosa
produces pyocyanin pigment which reduces active silver ions to inactivate silver ion leading to
resistance by reducing Ag+ to Ag metal. Pyocyanin is a blue-green redox-active secondary
metabolite (Fig.5.2) that is produced by Pseudomonas aeruginosa.359-361Pyocyanin acts as an
extracellular electron carrier and participate in redox reactions.361,362 Due to its redox activity,
pyocyanin increases the production of reactive oxygen species and also depletes the pools of
antioxidant molecules like glutathione.360,361,363 Pyocyanin is a zwitterion that can easily
penetrate biological membranes and is readily recovered in large quantities from the wound
exudates.360 Pyocyanin can also act as interspecies communication signal between P. aeruginosa
and S. aureus.364 These two common bacterial species are highly sensitive to Ag+ individually,
but when they are dwelling together, they develop resistance to silver ions.364
5.1.4 Silver therapy is widely used against burn wound infections.
Burn wounds are ideal site for harvest of bacteria and cause persistent infection than surgical
wounds, mainly because of the larger area involved and longer duration of patient stay in the
hospital.365-367 Bacterial infection is a major cause of morbidity and mortality in hospitalized
burn patients. About 75% of the mortality from burn injuries is estimated to be related to
bacterial infections rather than osmotic shock.365 Burn wound harbors microorganisms like
Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes.365,368 Burn wound
impetigo and folliculitis are usually caused by bacterial colonization (high concentrations (>105
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CFU bacteria/g of tissue) in the burn wound and scab. However, no evidence exists that the
infection is invasive.365,368 Burn wound infections usually harbors P. aeruginosa and large
amounts of pyocyanin have been identified in burn wound exudates of infected patients.369,370
Silver ion has been used as first line antibacterial to treat burn wound infections. Silver ioncontaining creams are favored topical ointments for large burns and marketed as Flamazine (10
mg/ml silver sulfadiazine) and Silvazine (10 mg/ml silver sulfadiazine plus 2 mg/ml
chlorhexidine digluconate).371 The silver-coated polyurethane negative-pressure wound therapy
(NPWT) sponge are newer silver products, which has the advantages of NPWT with a sustained
release of 20 to 40 ppm of silver ion.372,373 These products are also helpful against biofilmcausing organisms, such as Pseudomonas aeruginosa and Staphylococcus aureus, including
methicillin resistant staphylococcus aureus(MRSA) more than other silver formulations, leading
to faster healing in infected diabetic foot ulcers.372-374
5.1.5 Silver therapy face serious challenges in treatments of burn wounds.
Silver formulations are widely used for the treatment of second-degree burns. However,
sometimes silver therapy can have some of the worst outcomes in burn treatment, in terms of
infection and wound healing. Silver ion treatments suffer major concerns like silver ion is
effective only for the first few days/weeks, after which non-silver dressings should be used
instead. For clean wounds and closed surgical incisions, silver confers no benefit and can lead to
risk of resistance.356Burn wound infections have shown resistance to silver treatments.356,370,375
Silver ions formulation like silver sulfadiazine impairs wound healing.376,377
The Pseudomonas aeruginosa and Staphylococcus aureus are two notorious bacteria that
contribute to major burn wound infections and acquired resistance to silver therapy. The
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dominant flora of burn wounds during hospitalization changes from Gram-positive bacteria such
as Staphylococcus to Gram-negative bacteria like Pseudomonas aeruginosa.378 The pattern of
antimicrobial susceptibility of S. aureus and P. aeruginosa is a concern as these two species can
cross communicate and develop adaptive resistance to antimicrobial treatment.378-380 The
coexistence of S. aureus and P. aeruginosa have been extensively studied in cystic fibrosis
disease and coinfections leads to poor clinical outcomes381-383.
Even though S. aureus and P. aeruginosa frequently co-colonize chronic wounds,384-386
the connection between them in the chronically infected wound is not well understood. Biopsies
of chronically infected wounds have revealed that S. aureus and P. aeruginosa coexist,379 with P.
aeruginosa located in the deeper tissues and S. aureus at the wound's surface. These two
pathogens are believed to initially co-exist and interact in a beneficial manner to develop
resistance to antimicrobial therapy.385,386 P. aeruginosa and S. aureus coinfections are more
virulent than single infections.387,388 Thus, coexistence of these two organisms is believed to
create cooperative adaptive silver ion resistance.364
Farnesol is a sesquiterpene alcohol (Fig. 5.2) that exists widely in fruits such as peaches,
herbs such as lemon grass, chamomile, and in the essential oils of ambrette seeds and
citronella.389,390 Farnesol is nontoxic to humans and found to alleviate massive inflammation,
oxidative stress, and lung injury.389-391
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Figure 5.2 Structure and IUPAC names of Farnesol and Pyocyanin.
Here we report that how Farnesol, the naturally occurring sesquiterpenoid reduce production of
pyocyanin by P. aeruginosa and eradicate cooperative adaptive silver ion resistance when both
P. aeruginosa and S. aureus are present.
5.2 Results
5.2.1 Farnesol is not toxic to burn wound pathogens.
Farnesol has been shown to inhibit growth of different bacteria like Paracoccidioides
brasiliensis, Staphylococcus epidermidis.392-394 To test effect of Farnesol on growth of burn
wound bacteria, we established the growth curve of P. aeruginosa (wild type PA14) and
Staphylococcus aureus (SA) in the presence of different concentrations of farnesol (10 – 500
µM). We found that farnesol does not affect growth of wild type PA14 or S. aureus (Fig.5.3).
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Figure 5.3 Growth curves of P. aeruginosa wild type PA14 and S. aureus in the presence of
different concentrations of farnesol. Overnight cultures of A. wild type PA14 and B. S. aureus
were diluted in MHB to optical density (OD600) ~0.01 and incubated with different
concentrations of Farnesol (10, 100, 500 µM) for 24 hours at 37 ℃ under 250 rpm shaking. The
OD600 was measured at different time intervals.
5.2.2 Farnesol reduce pyocyanin production in P. aeruginosa PA14.
Pyocyanin has been shown to reduce toxic Ag+ ion to inactive Ag metal.395 We used mutant of
P. aeruginosa which has deletion of pyocyanin synthesis gene phzM.396The pyocyanin deficient
mutant strain (ΔphzM) showed increased susceptibility to silver ions (MIC = 5 ppm) in contrast
to wild type PA14 (MIC = 15 ppm).395 We tested minimum inhibitory concentration (MIC) of
silver ions against wild type PA14, ΔphzM with and without Farnesol. We found that 100 µM
Farnesol increased efficacy of silver ions against wild type PA14 by ~2 folds (MIC dropped
from 15 ppm to 8 ppm). Interestingly, for pyocyanin deficient mutant (ΔphzM), MIC of silver
ions was unaffected by presence of 100 µM Farnesol (Table 5.1). These results suggest that
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Farnesol enhances the silver ion efficacy against P. aeruginosa PA14, and this enhancement is
related to silver ion’s effect on pyocyanin production.

Table 5.1 Effect of farnesol on the efficacy of silver ions against P. aeruginosa PA14, and
pyocyanin deficient strains.
MIC* (ppm)
Strain

w/o Farnesol

w/ Farnesol

wild type PA14

15

8

ΔphzM

5

5

* Minimum Inhibitory Concentration (MIC) was defined as the lowest concentration of silver ions that completely
inhibit visible growth of bacteria.

To evaluate effect of farnesol on pyocyanin production, we cultured PA14 with and
without 100 µM Farnesol for 12 hours and quantified pyocyanin secreted in supernatant. We
found that farnesol reduces pyocyanin production in PA14 by 80% (from ~ 5.1 µg/ml to 0.84
µg/ml) (Fig.5.4A). As pyocyanin is known to destroy silver ions by converting Ag+ to Ag0and
reduce its biological activity,395 we test the hypothesis Farnesol increase silver ions efficacy by
reducing levels of pyocyanin. We examined the level of silver ions in PA14 cultures (12 hours)
with and without 100 µM Farnesol. Pyocyanin converts molecular oxygen to the superoxide free
radical by oxidizing reduced nicotinamide adenine dinucleotide phosphate (NADPH) to
Nicotinamide adenine dinucleotide phosphate (NADP+).360 We incubated silver ions (100 µM) in
PA14 supernatant and NADPH (100 µM), and determined Ag+ concentration by sensitive
dimethylaminobenzylidene rhodamine method. Without farnesol, PA14 supernatant reduced 80
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% of silver ions (Ag+) to silver metal (Ag0). The PA14 supernatant treated with farnesol only
reduced Ag+ by 15% (Fig.5.4 B).

Figure 5.4 Effect of Farnesol on Pyocyanin production and silver degradation by P. aeruginosa.
A. Pyocyanin levels in supernatant of planktonic cultures of wild type PA14 treated with and
without 100 µM of Farnesol for 12 h in fresh King’s A medium. The pyocyanin levels were
measured as µg/ml of supernatant. Images represent green pigment pyocyanin production with
and without Farnesol. More green color represents more pyocyanin production. Error bars are
standard error of the mean from three replicates. The rhamnolipids produced without Farnesol
was considered as control. *P = 0.01 vs control as evaluated using two-tailed unpaired Student’s
t-test. B. Silver ion concentration after treatment of 100 µM silver ions with supernatant of PA14
treated with and without Farnesol for 12 hours. A solution of Ag+ (100 μM) was reduced in the
presence of PA14 supernatant and NADPH (100 μM) in water (pH 7.0; 32°C) and remaining
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silver ions concentrations were determined by dimethylaminobenzylidene rhodamine dye
method. Error bars are standard error of the mean from three replicates. The silver ions
concentration without Farnesol was considered as control. *P = 0.05 vs control as evaluated
using two-tailed unpaired Student’s t-test.
5.2.3 Farnesol Increases rhamnolipid production in P. aeruginosa PA14.
P. aeruginosa uses quorum sensing (QS) to sense the presence of small molecules they secreted,
and thus their population, and response by forming different phenotypes. This QS is regulated by
the interlinked las, rhl, pqs gene systems. Interestingly, modulation of rhl and pqs activities
induces inverse regulation of pyocyanin and rhamnolipid production in P. aeruginosa.397,398 P.
aeruginosa produces biosurfactant named rhamnolipids which modulate motility and
biofilms.399,400 Our previous results showed that Farnesol reduces pyocyanin production in PA14,
here we also evaluated effect of Farnesol on rhamnolipids production. We quantified
rhamnolipids production in the presence of Farnesol by methylene blue complexation method.401
We found that Farnesol increased rhamnolipids production by 50% (94 µg/ml to 144 µg/ml)
(Fig.5.5).
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Figure 5.5 Effect of Farnesol on rhamnolipids production by P. aeruginosa PA14. Rhamnolipids
productions by planktonic cultures of wild type PA14 treated with and without 100 µM of
Farnesol for 18 hours were determined using an established methylene blue complexation assays.
The positively charged methylene blue form noncovalent complex preferentially with negatively
charged surfactants and does not bind to nonionic surfactants. The methylene blue bound with
negatively charged surfactants has an increased partition into the organic chloroform phase
bought in contact with the aqueous solution. The methylene blue in the chloroform phase were
measured for its UV absorbance, which infers the concentration of rhamnolipids (µg/ml) in the
culture. Error bars are standard error of the mean from three replicates. The rhamnolipids
produced without Farnesol was considered as control. *P = 0.02 vs control as evaluated using
two-tailed unpaired Student’s t-test.
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5.2.4 Farnesol Increased Dispersion in Dual Species Biofilms.
Considering that both P. aeruginosa and S. aureus may co-exist in wound infections, the impact
of these bacterial interaction on biofilm formation is inevitable. The mono and dual species
biofilms by these both bacteria are highly tolerant to silver ions.402,403 Pyocyanin in P.
aeruginosa biofilms contribute positively to silver tolerance.403,404 Moreover, dual species
biofilms are always hard to eradicate due to pyocyanin mediated cross signaling.364 S. aureus
showed enhanced biofilm dependent and biofilm independent tolerance during coexistence of P.
aeruginosa species.379,405 P. aeruginosa rhamnolipids enable and maintain the formation of
biofilm structure with channels and pores. For mature biofilms, rhamnolipids are also needed for
dispersing bacteria from biofilms.399,400 Thus, rhamnolipids have been used as dispersal agents
against P. aeruginosa biofilms (strain and concentration dependent)397,399,400,406,407 and S. aureus,
S. epidermidis.408,409 Because farnesol also increase the production of rhamnolipids, we
hypothesize that Farnesol can eradicate silver tolerance in mono and dual species biofilms. We
formed mono (S. aureus or PA14) and dual (S. aureus and PA14) species biofilms and treated
respective biofilms with Farnesol. Farnesol caused dispersion of S. aureus biofilms by 40%,
consistent with literature410 while moderately dispersed (16%) PA14 biofilms (Fig.5.6).
Interestingly, Farnesol showed enhanced biofilm dispersion (82%) in dual species (SA+PA14)
biofilms. These results together suggest that while Farnesol might not cause strong biofilm
dispersion for mono species, Farnesol can be more effective at dispersing biofilms of PA-SA
dual species biofilms.
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Figure 5.6 S. aureus and P. aeruginosa biofilms dispersion in the presence of Farnesol. Percent
biofilms remaining after treating 24-h biofilms grown on pegs with and without 100 µM farnesol
(100 rpm shaking) for another 24 h. The biofilms treated without Farnesol were considered as
100 % control. Error bars are standard error of the mean from six replicates.
5.2.5 Sub-lethal concentrations of silver ions promote swarming motility in P. aeruginosa PA14.
P. aeruginosa show increased resistance to antimicrobials by increased motilities like
swarming, surfing.246,247,411 Silver nanoparticles especially at sub-lethal concentrations showed to
enhanced motilities in E. coli, P. aeruginosa and contribute to silver resistance.412,413 We tested
effect of sub-lethal concentrations of silver ions on P.aeruginosa wild type PA14. We found that
sub-lethal concentration of silver ions (0.5 ppm, MIC = 15ppm) promoted swarming motility in
wild type PA14 by 43% (swarming diameter increased from 58 mm ± 3 mm to 83 mm ± 4 mm)
(Fig. 5.7A)
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5.2.6 Farnesol inhibits Ag+ promoted swarming motility in P. aeruginosa PA14.
PA14 always exhibit tendril formation when they swarm on a soft agar gel, whereas PAO1
swarm evenly outward radially, resulting in a circle pattern. There are currently no reported
chemicals that control the swarming of PA14. We previously showed that saturated farnesol
derivatives inhibit swarming motility in wild type PAO1, but not PA14.81 We tested effect of
farnesol on swarming motility of wild type PA14. We discovered that, when prepared in the
hydrated gel with a concentration as low as 10 µM, farnesol inhibits swarming motility of PA14
(Fig. 5.7B). The swarming motility of PA14 was completely abolished at farnesol concentration
higher than 10 µM with disappearance of tendrils. We also evaluated effect of farnesol on
swarming motility promoted by sub-lethal silver ions. In the presence of farnesol (10 µM), sublethal Ag+ ions did not promote swarming motility in PA14 (Fig. 5.7A).

Figure 5.7 Swarming motility assay. Effect of sub-lethal silver ions and Farnesol on swarming
motility of P. aeruginosa PA14. A. The representative images of swarming motilities PA14 on
semisolid gel (~0.5% agar) with and without sub-lethal silver ions (0.5 ppm) in the presence of
10 µM farnesol. B. The representative images of swarming motilities PA14 on semisolid gel
(~0.5% agar) with different concentrations of Farnesol. The concentrations are indicated below
228

the images. Pictures were taken after the plates were incubated at 37 ℃ for 12 h and then room
temperature for another 12 h.
5.2.7 Farnesol potentiate silver ions against P. aeruginosa PA14.
We previously tested efficacy of silver ions (Ag+) against P. aeruginosa wild type PA14.
The minimum inhibitory concentration (MIC) against PA14 was 15 ppm (15 mg/l). When we
added 100 µM Farnesol to PA14 cultures, MIC was reduced to 8 ppm (Table 5.1). This 2-fold
reduction in MIC against PA14 suggests a synergistic effect between farnesol and silver ions. To
further investigate effect of farnesol on efficacy of silver ion treatments, we treated PA14 culture
(108 CFU/ml) with Ag+ (50 ppm), and with and without 100 µM of farnesol. Silver ions (50
ppm) reduced viability after 24 hours where ~1% bacteria survived (Fig.5.8) without farnesol.
With farnesol, only ~0.02% bacteria survived silver treatment.
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Figure 5.8 Efficacy of silver ions against P. aeruginosa in the presence of 100 µM of Farnesol.
108 CFU/ml PA14 was treated with 50 ppm silver ions for 6 hours under 250 rpm shaking and
viability was measured by colony forming units on MHA plates. Error bars are standard error of
the mean from three replicates. The PA14 survival without Farnesol was considered as control.
*P = 0.02 vs control as evaluated using two-tailed unpaired Student’s t-test.

5.2.8 Farnesol eliminates P. aeruginosa - S. aureus cooperative silver resistance.
S. aureus alone is susceptible to silver ions at low concentrations but pyocyanin produced by P.
aeruginosa renders redox advantage to S. aureus against silver ions364,414. To investigate effect of
farnesol on S. aureus survival against silver ions in the presence of PA14, we exposed S. aureus
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to silver ions in the presence of bacteria free PA14 supernatant (obtained from PA14 treated with
and without farnesol). We could not use direct PA14 bacteria with S. aureus for this assay as
PA14 causes changes in viability of S. aureus.415 We found that supernatant from farnesoltreated PA14 culture caused more S. aureus killing (100 times) than that without farnesol
(Fig.5.9). We found that ~ 0.1% S. aureus bacteria survived in the absence of farnesol. In the
presence of 100 uM farnesol, less than ~ 0.001% bacteria survived silver ions treatment.

Figure 5.9 Survival of S. aureus under silver ions in the presence of P. aeruginosa (PA14)
supernatant. 108 CFU/ml S. aureus was treated with 50 ppm silver ions in the presence of PA14
supernatant (supernatant from PA14 treated with and without 100 µM Farnesol) for 6 hours
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under 250 rpm shaking and viability was measured by colony forming units on MHA plates.
Error bars are standard error of the mean from three replicates. The S. aureus survival in the
presence of PA14 supernatant without Farnesol treatment was considered as control. *P = 0.05
vs control as evaluated using two-tailed unpaired Student’s t-test.

5.2.9 Farnesol prevents formation of small colony variants (SCVs) in S. aureus in vitro.
S. aureus forms small colony variants in the presence of P. aeruginosa as a defensive
mechanism27,416,417 possibly through pyocyanin mediated stress417. Our previous results showed
that farnesol reduced cooperative resistance between S. aureus and P. aeruginosa, and farnesol
reduced pyocyanin production in PA14, we tested effect of Farnesol on PA14 supernatant treated
S. aureus culture. S. aureus shows SCVs when cultured with PA14 supernatant, consistent with
that reported in literature.416 For supernatant from a PA14 culture having 100 uM of farnesol, 10
times less SCVs were observed as compared to supernatant from culture without farnesol
(Fig.5.10A). These results suggest that Farnesol prevents formation of small colony variants
(SCV) by SA that are induced by PA14 supernatant. To test if pyocyanin secreted by P.
aeruginosa play role in SCV formation of S. aureus, we used supernatant of pyocyanin deficient
mutant of P. aeruginosa (ΔphzM)396 for S. aureus culture. We found that S. aureus treated with
ΔphzM supernatant showed no SCVs (Fig.5.10B). These results collectively suggest that
Farnesol inhibits SCV formation in S. aureus-P. aeruginosa coculture by inhibiting PA14’s
pyocyanin production.
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Figure 5.10 Visualization of Small colony variants of S. aureus A. Effect of Farnesol on small
colony variants SCVs formation in S. aureus. B. Effect of ΔphzM supernatant on S. aureus SCVs
were identified by their appearance on Luria-Bertani agar (LBA) generally appearing to be
<1/10th the size of wild-type colonies.
5.3 Discussion
The sil genes are responsible for bacterial silver resistance and served as predictors of
resistance in the wound environment.353,418 Muller have shown that pyocyanin-caused resistance
against silver ions is independent of the sil genes and the silver-binding proteins and efflux
pumps.395 Pyocyanin-caused silver resistance is likely due to pyocyanin caused reduction of Ag+
to Ag metal, inactivating the Ag+ ions.395
Our results showed that Farnesol reduced pyocyanin levels in P. aeruginosa and pyocyanin is
known to reduce silver ions to inactive silver metal, hence silver ions showed increased efficacy
in the presence of Farnesol. Pyocyanin and rhamnolipids are inversely correlated in P.
aeruginosa PA14. As farnesol negatively regulated pyocyanin we hypothesize that farnesol
might have effect on rhamnolipids production. Our results showed that Farnesol increased
production of rhamnolipids in P. aeruginosa. Rhamnolipids not only disperse multi species
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biofilms,407,419,420 but also increase efficacy of antibiotics against different bacteria.414,421-423 Our
results indicates that Farnesol disperse mono and dual species biofilms of wound pathogens P.
aeruginosa and S. aureus, likely by increasing production of rhamnolipids as one of the
contributing factors. Rhamnolipids also promote wound healing and used as anti-scar therapy in
wound therapy.424-426
We demonstrated that Farnesol inhibits swarming motility In P. aeruginosa PA14. We
previously showed that rhamnolipids inhibit swarming of P. aeruginosa PA14 at concentration
higher than 60 µM.427 As Farnesol increased rhamnolipids production in P. aeruginosa PA14,
Farnesol caused inhibition of swarming motility via increased rhamnolipids production.
Swarming motility has been positively correlated to increased antibiotic resistance.247,411 Because
sub-lethal concentrations of antibiotics are known to promote swarming motility in P.
aeruginosa,30 antibiotic and swarming motility becomes vicious cycle. We showed that sublethal silver ions promote swarming motility of P. aeruginosa PA14, and Farnesol abolished
promotion of swarming motility by silver ions in PA14.
Under clinical settings, higher pyocyanin concentrations have been detected in burn
wound fluids.370 P. aeruginosa is shown to reside in the immediate vicinity of pyocyanindeficient species like S. aureus, and provide S. aureus protection from silver ions.364 The absence
of pyocyanin can lead to increased efficacy of silver ions. Farnesol cuts down pyocyanin supply
to S. aureus and increased efficacy of silver ions against S. aureus.
Farnesol inhibited small colony variants of S. aureus in the presence of P. aeruginosa
supernatant. P. aeruginosa and S. aureus frequently are coisolated in burn wound patients and
prolonged growth of S. aureus in the presence of P. aeruginosa leads small colony variants of S.
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aureus.416 Externally added pyocyanin or oxidative stress are shown to be responsible for small
colony variants in S. aureus.416 Farnesol may be inhibiting small colony variants by inhibiting
pyocyanin production.
5.4 Conclusion
We showed that Farnesol inhibits pyocyanin production in P. aeruginosa. Farnesol also
increased production of rhamnolipids which results in not only dual species biofilm dispersion
but also contribute to inhibiting swarming motility of P. aeruginosa. We also showed that
Farnesol increased efficacy of silver ions against wound pathogens P. aeruginosa and S. aureus.
Farnesol inhibited small colony variant formation in dual species cultures, which may also
reduce small colony variants mediated antibiotic persistence. We believe that Farnesol can be
great adjuvant to silver ion treatments because of its synergy with silver ions, which not only
increase the potency of silver ions, but also prevents tolerance and resistance development
against silver ions.
5.5 Experimental Section
5.5.1 Materials
Farnesol was dissolved in sterile (autoclaved) water. Farnesol has solubility of 0.059 g/l in water
~ 265 µM. All assays were performed at concentration less than 265 µM.428 For concentration,
higher than 265 µM , Farnesol was dissolved in sterile dimethyl sulfoxide. Silver nitrate (10
mg/ml) was prepared in sterile (autoclaved) water. Stock solutions of agents were further filtered
through cellulose acetate syringe filter (0.2 µm pore, Millipore). All overnight cultures of
bacteria were grown in Mueller Hinton II Broth (MHB-Cation-Adjusted, Beef extract 3 g/l, Acid
Hydrolysate of Casein 17.5 g/l, Starch 1.5 g/l). All biofilm assays were performed by immersing
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the pegs of a modified polystyrene microtiter lid of MBEC™ plates (Innovotech, Alberta,
Canada) in M63 medium. For pyocyanin extraction, King’s A medium; 1.5 g/l dipotassium
hydrogen phosphate, 1.5 g/l magnesium sulfate, 20 g/l mixed peptone (Himedia, Mumbai, India)
was used. All the optical density/absorbance measurements were carried out on Biotek
ELx800™ absorbance microplate reader (BioTek Instruments, Inc. Winooski, VT). P.
aeruginosa wild type PA14 strain was obtained from Dr. George O’Toole, Geisel School of
Medicine at Dartmouth. Staphylococcus aureus 23235 was obtained from Dr. Olga Makhlynets
from Department of Chemistry, Syracuse University. ΔphzM was obtained from Manoil lab,
University of Washington.
5.5.2 Bacterial Growth Curve analysis
An overnight culture (150 µL) of bacteria (wild type PA14, S. aureus) in MHB was diluted in 15
mL of fresh MHB and incubated with and without different concentrations of Farnesol at 37°C
under 250 rpm shaking. The 200 µL of bacterial cultures were removed and the optical density
was measured at 600 nm at different time intervals.
5.5.3 Preparation of pyocyanin rich bacterial supernatant
An overnight culture of wild type PA14 (100 µL) was added to 10 mL fresh King’s A medium429
with and without 100 µM Farnesol and incubated with 160 rpm shaking for 12 h. After 12 h at
37°C with shaking, cultures were centrifuged at 6000 rpm for 15 min. Supernatants so obtained
were filtered with 0.45-µm pore-size filter (SCBT, USA). The filtered supernatant was used as
source of pyocyanin for biological assays.
5.5.4 Pyocyanin assay131
An overnight culture of wild type PA14 (100 µL) was added to 10 mL fresh King’s A medium ,
5 mL of which were grown with and without 100 µM Farnesol for 12 h. The absorbance of
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bacterial culture was measured at 600 nm (A600), and then centrifuged to remove bacterial pellet.
Bacterial supernatant (5 mL) was extracted with 3 mL chloroform. The pyocyanin-containing
chloroform layer was acidified with 2 mL of 0.1 N HCl to give a pink solution, the absorbance at
520 nm of 200 µL of the solution was measured. The absorbance reading at 520 nm was
converted into µg/ml of supernatant with standard curve reported in literature. Pyocyanin levels
were expressed as µg/ml of supernatant.
5.5.5 Assay for free silver ions (Ag+).
The concentration of free Ag+ was determined using the sensitive dimethylaminobenzylidene
rhodanine method, as described previously.430 Silver nitrate (100 µM, 500 µL) was incubated
with 500 µL wild type PA14 supernatant (obtained by method described previously) and
NADPH (100 µM) in water (pH 7.0; 32°C) for 10 mins. Ag0 nanoparticles were removed prior to
assay of Ag+ by centrifugation at 5,000 rpm for 5 min using an Eppendorf microcentrifuge. 1000
µL of 25 µM 5-(4-dimethylaminobenzylidene) rhodanine (Sigma Aldrich) in acetone, mix, and
incubate 2-5 min at room temperature. Centrifuge for 2 min at 15,000 rpm to remove the silverdye chelate and measure the absorbance of the supernatant at 463 nm. The standard curve
obtained from literature430 for correlation between silver ions concentration and absorbance was
used to calculate free silver ions concentration.
5.5.6 Crystal violet dye-based biofilm dispersion assay120
An overnight culture (100 µL) of bacteria (wild type PA14, S. aureus) in MHB was diluted in 10
mL of M63 and incubated to reach an OD600 value of ~0.1. The bacterial culture (150 µL) was
added to the wells of MBEC™ microtiter plate. The MBEC™ plates were incubated under
stationary conditions at 37 ℃ for 24 h. After incubation, the pegs were transferred and immersed
into 96 wells containing sterile water (200 µL) twice to briefly rinse the biofilms to remove
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unattached or loosely attached bacteria and resuspended in wells containing 100 µM Farnesol in
M63 media and incubated at 37 ℃ for 24 hours. After incubation, the pegs were transferred and
immersed into 96 wells containing sterile water (200 µL) twice to briefly rinse the biofilms to
remove unattached or loosely attached bacteria and air dried for 30 min in BSL-2 hood. The pegattached biofilms were immersed into 96 wells containing crystal violet (CV) dye solution (150
µL, 0.1%) at ambient temperature for 30 min, to stain the biofilms. The CV-stained pegs were
then washed twice with sterile water (200 µL). To solubilize the CR stains, 150 µL of 30% acetic
acid solution was added to wells, and the pegs was immersed in the wells, the plates were shake
on a microplate mixer (Scilogex MX-M) at 100 rpm for 15 min. The amount of biofilms was
inferred and quantified by measuring the OD600 of the 150 µL acetic acid solution on plate
reader. The absorption from stained pegs containing just M63 medium was subtracted from pegs
treated with agents.

5.5.7 Rhamnolipid assay118
Quantification of rhamnolipids in planktonic cultures of P. aeruginosa was determined by
methylene blue-rhamnolipid complex assays by an established assay.118 In this assay, the
positively charged methylene blue form noncovalent complex preferentially with negatively
charged surfactants, and does not bind to nonionic surfactants. The methylene blue bound with
negatively charged surfactants has an increased partition into the chloroform phase bought in
contact with the aqueous solution. The methylene blue in the chloroform phase were measured
for its UV absorbance, which infers the amount of negatively surfactants. Briefly, 100 µL wild
type PA14 bacteria from overnight cultures in MHB were diluted in fresh MHB to an OD600 of
0.01 with and without 100 µM Farnesol. After 18 h at 37°C with shaking, culture supernatants
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were filtered with 0.45-µm pore-size filter (SCBT, USA). The filtrate pH was first adjusted to
2.3 ± 0.2 using 1 N HCl. The acidified sample was then extracted with five-fold volume of
chloroform. The chloroform extract (4 mL) was transferred to put in contact with 5 mL of a
freshly prepared methylene blue aqueous solution (40 µg/ml, pH pre-adjusted to 8.6 ± 0.2 by
adding the 15 µL 50 mM borax buffer). After being vigorously mixed for 4 min, the samples
were left to stand for 15 min. The bottom chloroform phase (1 mL) was transferred into a cuvette
and the absorbance was measured at 638 nm with a UV/Vis spectrophotometer with a reference
of blank chloroform. The absorbance values were converted to rhamnolipid concentrations using
a calibration curve.
5.5.8 Bacterial Swarming assay80
The soft gels for swarming motility were prepared by autoclaving 0.5 wt% Bacto Agar in M8
medium (0.6 % Na2HPO4, 0.3 % KH2PO4 and 0.05 % NaCl). The gel solution was cooled to ~60
ºC, supplemented with filtered 0.2 % glucose, 0.5 % casamino acid, and 1 mM MgSO4 (0.22 µ
filter). The gel solutions were poured into a Falcon tube for 20 mL portions, followed by adding
aliquots of (1-20 µL) of Farnesol, silver nitrate stock solutions to achieve the desired
concentrations. The falcon tubes were closed, the agar solution was mixed by gently rocking, and
then poured into polystyrene petri dishes (10 cm-diameter). The agar solution was solidified by
cooling and air-drying in a laminar hood for 1 h. Bacterial culture of wild type PA14 (3 µL) with
an OD600 between ~0.4–0.6 was inoculated on the center of the surface of the soft agar gel. These
“swarm plates” were incubated at 37 oC for 12 h and then incubated for additional 12 h at room
temperature. After a total of 24 h, pictures of the swarming plates were taken.
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5.5.9 Bacterial killing by silver ions
To determine the efficacy of silver ions against killing of the wild type PA14 and S. aureus in
the presence of Farnesol, the bacterial culture (108 CFU/ml) was treated 50 ppm silver nitrate for
6 h. For PA14, overnight culture (100 µL) of bacteria in MHB was diluted in 10 mL of MHB and
incubated to reach 108 CFU/ml with and without 100 µM Farnesol. The bacterial culture (108
CFU/ml) was treated with 50 ppm silver nitrate for 6 h. For S. aureus, supernatant obtained from
PA14 treated with and without Farnesol was added to bacterial culture (108 CFU/ml) and then
treated with 50 ppm silver nitrate for 6 h. 100 µL aliquots were removed from cultures and the
number of CFU was determined by serial dilution on MHA plates.
5.5.10 In vitro Small colony variants assay71
Overnight cultures (100 µL) of S. aureus was diluted 9 mL of MHB containing 1 mL of
supernatant of wild type PA14 or ΔphzM (prepared as described above) and incubated at 37°C
with 250 rpm shaking for 6 h. These cultures were diluted (105-107) in MHB medium and spread
on Mueller Hinton Agar (MHA) plates and incubated at 37°C for 1 day.
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Chapter 6 Conclusions and Future Perspective
6.1 Conclusions from this thesis
In this thesis, we described class of synthetic adjuvant molecules which targets two
receptor proteins in P. aeruginosa. We identified type IV pili and Lectin LecA which serve as
adhesin proteins P. aeruginosa as a target for these synthetic adjuvant molecules. We
demonstrated how inhibition of pili and LecA controls different phenotypes in P. aeruginosa.
These phenotypes are antibiotic tolerant and persistent and eventually lead to resistance in
bacteria. We also explored anti-adhesin abilities of synthetic adjuvant molecules against pili and
LecA. We showed that pili and LecA recognized asialo-GM1 glycosphingolipid in mammalian
cells and promote motilities and adherence. We demonstrated how chimeric ligands inhibits pili
and LecA binding to asialo-GM1 and thwart asialo-GM1 promoted motilities, adherence.
Inspired from designed of adjuvant molecules which inhibit pili and LecA, we developed
new class of antibiotic, Farnesol triazole cellobioside (FTC) which inhibits penicillin binding
proteins and showed broad spectrum antibacterial activity. We also showed that this new class of
antibiotic did not develop resistance in P. aeruginosa after repeated exposures. Farnesol triazole
cellobioside also did not promote phenotypes like enhanced motility, biofilms, and small colony
variants unlike other conventional antibiotics. We also showed how Farnesol based antibiotics
can prevent horizontal gene transfer via pili inhibition. This discovery by Luk group can be
utilized in the future to design more antibiotics with inhibitory control over horizontal gene
241

transfer. Burn wounds microbiome show enhanced resistance to silver therapy. We demonstrated
use of farnesol as adjuvant molecule in silver therapy. Farnesol inhibits pyocyanin, one of the
virulence factor in P. aeruginosa which is responsible for silver resistance.
6.2 Future work and thoughts
Other strains. Antibiotic resistance in P. aeruginosa is still a major issue in infections.
As a result, new techniques of eradicating diseases caused by drug-resistant bacteria strains are
constantly being pursued. The Luk lab's synthetic ligands bind to adhesin proteins, pili and LecA
and inhibit emergence of phenotypes associated with these proteins. In this thesis, we primarily
focused on P. aeruginosa pathogen, but pili and LecA proteins are not limited to just P.
aeruginosa. In future, these molecules have potential to be broad spectrum and show efficacy at
controlling phenotypes of other microbes.
Do bacteria develop resistance towards non-killing bacterial drugs? Bacteria
develop resistance as response to the antibiotic “attack”. “Survival of the fittest” is a
consequence of an immense genetic plasticity of bacteria that trigger variety of responses that
result in mutational adaptations, acquisition of genetic material or alteration of gene expression.
This resistance development comes with a fitness cost. The ability of the bacteria to genetically
compensate for such fitness costs determines development of resistance. Do bacteria incur such
fitness costs only under severe stress and “need for survival”? Researchers have shown that
antibiotic adjuvants molecules do not develop resistance after repetitive usage. In this thesis, we
show that inhibiting LecA lead to reduction of biofilm formation, which does not kill bacteria,
but increase the susceptibility of bacteria to antibiotics. We ask the question if bacteria are
repeatedly exposed to LecA inhibitor, will bacteria mutate to regain the ability to form biofilms?
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Likewise, inhibiting pili does not kill bacteria but inhibits swarming motility and horizontal gene
transfer, which increase the susceptibility of a bacteria population to antibiotics. We ask the
similar question if a bacteria population is repeatedly exposed to a pili inhibitor in both
planktonic culture and on hydrated soft gel, will bacteria ever mutate to regain the ability to
swarm, and conduct other surface appendage functions to facilitate horizontal gene transfer? In
other words, killing stresses cause bacteria to mutate to increase survival chances, does inhibition
of certain phenotypes cause bacteria to mutate regain that phenotype? Specifically for
phenotypes associated with LecA and or pili, answer to this question leads to another important
question. If, in the presence of such inhibitors, bacteria do not regain the ability to form biofilm
and conduct horizontal gene transfer, does that mean the path to drug tolerance is permanently
blocked, and thus drug resistance to agents such as FTC will never be developed?
Correlation or causation for signaling by LecA inhibition and low cdG levels?
Tolerance “cultivates” resistance development. Our results showed that inhibition of Lectin A
and pili proteins controlled different tolerant phenotypes. These tolerant phenotypes are
precursor of resistant bacteria. Lectin A is correlated to high cdG phenotypes but direct
correlation between Lectin A and cdG is still missing. It is unclear if Lectin A transduce signals
to control levels of cdG or cdG levels control Lectin A activities. We need to do more
experiments to map correlation between LecA and cdG to get better control over tolerant
phenotype. Pili functions at low and high levels of cdG which makes control of cdG levels
tricky. Again, direct correlation between pili and cdG is not clear in literature. We can perform
few basic experiments to establish Lectin A and Pili receptor correlation to cdG. We can use
high and low cdG mutants and determine levels of Lectin A and pili gene expression and
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proteins in these mutants. We can also use commercially available cdG modulator like nitric
oxide donors to see changes in levels of Lectin A and pili genes as function of cdG levels.
Covalent conjugate between antibiotics and inhibitor of horizontal gene transfer?
Horizontal gene transfer is a major cause of resistance development in bacteria. Pili play an
important role in horizontal gene transfer and pili inhibitor can prevent potential horizontal gene
transfer. Luk group has demonstrated that farnesol (saturated and unsaturated) derivatives inhibit
horizontal gene transfer. The use of farnesol derivatives as adjuvant could be one strategy to
develop antibiotic therapy without emergence of resistance. Antibiotic conjugates are one of new
approach to prevent antibiotic resistance. The farnesol conjugated conventional antibiotics can be
very promising in future. From another perspective, FTC is a covalent integration between
chimeric ligands for LecA and pili, and a killing agent targeting cell wall enzymes.
Effect of inhibiting horizontal gene transfer in the bacteria world.

The

significance of horizontal gene transfer on the bacteria’s gene composition is still of debate to
this date. To the gene composition, the contribution of horizontal gene transfer is difficult to be
clearly separated from the veritical inheritance. Here, we have created a unique opportunity of
isolating out the horizontal gene communication between bacteria, and ask the open question of
what will happen in the long run. Bacteria communicate with its environment and each other by
protein appendages, when two major ones, LecA and pili, are shut down, what happen to their
mutation in general over time? What happen also between bacterial strains killing each other?
Furthermore, for a population of bacteria, when spontaneous mutation occurs, it is unlikely that
the same mutation occur at the same time for the entire population, and thus, horizontal gene
transfer likely play role for contributing to spreading the dominating mutation in the population.
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In the presence of an inhibitor for HGT, what happen to the frequency and stability of
spontaneous mutation is another open question for exploration when HGT is inhibited.
Other protein targets by chimeric ligands? In this thesis, we described that chimeric
ligands inhibit pili activities in P. aeruginosa. We also suggested pilT protein mediated
inhibition of retraction as possible mode of action of chimeric ligands. Whether chimeric ligands
also bind to pilT protein to inhibit subsequent signal transduction is not clear. We believe that
methylated hydrocarbon shows inhibitory effect on P. aeruginosa motilities and results as
chemorepellent. To explore if methylated hydrocarbons inhibit motility through inhibition of
pilT mediated retraction, additional experiments must be conducted. We suggest direct
observation of extension and retraction of type IV pili in P. aeruginosa.
Nature of low resistance observed in serial passage assay. For multi-step resistance
assay for farnesol triazole cellobioside (FTC), we observed slight increase in minimum
inhibitory concentration against P. aeruginosa. It is very interesting to see if bacteria survived at
end of 21 passages are truly resistant genotype or tolerant/persistent phenotype mutations. If
bacteria are resistant genotype, the total gene sequencing of bacteria at end of 21 passages should
be done to understand site of mutation in bacteria.
Effect on persisters. The conventional antibiotic induces persister formation and leads to
recurrent infections. The efficacy of antibiotic farnesol triazole cellobioside (FTC) against
persister formation and preexisted persisters should be tested.
develop antibiotic therapy without emergence of resistance. Antibiotic conjugates is one of new
approach to prevent antibiotic resistance. The farnesol conjugated conventional antibiotics can be
very promising in future.
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Educational Background
•

•

•

•

Ph.D (Chemistry) Syracuse University, USA ( 2016-April 2022,expected)
(Under the guidance of Dr.Yan Yeung Luk)
Research highlights: Synthesis and evaluation of adjunct molecules to prevent antibiotic drug
tolerance and resistance in Cystic fibrosis. Design and synthesis of preventive medicine for SARS-CoV-2
viral infection.
Senior Research Fellow(Biomedical engineering) (DST project) IIT, Mumbai (2015-2016)
(Under the guidance of Prof. Rohit Srivastava)
Research highlights: Hemostatic wound healing product for trauma care.
M.tech ( Pharmaceutical Sciences and Technology ) ICT/IIT, Mumbai (2013-2015)
(Under the guidance of Prof.K.G.Akamanchi)
Thesis title: Design and synthesis novel dendritic heterolipids for pharmaceutical applications.
GPA: 9.23/10
Class Rank: 1st Rank in M.tech (Pharma) and 2nd Rank in Department of Pharmacy,Mumbai.
B.Tech ( Pharmaceutical Sciences and Technology) ICT, Mumbai (2009-2013)
GPA: 7.45/10

Research Experience
•
•
•

•

•
•
•

Research Project 1: Working on preventive medicine for SARS-CoV-2 infections(2020-ongoing)
Research Project 2: Working on design and synthesis of molecules for controlling bacterial behaviour
in cystic fibrosis patients (2017-ongoing).
Research Project 3: Worked on design and synthesis of dendritic heterolipids for solubility
enhancement of drugs (2014)
✓ Synthesis of novel heterolipid as solubility enhancer for Amphotericin B and Camptothecin.
Research Project 4: Worked on polymeric formulation ‘Wound Healing Wafers’(2014)
✓ Wound Healing Wafers with dendritic surfactant as advanced penetration enhancer for transdermal
drug delivery.
Research Project 5: Designed and formulated lipidic formulation LipiSol(2014)
✓ Use of heterolipid as oil based system to improve solubility and permeability of drugs.
Research Project 6: Designed flow reactor for Sandmeyer Reaction and IBX Synthesis.
✓ Use of flow reactor in order to get pure and high yeild of various reactions.(2013)
Research Project 7: Synthesized nanocatalyst for hydrogenation of nitriles(2012)
✓ Study of Chemical kinetics of nanocatalyst for hydrogenation reaction.
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Industrial Training
1. Internship at LifeUnit INC. to develop synthetic molecules to eradicate drug tolerance in Cystic fibrosis.
2. Underwent a four week In-Plant Training (Internship) at the Formulation plant of Rubicon Private
Ltd.,Mumabai, India. And successfully completed the assigned project work.
3. Internship at Arch Ltd ., an Active Pharmaceutical Ingredient (API) manufacturing unit. I worked with
the Technology Transfer Department on an assignment on Process and Scale-Up Design.My
suggestions were well appreciated and implemented in the production batches
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Presentations and Seminars
1. Delivered a presentationon “Carbon Sequestration Techinques : A Concise Review”at a seminar
organized by the Department of Pharmaceutical Sciences and Technology at ICT under the
guidance of Prof. K.G. Akamanchi (2013).
2. Presented a Technical Paper solution to a problem statement (Industrial Defined Problem based on
Post Operative Wound Healing Technolgy) posed by VBP Research Group.
Awarded the 2nd prize (2013).
3. Delivered a seminar on “Oxide Supported Thin Film Catalyst” as a part of the curriculum under
guidance of Dr.V.N.Telvekar (2012).

Conferences and Workshops
1. Participated as Delegate at the ISDNDD -2014 (2nd International Symposium On Dendrimer in Nano
Drug Delievry) CSIR-CDRI, Lucknow and delivered oral presentation entitled
“Oleodendrimer:A chemical Penetration Enhancer for Transdermal Drug Delievry”.
2. Participated in the International Workshop On “Research Writing Skills – Publish or Perish” held
on Nov 2013.
3. Participated in the International Workshop by American Chemical Society ACS On “How to get
Published,a lecture on “Excitement in Chemical Sciences and Engineering” held on Nov 2014.

Achievements
1. Featured in Graduate student spotlight-2020 Syracuse Chemistry department.
2. Qualified and ranked AIR 10 in GATE 2013( Graduate Apptitude Test in Engineering ) in Chemical
Engineering.
3. Merit certificate from the State Board of Maharashtra awarded to TOP 0.1% of over 1 million
students appearing for the SSC Exams.

Research skills
1. Competent with the multistep organic synthesis, HPLC, spectroscopy, and PCR, ELISA.
2. Worked on high Pressure autoclave hydrogenation apparatus, flow reactors.
3. Worked with Biosafety level II microbes(bacteria, viruses).
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